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Abstract
ChIP-seq experiments can identify the genome-wide binding site motifs of a transcription
factor (TF) and determine its sequence specificity. Multiple algorithms were developed to
derive TF binding site (TFBS) motifs from ChIP-seq data, including the entropy
minimization-based Bipad that can derive both contiguous and bipartite motifs. Prior studies
applying these algorithms to ChIP-seq data only analyzed a small number of top peaks with
the highest signal strengths, biasing their resultant position weight matrices (PWMs) towards
consensus-like, strong binding sites; nor did they derive bipartite motifs, disabling the
accurate modelling of binding behavior of dimeric TFs.
This thesis presents a novel motif discovery pipeline by adding the recursive masking and
thresholding functionalities to Bipad to improve detection of primary binding motifs.
Analyzing 765 ENCODE ChIP-seq datasets with this pipeline generated contiguous and
bipartite information theory-based PWMs (iPWMs) for 93 sequence-specific TFs, discovered
23 cofactor motifs for 127 TFs and revealed six high-confidence novel motifs. The accuracy
of these iPWMs were determined via four independent validation methods, including
detection of experimentally proven TFBSs, explanation of effects of characterized SNPs,
comparison with previously published motifs and statistical analyses. Novel cofactor motifs
supported previously unreported TF coregulatory interactions. This thesis further presents a
unified framework to identify variants in hereditary breast and ovarian cancer (HBOC),
successfully applying these iPWMs to prioritize TFBS variants in 20 complete genes of
HBOC patients.
The spatial distribution and information composition of cis-regulatory modules (e.g. TFBS
clusters) in promoters substantially determine gene expression patterns and TF target genes.
Multiple algorithms were developed to detect TFBS clusters, including the information
density-based clustering (IDBC) algorithm that simultaneously considers the spatial and
information densities of TFBSs. Prior studies predicting tissue-specific gene expression
levels and differentially expressed (DE) TF targets used log likelihood ratios to quantify
TFBS strengths and merged adjacent TFBSs into clusters. This thesis presents a machine
learning framework that uses the Bray-Curtis function to quantify the similarity between

tissue-wide expression profiles of genes, and IDBC-identified clusters from iPWM-detected
TFBSs to predict gene expression profiles and DE direct TF targets. Multiple clusters enable
gene expression to be robust against TFBS mutations.
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Chapter 1

1

Background

In this chapter, we will introduce preliminary knowledge necessary for understanding our
studies described in this thesis, and review previous relevant studies in the literature.

1.1 Transcription Factors
Transcription factors (TFs) are a class of proteins that interact with regulatory elements in
genes to facilitate or repress transcription (1). There are two types of TFs, DNA-binding
ones and non-DNA-binding ones (2). DNA-binding TFs recognize specific sequence
motifs and physically contact these binding sites. Non-DNA-binding TFs form
complexes with those sequence-specific TFs as interacting cofactors and are indirectly
recruited to regulatory sequences (Figure 1.1). Approximately 2,000-3,000 sequencespecific DNA-binding TFs are estimated to be encoded in the human genome (3).
Sequence-specific TFs can be further divided into two types, depending on whether the
binding sites recognized are contiguous or bipartite (4) (Figure 1.1). A contiguous (or
single-block) binding site, within which no gap (or spacer) is present, is bound by an
individual TF protein (e.g. CAGCTG bound by the TF AP4). A bipartite binding site
consists of a left half site, a right half site and a variable-length gap between the two half
sites (e.g. TGANTCA/TGANNTCA bound by the TF AP1, where N stands for any base).
It is bound by either a homodimer formed by two identical TF subunits, or a heterodimer
formed by two different subunits. Among all possible gap lengths, the one which the
largest number of binding sites have is referred to as the dominant length.
In general, the binding site motifs of a TF within the entire genome highly resemble each
other. However, significant variability in the bases appearing at most positions is present
as well. For example, all four sequences (CAGCTG, CACCTG, AACCTG, ATGCTG)
are true binding sequences of the TF AP4. TFs exhibit different levels of affinities in their
physical association with these different sequences. For example, among these four
binding sequences, AP4 has the highest affinity to CAGCTG and the lowest affinity to

2

Figure 1.1: Transcription factors. DNA-binding TFs physically associate with binding
sites with specific sequence motifs, whereas non-DNA-binding TFs can only be
indirectly recruited by forming complexes with sequence-specific TFs. A contiguous TF
binding site (TFBS) is recognized by an individual protein, whereas in a bipartite binding
site the left and right half sites are respectively recognized by the two subunits of a TF
dimer. There also exists coordinate cobinding between sequence-specific TFs. The
association of TFs with their binding sites in the promoter effectively regulates the gene
transcription rate and expression level.
AACCTG; thus we say CAGCTG are a stronger binding site than AACCTG for AP4.
The strongest binding sequence of a TF is referred to as the consensus sequence (e.g.
CAGCTG is the consensus sequence of AP4).
Apart from the interplay between the two types of TFs, interactions between sequencespecific TFs also abound across the whole genome (2, 5), which results in the close
proximity of their binding sites (Figure 1.1). For instance, NF-Y extensively coassociates
with FOS over all chromatin states, and CTCF extensively colocalizes with cohesins
consisting of SMC1/SMC3 heterodimers and two non-SMC subunits RAD21 and SCC3
(6, 7).
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Functionally, the three-dimensional structure of a TF protein can be divided into multiple
domains, including the DNA-binding domain (DBD) and the trans-activating domain
(TAD) (8). The DBD is responsible for recognizing and physically associating with
specific sequence motifs. The TAD is responsible for forming complexes with interacting
cofactors.
TFs can be grouped into major families, based on their structural similarity and
behavioral cooperation. For example, the three TFs (FOXA1, FOXA2, FOXA3) belong
to the FOXA family, since they share the same DBD named the Forkhead box within
their three-dimensional protein structure. And the JUN, FOS and ATF subfamilies belong
to the AP1 family, since their members dimerize with each other (e.g. FOS-JUNB and
JUND-ATF1) to recognize the bipartite AP1 binding sites with the consensus sequence
TGANTCA. Additionally, many TFs are mainly expressed and thus play a role in
specific tissues. For example, the FOXA family are predominantly expressed in liver.
Some TFs only act as activators (e.g. SP1 and GATA1) or repressors (e.g. ETV6 and
PRDM1); that is, activating TFs can only facilitate the transcription of target genes, and
repressing TFs can only impede it. However, there are also a number of TFs that can
exert bidirectional effects, partly depending on the interacting cofactors. For example,
YY1 induces expression of the NDUSF8 gene encoding the mitochondrial complex I by
forming a complex with SP1 (9), whereas YY1 acetylation mediated by the P300 cofactor
leads to its repressor activity (10).

1.1.1

Determinants of Transcription Factor Binding

Apart from the core binding sequence physically contacting the TF protein, a number of
other determinants can also affect the DNA-binding ability and affinity of TFs, including
the sequences flanking the core binding site, local DNA structure and modifications,
histone modification patterns surrounding the binding site, chemical modifications within
the TF protein itself, interacting cofactors and ligand signals, and the spacer sequences
within bipartite binding sites (Table 1.1).
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Table 1.1: Determinants affecting TF binding besides the core binding sequence
Determinant

Evidence

Reference

The base pairs flanking an EGR1 binding site in the
LHB promoter modulates the affinity and structure of

(11)

the protein-DNA complex.
Flanking
sequences

The nucleotides flanking GR binding sites change the
3D structure of the binding site, the DNA-binding
domain of GR and the quaternary structure of the

(12)

dimeric complex.
Zinc finger TFs of C2H2 type prefer GC-rich over the
AT-rich flanking sequences.

(13)

The A-DNA structure is only present in DNA bound
to TFs and avoided in DNA bound to nucleosomes,
whereas the BII-DNA structure periodically occurs

(14)

every 10.3 dinucleotide steps in DNA bound to
nucleosomes.
DNA shape

Both global DNA shape (e.g. an overall bend) and
local shape (e.g. a kinked base pair or a narrow minor

(15)

groove) determine the TF binding specificity.
The inherent deformability of the TATA sequence
assists in TBP to distinguish bound from unbound

(16)

sites.
DNA
modifications

Histone
modifications

Promoter methylation levels of the MGMT gene in
the glioma cell line correlates with chromatin

(17)

accessibility and SP1-DNA interaction levels.
HM patterns surrounding binding sites differ
considerably from those surrounding non-sites in a
TF family-specific manner.

(18)

5

TF protein
modifications

Phorbol ester-induced dephosphorylation of JUN
strongly increases its DNA-binding potential.

(19)

NR3C1 (GR) activated by glucocorticoid complex
Cofactors

with NFKB, AP1, T-bet and GATA3 to inhibit their

(20–23)

DNA-binding ability.
Ligand
signals
Spacer

Association with glucocorticoid hormone activates
NR3C1, enabling it to directly bind the response
element or complex with other TFs.
A single pyrimidine nucleotide at the third position of

sequences (for the spacer in the TR/RXR bipartite site enhanced its
dimer TFs)

(24)

(25)

binding and transactivation.

The 3-5 nucleotide (nt) sequences flanking the core binding site can profoundly affect TF
binding by altering the DNA shape, TF DBDs, the quaternary structure of dimeric TFs,
and possibly TF search dynamics (34, 48, 49). The effects of the flanking sequences can
even be asymmetric. For example, a binding site of EGR1 harboring three zinc fingers
(ZF1, ZF2, ZF3) is present in the LHB gene promoter (11). Base substitutions in the
sequence flanking ZF3 resulted in a more significant change in the binding site strength
(11). In addition, the similarity of the flanking sequence composition positively correlates
with the core binding site strength. For instance, the C2H2-type zinc finger DBD
recognize GC-rich sequence motifs, consistent with the finding that the TFs with this
DBD prefer GC-rich over the AT-rich flanking sequences (13).
Individual TF proteins combine two readout mechanisms, recognition of a unique DNA
base sequence (base readout) and of a sequence-dependent DNA shape (shape readout) to
achieve DNA-binding specificity (15). The specificities of different TF families differ in
the base readout in the major groove, whereas shape readout distinguishes between
members within a family (15). Promoter methylation levels of the MGMT gene was also
found to be related to TF binding levels by altering chromatin accessibility (17). Within
open chromatin, different TF families also exhibited different preferences for HM
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patterns surrounding binding sites, with high consistency across cell lines (18). Phorbol
esters, a tumor-promoting agent, induced the dephosphorylation of JUN proteins which
dimerize with other members of the AP1 TF family. This subsequently increased the
DNA-binding activity of the TF to AP1 bipartite sites (19). Association with other
cofactors can also alter TF binding, e.g. NFKB, AP1, T-bet and GATA3 are inhibited by
complexing with activated NR3C1 (20–23). Hormone receptors (e.g. NR3C1) can only
be activated by binding to the corresponding hormone ligands (24).
As described above, for dimeric TFs, the spacer length between the two half sites affects
the TF affinity to the bipartite binding site, with the dominant spacer length being the
most favored (4). In addition, the spacer sequence also modulates the binding site
strength and further the activation potency that the TF exerts on gene transcription. For
example, between the directly repeated half sites with a 4-nucleotide (4nt) spacer
recognized by the heterodimer of TR (thyroid hormone receptor) and RXR (retinoid-X
receptor), some spacer sequences allowed little or no transactivation, whereas other
sequences supported strong transactivation (25). Specifically, a single pyrimidine
nucleotide at the third position of the spacer enhanced TR/RXR binding and
transactivation (25). Heterodimers between RXR and other receptors exhibited a similar
but distinct specificity for the spacer sequence (25).
Most TFs are unable to bind DNA within closed chromatin; however, there is one
category, pioneer TFs (e.g. FOXA1, POU2F2, PAX7 and SPI1), that can be the first to
target closed chromatin and engage binding sites (26). Such initial binding enhances
transcription by reducing the number of additional factors that are needed to bind the
DNA, and actively opening up the local chromatin to enable other factors to bind (26–
28). On the other hand, pioneer factor binding can also lead to repressed chromatin,
through binding adjacent to repressors or corepressors and reduced local nuclease
sensitivity (29–31).

1.1.2

Impacts of Transcription Factor Binding

As described above, TF binding to target sites can eventually result in the effective
regulation of the gene transcription rate and expression level; this is achieved first via
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direct physical impacts that TF binding causes on DNA conformation and chromatin
structure, including DNA bending, over-twisting and/or untwisting, and nucleosome
displacement (Table 1.2).
Table 1.2: Physical impacts of TF binding on DNA and chromatin
Impact

Evidence

Reference

Within MADS-box proteins, SRF induces considerable
DNA bending into its binding sites, whereas MEF2A

(32)

induces minimal DNA bending.
TBP induces linear, stepwise DNA bending with an
intermediate state distinguished by a distinct bending

(33, 34)

angle.
U-turn: The human TRAM TF forces mitochondrial
DNA bending

promoter DNA to undergo a U-turn, reversing the

(35, 36)

direction of the DNA helix both in vivo and in solution.
Looping: Ribosomal promoter DNA is looped into a
single 180-base pair turn around the xenopus UBF

(37)

dimer, probably by in-phase bending.
Supercoiling: Topological stresses caused by TFinduced pronounced bending on circular DNA are

(38)

compensated by DNA supercoiling.
The 434 repressor overtwists its binding site upon DNA
DNA over-

binding.

(39)

twisting and
untwisting

The zinc finger DBDs of SP1, GLI and ZIF268 unwind
DNA upon binding.

Nucleosome

TFs compete with nucleosomes for binding DNA to

displacement

produce nucleosome free regions in promoters.

(40–42)

(43)
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DNA bending induced by TFs is thought to be an important facet of their function, and
plays a role in the DNA recognition process and determining the correct architecture of
nucleoprotein complexes at promoters and enhancers (32). For example, within the TF
family sharing the MADS-box DBD, SRF induces considerable DNA bending into its
binding sites (44); by contrast, MEF2A induces minimal DNA bending (45). The local
DNA architecture surrounding the promoter-bound SRF and MEF2A will therefore differ
significantly, and may contribute to their different biological functions (32). The TFIID
complex that includes the DNA-binding TBP as the core subunit induces a linear,
stepwise bending process with an intermediate state hallmarked by a distinct bending
angle around the TATA motif (33, 34).
An extreme case of DNA bending is a U-turn shape where the direction of the DNA helix
is completely reversed, such as the one induced by the TF TRAM on the mitochondrial
promoters (35, 36). If the two ends of a U-turn bending intersect, then a loop, maybe
around TF proteins themselves (37), will form. On a circular DNA molecule, topological
strain caused by sufficiently strong bending will be balanced by supercoiling, which can
be seen as another higher-level double helix besides the inherent double helix formed by
the two DNA strands (38).
DNA untwisting resulting from binding of TFs with DBDs of zinc finger type (e.g. SP1,
ZIF268, GLI) may affect binding site affinities and TF-cofactor interactions (40–42); by
contrast, TF binding can also overtwist binding sites, such as the bacteriophage 434
repressor (39). In addition, TFs also compete with nucleosomes for binding DNA (43).
Larger nucleosome free regions in promoters, which likely are open chromatin and have a
much more significant impact on gene expression, are determined mainly by TF binding
(43).

1.2 Information Theory-based Position Weight Matrices
Since the bases appearing at most positions of the binding site of a TF are highly
variable, the single consensus sequence is not able to accurately represent the binding
specificity of the TF by only indicating the most frequent base at each position. In
contrast, a position weight matrix (PWM) can more accurately describe the base
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preference of the TF by accounting for the conservation level of each base at each
position. It is a commonly used representation of motifs in biological sequences (46). It
has one column for each position in the motif, and one row for each symbol of the
alphabet: 4 rows for nucleotides in DNA sequences or 20 rows for amino acids in protein
sequences.

1.2.1

Derivation of Information Theory-based Position Weight
Matrices

Contiguous and bipartite information theory-based position weight matrices (iPWMs)
respectively can quantitatively describe the base preferences of TFs recognizing
contiguous and bipartite binding sites.
A contiguous iPWM is derived from a set of aligned binding sites based on Shannon
information theory (4, 47) (Figure 1.2). From a multiple alignment of 𝑛 binding sites in
the reference genome (48), the iPWM is computed from
𝑅𝑖𝑤 (𝑏, 𝑙) = 2 − (− log 2 𝑓(𝑏, 𝑙) + 𝑒(𝑛(𝑙))) (𝑏𝑖𝑡𝑠 𝑝𝑒𝑟 𝑏𝑎𝑠𝑒)

[1.1]

where 𝑓(𝑏, 𝑙) is the frequency of base 𝑏 at position 𝑙 in the alignment (i.e. the count of 𝑏
at 𝑙 divided by 𝑛), and 𝑒(𝑛(𝑙)) is a sampling error correction factor (49) at position 𝑙 for
the 𝑛 sequences used to create 𝑓(𝑏, 𝑙) (50, 51). 𝑒(𝑛(𝑙)) exists, since this set of binding
sites does not include all possible binding sites in the genome and using sampling
frequencies in place of population probabilities leads to a bias in the uncertainty
measurement (49, 52). It is approximately computed from
𝑒(𝑛(𝑙)) =

𝑠−1
2 ln(2)𝑛

[1.2]

where 𝑠, the number of symbols, is 4 for nucleotides (49, 52). It is inaccurate for small 𝑛
values but accurate for large 𝑛 values (49). The exact method is given in Appendix A.2.
In the two-dimensional matrix 𝑅𝑖𝑤 (𝑏, 𝑙), row 𝑏 corresponds to one of the four nucleotides
in DNA and column 𝑙 is the position along the aligned binding sites (50). Following
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Shannon’s convention, 𝑅𝑖𝑤 stands for “Rate of information transmission, Individual
Weight” (51). Bits per base is a rate like bits per second, especially if we consider the
average binding rate in bases per second (49). This individual information matrix
represents the sequence conservation of each nucleotide, measured in bits of information
(50). A bipartite iPWM consists of two contiguous iPWMs, each of which corresponds to
a half site, separated by a range of sequence gaps with penalties (4).

Figure 1.2: Derivation of a contiguous iPWM from a multiple alignment of binding
sites. An aligned set of 22,794 binding sites of the TF AP4 is shown. A count matrix is
obtained from the alignment by counting the occurrence of each base at each position.
The information theory-based Equation 1.1 converts the count matrix to an iPWM using a
pseudocount 0.375 for each base (4). Equation 1.3 uses the iPWM to compute the 𝑹𝒊
values of all binding sites in the alignment from which the 𝑹𝒔𝒆𝒒𝒖𝒆𝒏𝒄𝒆 value is computed.

1.2.2

Computation of the Information Content of an Individual
Binding Site

The individual information content of a contiguous binding site sequence 𝑗, which
represents its strength, can be determined using a contiguous iPWM. It is the dot product
between the sequence and the iPWM:
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𝑇

𝑅𝑖 (𝑗) = ∑ ∑ 𝑠(𝑏, 𝑙, 𝑗)𝑅𝑖𝑤 (𝑏, 𝑙) (𝑏𝑖𝑡𝑠 𝑝𝑒𝑟 𝑠𝑖𝑡𝑒)

[1.3]

𝑙 𝑏=𝐴

where 𝑠(𝑏, 𝑙, 𝑗) is a binary matrix for the sequence 𝑗, in which cells have a value of 1 for
base 𝑏 at position 𝑙 and a value of 0 elsewhere (50, 51) (Tables 1.3 and 1.4).
Table 1.3: The binary matrix of the binding site sequence “CATCTGGG” of AP4
Base 𝑏

A
C
G
T

C
1
0
1
0
0

A
2
1
0
0
0

T
3
0
0
0
1

Position 𝑙 *
C
T
4
5
0
0
1
0
0
0
0
1

G
6
0
0
1
0

G
7
0
0
1
0

G
8
0
0
1
0

There is only one “1” in each column, indicating the base appearing at that position.

*

Table 1.4: Calculation of the Ri value of the binding site sequence “CATCTGGG”
Base 𝑏

A
C
G
T
*

C
1
-3.60812
1.80923
-1.27543
-13.8916

A
2
1.61077
-5.21564
-2.50879
-0.428623

T
3
-7.60004
-0.730304
1.69645
-2.72941

Position 𝑙 *
C
T
4
5
-10.3473 -13.8916
1.99958 -13.8916
-13.8916 -13.8916
-13.8916 1.99983

G
6
-13.8916
-13.8916
1.99983
1.99983

G
G
7
8
-0.396613 -2.48876
-6.88037 -0.129385
1.09808 1.23945
0.125534 -0.872293

In this iPWM, the individual weights selected by the binary matrix of the binding site are

bolded. In Equation 1.3 the 𝑅𝑖 value is the sum of the selected weights.
The 𝑅𝑖 value of a bipartite binding site sequence 𝑘 is the sum of the 𝑅𝑖 values of the two
half sites, each of which is computed from Equation 1.3, subtracting the gap penalty (4):
𝑅𝑖 (𝑘) = 𝑅𝑖 (𝑘𝑙 ) + 𝑅𝑖 (𝑘𝑟 ) − 𝑔(𝑑)

[1.4]

where 𝑘𝑙 and 𝑘𝑟 are the two half sites of 𝑘, 𝑑 is the gap length between 𝑘𝑙 and 𝑘𝑟 , and
𝑔(𝑑) is the function used to compute gap penalties:
𝑔(𝑑) = 1 − log 2 (1 + cos(2𝜋(𝑑 − 𝑐)⁄𝐵 ))

[1.5]
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where 𝑐 is the dominant gap length (i.e. the number of binding sites with the gap length 𝑐
in the alignment from which the bipartite iPWM is computed is the largest), and 𝐵 is a
DNA helical turn (10.4 bases/turn) (4, 53). Equation 1.5 incorporates the geometry of the
TF recognition to binding sites, that is, the preference of dimeric TFs for binding across
adjacent major grooves in DNA helices (53).

1.2.3

Relationship between 𝑅𝑖 Values and Thermodynamics

According to the Second Law of Thermodynamics, the relationship between information
(i.e. 𝑅𝑖 values) and the heat 𝑞:
𝑘𝐵 𝑇 ln(2) ≤

−𝑞
𝑅𝑖

[1.6]

where 𝑘𝐵 is Boltzmann’s constant (1.38 × 1023 joules/K), 𝑇 is the absolute temperature
in Kelvin.
Equation 1.6 implies that the association process of a TF protein with a binding site (𝑅𝑖 >
0) dissipates heat energy (𝑞 < 0), and the association process of a TF protein with a nonsite (𝑅𝑖 < 0) absorbs heat energy (𝑞 > 0). This suggests that TFs have a natural tendency
to complex with its binding sites, and the association of TFs with non-sites does not
naturally occur. Furthermore, Equation 1.6 implies that if a SNP results in a 1-bit increase
in the 𝑅𝑖 value of a binding site, the amount of heat energy dissipated by the association
of a TF protein with this site will at least increase by 𝑘𝐵 𝑇 ln(2). The derivation starting
from the Second Law of Thermodynamics to obtain Equation 1.6 is in Appendix A.1.
Thus based on the 𝑅𝑖 value, a nucleotide sequence can be predicted to be a binding site or
not; if 𝑅𝑖 > 0 it is a binding site, and if 𝑅𝑖 < 0 it is a non-site. The 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 value of an
iPWM is the mean of the 𝑅𝑖 values of all binding sites used to compute the iPWM,
representing the average binding strength of the TF (50, 51). The distribution of 𝑅𝑖 values
is approximately Gaussian, with the mean being 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 ; however, the lower and upper
bounds are zero bits and the 𝑅𝑖 value of the consensus sequence (50, 51).
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The change in the binding site strength caused by a SNP can be quantitatively computed
from the change (∆𝑅𝑖 ) in the 𝑅𝑖 value of the binding site (50, 51) (Appendix A.3). If the
𝑅𝑖 values of the normal and variant binding sites are respectively 𝑅𝑖,𝑛𝑜𝑟𝑚𝑎𝑙 and 𝑅𝑖,𝑣𝑎𝑟𝑖𝑎𝑛𝑡 ,
then ∆𝑅𝑖 = 𝑅𝑖,𝑣𝑎𝑟𝑖𝑎𝑛𝑡 − 𝑅𝑖,𝑛𝑜𝑟𝑚𝑎𝑙 . Then the minimum fold change between the binding
affinity of the two sites is 2∆𝑅𝑖 (50, 51). 𝑅𝑖 and ∆𝑅𝑖 will be used to detect experimentally
confirmed binding sites and interpret experimentally measured effects of SNPs in
Chapter 3, to detect and prioritize TFBS variants in Chapters 4 and 5, and to perform
mutation analyses on promoters of TF target genes in Chapter 6.

1.2.4

Sequence Logos

An iPWM can quantitatively describe the binding specificity of a TF, but it is not very
intuitive. Sequence logos provide a means to intuitively visualize iPWMs in Chapter 3
(Figure 1.3) (54). In a sequence logo, the abscissa is the position along the aligned
binding sites; the ordinate is the individual weight in the iPWM, so that the height of a
base letter indicates the conservation level of the base at the position among binding sites.

Figure 1.3: Sequence logos. The height of each base letter is its individual weight at the
position in the iPWM. The 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 value of the iPWM is indicated at the bottom of its
logo. (A) This logo visualizes the contiguous iPWM of AP4 derived in Figure 1.5. (B)
This logo visualizes a bipartite iPWM of the TF BATF. From this logo, we can see that
the length of both half sites is 3bps and the dominant gap length is 1bp.

1.3 Derivation of Transcription Factor Binding Site Motifs
As described above, binding site sequences recognized by a TF are highly variable; thus
one question is how we can identify all these true binding site sequences. Previous
studies, using either in vitro experimental techniques or computational approaches based
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on in vivo generated ChIP-seq datasets, have derived TF binding site sequence motifs and
characterized TF binding specificities. Compared to experimental techniques, the
computational approaches are less labor intensive and more cost effective.

1.3.1

Using Experimental Techniques

In Weirauch et al. (55), binding site motifs of more than 1,000 TFs belonging to 54
different DBD classes from 131 eukaryotes were derived using PBMs (protein binding
microarrays) to determine their sequence preferences. In each PBM, each possible 8-mer
is present 32 times, allowing for a robust and unbiased assessment of TF binding affinity.
Since closely related DBDs have similar sequence preferences, they were further able to
infer motifs for 34% of the approximately 170,000 known or predicted eukaryotic TFs
(55). These binding site motifs were validated by the fact that they are enriched in ChIPseq peaks and upstream of TSSs (55). Their results, in the form of frequency matrices,
were stored in the CIS-BP database (55).
In Jolma et al. (56), HT-SELEX (high-throughput systematic evolution of ligands by
exponential enrichment) experiments were performed to identify binding site motifs for
151 human full-length TFs and 303 human DBDs, and PWMs were further generated
using a multinomial model. Pairwise comparison between the results of full-length TFs
and their DBDs revealed that the sequence preference of a TF is primarily determined by
its DBD (56). The vast majority of physical interactions between a TF and individual
DNA bases were found to be independent of each other (56). Bipartite binding site motifs
of TF homodimers with strong orientation and spacing preferences were also observed
based on the presence of two similar sites in a single oligonucleotide (56).
However, these oligonucleotide-based approaches have a number of limitations:
1) Weirauch et al. did not derive bipartite binding sites of dimeric TFs from their PBM
experiments; Jolma et al. only generated contiguous PWMs with dominant gap lengths to
describe bipartite motifs of homodimers, which are unable to account for the variability
of gap lengths.
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2) Since these techniques use oligonucleotides whose lengths are fixed and limited, they
are unable to completely derive motifs of TFs whose binding site lengths exceed the
oligonucleotide lengths.
3) There is no way to discover potential binding sites of interacting cofactors, since only
the primary TF proteins of interest are added to each experiment.

1.3.2
1.3.2.1

Using Computational Approaches
Chromatin Immunoprecipitation-Sequencing Assays

ChIP-seq, which combines chromatin immunoprecipitation with massively parallel DNA
sequencing, is an in vivo experimental method to identify the genome-wide repertoire of
binding sites of chromatin-associated proteins (e.g. TFs) and the distribution of histone
modifications (57) (Figure 1.4).
After cross-linking proteins to DNA in living cells, DNA molecules are sheared into short
fragments by sonicating. Using an antibody against the protein of interest, chromatin
immunoprecipitation (ChIP) isolates the DNA-protein complexes, resulting in a library of
DNA fragments directly bound to the protein (Figure 1.4). Then these fragments are
sequenced and mapped to the reference genome, ultimately producing a dataset file
containing genome coordinate intervals (Figure 1.4). In this dataset, each interval,
typically several hundred nucleotides long, has a signal value that indicates the
enrichment level of mapped DNA fragments within this interval; thus in general, the
signal value is positively correlated with the strength of the binding site contained in the
interval. Each interval is referred to as a peak. The process of mapping DNA fragments to
the genome, merging DNA fragments into peaks based on their local enrichment levels,
and determining the signal values of these peaks is referred to as peak calling. In the case
of TFs, the DNA fragments in the library also contain binding sites of cofactors, due to
either the proximity between their binding sites resulting from the TF-cofactor
coordination or the recruitment of non-DNA-binding TFs by sequence-specific cofactors.
The ENCODE (Encyclopedia of DNA Elements) Consortium conducted ChIP-seq assays
for human TFs and histone modifications, and generated an initial peak dataset for each
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replicate of each assay using a uniform peak calling pipeline (57, 58). To improve the
consistency between the initial peaks from multiple replicates of the same assay, for some
assays it also produced optimal and conservative IDR (irreproducible discovery rate)thresholded peaks after applying the IDR framework to the initial datasets (59). In
addition, members of the ENCODE Consortium also individually generated refined
datasets using the SPP peak calling software (60).

Figure 1.4: ChIP-seq assays. The protein binding to DNA fragments in vivo is
immunoprecipitated by an antibody. These fragments that frequently contain binding
sites of cofactors and form a library containing a genome-wide set of binding sites of the
protein, are sequenced. The peak calling algorithm identifies all intervals (or peaks) with
high enrichment of the DNA fragments and computes associated signal values. The
genome intervals and signal values are stored in a peak dataset file.

1.3.2.2

Motif Discovery Algorithms

A peak in a ChIP-seq dataset contains a binding site sequence of the TF; however, it also
contains long unnecessary sequences flanking the binding site at the same time. Previous
studies have developed multiple algorithms and corresponding software programs to
identify the accurate binding site motifs from ChIP-seq datasets (Table 1.5). These motif
discovery algorithms fall into six categories, depending on the mathematical principle
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Table 1.5: Motif discovery algorithms
Mathematical principle

Bipad

Entropy minimization

√

(4)

MEME
/MEME-ChIP

Expectation maximization

×

(61–63)

SeqGL

Group lasso regularization

×

(64)

MotifCut

Maximum density subgraph

×

(65)

AlignACE

×

(66, 67)

ANN-Spec

×

(68)

×

(69)

GLAM2

√

(70)

MotifSampler

×

(71)

SeSiMCMC

√

(72)

MDscan

×

(73)

Trawler

×

(74)

Weeder

×

(75)

×

(76)

DREME

×

(77)

HOMER

×

(78)

YMF

×

(79)

GLAM

MITRA

†

Ability to derive

Algorithm†

Gibbs sampling

String matching

bipartite motifs

Reference

The rows of the motif discovery algorithms using the same mathematical principle have

the same background shade.
used, including entropy minimization (used by Bipad), expectation maximization (used
by MEME), group lasso regularization (used by SeqGL), maximum density subgraphs
(used by MotifCut), Gibbs sampling (used by AlignACE, ANN-Spec, GLAM/GLAM2,
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MotifSampler, SeSiMCMC), string matching-based enumeration (used by MDscan,
Trawler, Weeder, MITRA, DREME, HOMER, YMF).
These algorithms were benchmarked on 52 datasets, finding that Weeder outperformed
others on most datasets (80); however, Bipad was excluded from the comparison. Among
these algorithms, only three (i.e. Bipad, GLAM2 and SeSiMCMC) are capable of
deriving bipartite motifs. Both MEME and SeqGL are discriminative methods that
distinguish motif from background DNA in a mathematically optimal way using
background nucleotide frequencies computed from all input sequences (60, 61, 63).

1.3.2.2.1

The Bipartite Pattern Discovery Algorithm

The Bipartite Pattern Discovery (Bipad) algorithm, that uses an entropy minimizationbased Monte Carlo framework, can derive both contiguous and bipartite iPWMs from the
multiple alignment of binding sites identified from a ChIP-seq dataset (4). Chapter 3 will
improve its ability to discover known TFBS motifs and use it to analyze ENCODE ChIPseq datasets.
The Bipad algorithm assumes that the sequence associated with each peak in a ChIP-seq
dataset contains one binding site. Given the length 𝐽 of the contiguous binding sites of
the TF and the peak count 𝑛 in the dataset, all peaks form a multiple alignment search
space Θ. In Θ each multiple alignment is derived by extracting a sequence fragment of
length 𝐽 from each peak and aligning them; thus it is of width 𝐽 and size 𝑛. Given a
multiple alignment 𝑀𝐴 in Θ, the entropy of the position 𝑙 is computed from:
𝐻𝑙 = ∑ 𝑓(𝑏, 𝑙) log 2
𝑏∈𝐵

1
, 𝐵 = {𝐴, 𝐶, 𝐺, 𝑇}
𝑓(𝑏, 𝑙)

[1.7]

where 𝑓(𝑏, 𝑙) is the frequency of base 𝑏 at position 𝑙. The entropy of the alignment 𝑀𝐴 is
computed from:
𝐽

𝐻𝑀𝐴 = ∑ 𝐻𝑙

[1.8]

𝑙=1

Similarly, in the instance of bipartite binding sites of a dimeric TF, the entropy of the
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bipartite alignment 𝑀𝐴 is computed from:
𝐽𝑠

𝐻𝑀𝐴 = ∑ (∑ 𝐻𝑙 )
𝑠∈{𝐿,𝑅}

[1.9]

𝑙=1

where 𝐽𝐿 and 𝐽𝑅 are respectively the lengths of the left and right half sites.
The Bipad algorithm uses multiple Monte Carlo cycles to search Θ for the optimal
alignment with the minimum entropy (Figures 1.5 and Appendix A.4). Its objective
function is:
𝑜𝑀𝐴 = 𝑎𝑟𝑔 min (𝐻𝑀𝐴 )
𝑀𝐴∈𝜃

[1.10]

where 𝑜𝑀𝐴 is the optimal alignment with the minimum entropy, and 𝑀𝐴 is a contiguous
or bipartite alignment in Θ. Its time complexity and space complexity are respectively
𝑂(𝐽𝐿𝑛𝑐) and 𝑂(𝐿𝑛), where 𝐿 is the length of a ChIP-seq peak and 𝑐 is the Monte Carlo
cycle count.
At the beginning of each cycle, the initial position of the binding site in each peak, and
thus the initial alignment, are randomly generated. Each cycle performs multiple
iterations; in each iteration, the binding site in each peak moves to every possible position
(including every possible gap length at every position in the instance of bipartite binding
sites) to generate a new alignment. The end of each cycle converges to a locally optimal
alignment in a subspace of 𝜃.

1.3.2.3

Application of the Motif Discovery Algorithms to ChIP-seq
Datasets

These motif discovery algorithms have been applied by prior studies to ChIP-seq
datasets. For example, Wang et al. performed de novo motif discovery from top 500
peaks with the highest signal values of 457 ChIP-seq datasets of 119 human TFs using
the MEME-ChIP software (2, 63). Apart from known and new motifs of primary TFs,
they also derived cofactor motifs adjacent to them, indicating tethered binding and
cobinding between multiple TFs (2). Specifically, they observed cell line-specific
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Figure 1.5: An execution of the Bipad algorithm on a ChIP-seq dataset. Using
multiple entropy minimization-based Monte Carlo cycles, the Bipad algorithm searches
the multiple alignment search space formed by all peaks, in an attempt to find the optimal
alignment with the minimum entropy.
cofactor motifs that mediate the binding of the histone deacetylase HDAC2 and the
enhancer-binding protein EP300 (2). They created the Factorbook database to make the
derived binding site motifs publicly available (2). Kheradpour et al. also confirmed
known binding motifs and revealed potential cofactors from top 250 peaks of 427 ChIPseq datasets of 123 TFs using five motif discovery tools (AlignACE, MDscan, MEME,
Trawler, Weeder) (81).
Setty et al. applied SeqGL to top 2,000 peaks of 105 ChIP-seq datasets from the
GM12878 and H1-hESC cell lines, and found that it outperformed three other widely
used motif discovery algorithms (HOMER, DREME and MEME-ChIP) in terms of both
locating motifs of primary TFs and revealing new cell type-specific cofactors (64). In
addition, SeqGL also successfully detected binding site motifs from DNase-seq and
ATAC-seq datasets (64).
These previous studies mined a wealth of valuable information in terms of TF binding
specificities and TF-cofactor interactions. However, they also have a number of
limitations:
1) They only derived contiguous binding site motifs, and did not generate bipartite motifs
with variable-length gaps for dimeric TFs. Thus the contiguous PWMs they provided are
unable to accurately reflect the binding behavior of dimeric TFs or further detect their
binding sites.
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2) They only respectively analyzed top 500, 250 or 2,000 peaks. Because the signal value
of a peak is generally positively correlated with the strength of the binding site contained
in the peak, this implies that they only obtained strong binding sites, resulting in the fact
that the PWMs only represent strong sites and cannot accurately detect weak sites.
3) The PWMs that they generated to describe the binding site motifs were not Shannon
information theory-based. The log likelihood ratios computed from these PWMs to detect
TFBSs indicate the probabilities that DNA sequences are binding sites, which are not
quantitatively related to the amount of dissipated binding energy by Equation 1.6. Thus
these PWMs are unable to quantify binding site strengths as accurately as iPWMs by
computing 𝑅𝑖 values.
4) Both the MEME and SeqGL algorithms compute background nucleotide frequencies
from all input sequences, then use them to discriminate binding site motifs from
background sequences. Thus they may fail to discover motifs with compositions similar
to the background.

1.3.3

Transcription Factor Binding Site Motif Databases

Multiple databases have been created to store PWMs and sequence logos describing
TFBS motifs experimentally or computationally derived by these prior studies (Table
1.6). The PWMs in these databases have been widely used to detect binding sites in
previous studies.
The JASPAR database initially only contained 111 pan-species count matrices derived
from a limited number of experimentally validated binding sites (82), but the core
collection of its latest 2018 version has been significantly expanded to 1404 pan-species
non-redundant position frequency matrices (PFMs) by incorporating TFBS motifs
computationally derived from ChIP-seq datasets (83). The Factorbook database (84),
containing binding site motifs derived from top 500 peaks of ChIP-seq datasets using the
MEME-ChIP software (2), was also increased from the initial 119 TFs to 167 TFs. The
CIS-BP database contains the frequency matrices derived from the octanucleotide-based
PBMs by Weirauch et al. (55). The TRANSFAC database (85) currently contains 7,371
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Table 1.6: TFBS motif databases
Human
Database
JASPAR (Core
collection)
Factorbook

TF/PWM count†
537 PWMs
167 TFs

PWM source
Experimental (PBM, HT-SELEX,
etc) and computational (ChIP-seq)

Reference

(83)

Computational (ChIP-seq)

(84)

PBM experiments

(55)

972 PWMs,
CIS-BP
1734 TFs
TRANSFAC
† We

Unavailable

Computational (phylogenetic
analysis) and possibly experimental

(85)

were not able to obtain accurate both human TF and PWM counts for JASPAR and

Factorbook. Neither human TF nor PWM counts could be obtained for TRANSFAC.
pan-species PWMs, a small fraction of which are freely available due to its commercial
orientation.

1.4 Transcription Factor Binding Site Variants
One source that can result in misregulation of gene expression is variation. A genetic
variation in the human genome is defined as a difference in the DNA sequence between
two individuals or paired chromosomes in an individual (86). Multiple types of variants
(e.g. nucleotide substitutions, insertions and deletions) can occur within both the noncoding and coding regions of genes, affecting the binding sites of TFs, splicing regulatory
proteins and RNA-binding proteins, and protein structure (50, 87, 88). Specifically,
genetic variants within exons of the coding region of a gene can alter individual residues
in the amino acid chain of the protein or result in a prematurely truncated chain, and
variants within splicing sites can also change the polypeptide by altering the strengths of
splice sites and potentially the boundaries between introns and exons (50, 87). Thus
variants are often associated with the increased risks of a variety of diseases (89, 90). For
example, nine splice site variants in the promoter of the ABCR gene are found to be
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associated with the onset of the STGD (autosomal recessive Stargardt disease) and AMD
(cone-rod dystrophy) (91).
Among variants within TFBSs, a single nucleotide polymorphism (SNP) is the simplest
case, which is a naturally occurring substitution of one single nucleotide with a
prevalence rate exceeding 1% in a population (92). It can significantly alter the strength
of the binding site, and further the gene expression level (Figure 1.6). The expression
level of the gene will increase after a SNP strengthens a binding site of an activating TF
or weakens a site of a repressing TF; by contrast, it will decrease after a binding site of an
activating TF is weakened or a site of a repressing TF is strengthened (Figure 1.6).

Figure 1.6: The impacts of a SNP on the TFBS and gene expression level. The
strengthening or weakening of the binding site of an activating TF caused by a SNP
respectively leads to an increase or decrease in the gene expression level. The
strengthening or weakening of the binding site of a repressing TF caused by a SNP
respectively leads to a decrease or increase in the gene expression level.
PWMs have been used to detect variants within TFBSs and splice sites and predict their
effects, either as online web-based services or stand-alone software programs (Table 1.7).
The majority of these platforms use the PFMs from the JASPAR database to compute log
likelihood ratio scores, except for Shannon pipeline using iPWMs. These scores are not
Shannon information theory-based, so that they are unable to quantify binding site
strengths as accurately as 𝑅𝑖 values.

1.5 Clustering of Transcription Factor Binding Sites
The distinctive organization and combination of transcription factor binding sites
(TFBSs) and regulatory modules in the promoters of human genes substantially dictate
specific expression patterns within a set of genes (93). Clustering of multiple adjacent
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Table 1.7: Platforms applying PWMs to detect TFBS and splice site variants
Platform

PWM
Type

Shannon pipeline

iPWM

rSNP-MAPPER

PWM source

Type

Manually curated

JASPAR, TRANSFAC

(95)
Web-based

OncoCis

Reference

(94)

splice sites

SNP2TFBS

RAVEN

Service

JASPAR

(96)
(97)

PFM

(98)

atSNP

JASPAR, Kheradpour et al.

TRAP

JASPAR, TRANSFAC

motifbreakR

JASPAR, Factorbook

(99)
Stand-alone

(100)
(101)

binding sites for the same TF (homotypic clusters) and for different TFs (heterotypic
clusters) defines regulatory modules, and are prevalent in both promoters and more distal
enhancers (102). Evolutionarily conserved homotypic clusters occupy nearly 2% of the
human genome. The promoters of more than half of human genes contain homotypic
clusters, with a concentrated distribution around the TSS (103). For example, highly
degenerate binding sites of NRSF, MYC, p53, HNF1 and CREB were found to have a
tendency of non-randomly clustering around the cognate binding sites (104).

1.5.1.1

Impacts of Transcription Factor Binding Sites Clusters

There are two scenarios under which a homotypic TFBS cluster can influence gene
expression, depending on whether individual binding sites within the cluster interact with
one another (102).

1.5.1.1.1

Absence of Interaction Between Individual Sites

If there is no interaction between individual sites at all, all binding sites in a cluster are
equally likely to be bound, and the likelihood may be associated with an external variable
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to the system, such as TF concentration (102). This scenario can be further divided into
the following four different cases (here we assume an activating TF increasing the gene
expression level; a repressing TF is similar in the sense that the expression level is
decreased) (Table 1.8).
The first case is that only after all binding sites are bound, the cluster is able to alter the
gene expression level. The cluster can only produce two different expression levels: zero
or maximum (105, 106) (Table 1.8). Thus it prevents spurious transcription until the TF
concentration is high enough such that all binding sites are occupied, and consequently
reduces leaky gene expression and noise in mRNA levels (102, 107). In addition, it slows
the initiation of gene transcription by requiring a longer time for all sites to become
bound (102, 107).
The second case is that as long as one binding site is bound, the cluster is able to increase
gene expression to the maximum level (Table 1.8). Thus it makes a promoter more
sensitive to low concentrations of TFs and less sensitive to higher concentrations of TFs
(102). In addition, it expedites gene expression by only requiring one site to become
bound (102, 108).
The third case is that each binding site in a cluster independently and equally contributes
to gene transcription, so that the gene expression level is proportional to the number of
bound sites (102) (Table 1.8). In vivo this case does not always happen; different sites
have different amounts of contribution, which is the fourth case (Table 1.8). For example,
certain TFs have optimal distances from the TSS that maximize their interaction with the
transcriptional machinery (109, 110). There may also be a periodic relation between the
distance of a TFBS from the TSS and the level of transcription, possibly because the
influence of TFs on gene expression is dependent on the nucleosome context (111).

1.5.1.1.2

Presence of Interaction Between Individual Sites

If direct or indirect interactions are present between individual binding site within a
cluster, the gene expression level after all sites are bound exceeds the sum of the
expression levels when each single site is bound (Table 1.8); that is, the clusters can
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Table 1.8: Impacts of a homotypic TFBS cluster on the gene expression level
Cluster†

Interaction absent‡

Interaction

1st site

2nd site

1st case

2nd case

3rd case

4th case

present‡

×

×

0%

0%

0%

0%

0%

×

√

0%

100%

50%

25%

25%

√

×

0%

100%

50%

75%

25%

√

√

100%

100%

100%

100%

100%

† The

cluster consists of two binding sites of the TF. × indicates that the site is not bound,

and √ indicates that the site is bound.
‡ The

percentage in each cell is the ratio of the expression level induced by the current

binding situation of the cluster to the maximum expression level.
amplify the influence of individual binding sites on gene expression, through increased
binding stability, funnel effects and facilitated diffusion mechanisms (102).
Highly degenerate TFBSs whose sequences differ much from the consensus sequence
tend to occur in homotypic clusters (104). These adjacent weak binding sites, which
individually may not be strong enough to bind TFs and activate transcription, can
stabilize each other’s binding by direct TF-TF dimerization and indirect nucleosome
displacement (112, 113) (Figure 1.7). In addition, the weaker sites flanking a strong
binding site in a cluster can direct the TF molecule to the strong site and extend the
period of the molecule physically associating with the strong site, which is known as the
funnel effect (114–116) (Figure 1.7).
TFs search for binding sites by a combination of three-dimensional diffusion in the
nucleoplasm and one-dimensional random walk on the DNA, which is known as the
facilitated diffusion mechanism (117–119) (Figure 1.7). The speedup in the search
process results from the reduction of the dimensionality of the search process from three
dimensions to one-dimension (102) (Figure 1.7). In vitro TFs associate with longer
synthesized DNA fragments more rapidly compared to shorter DNA fragments that
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Figure 1.7: Cooperation between adjacent binding sites in a cluster. The size of a
block arc positively correlates with the strength of the binding site. (A) If a TF molecule
associates with DNA within the sliding window, it can perform a 1D random walk to find
the binding site faster and with higher probability than the 3D diffusion. (B) Multiple
adjacent weak binding sites within a cluster are able to stabilize each other’s binding, and
extend the sliding window to reduce TF search time. (C) TF molecules are directed to the
central stronger site by the flanking weaker sites, which is known as the funnel effect.
contain the same binding site in the middle (120), which indirectly proves the existence
of facilitated diffusion (102). This mechanism is called the antenna effect, which assumes
that a longer DNA fragment increases the contribution of the one-dimensional random
walk component to the TF search process (121).

1.5.1.2

Computational Algorithms Detecting Transcription Factor
Binding Site Clusters

Previous studies have developed multiple algorithms to computationally detect TFBS
clusters. These algorithms fall into two main categories, window-based and model-based
(Table 1.9).
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Table 1.9: Algorithms detecting TFBS clusters
Algorithm

Category

SCORE

Method to detect TFBSs

Reference

Consensus sequences

(122)

CIS-ANALYST

(123)
Window-based

PWMs

MSCAN

(124)

IDBC

iPWMs

Cister

(126)

Comet
MCAST

(125)

PWMs
Model-based

(127)
(128)

Cluster-Buster

Count matrices

(129)

Poisson distribution-based

Consensus sequences

(130)

The window-based algorithms, such as SCORE (122), CIS-ANALYST (123), MSCAN
(124) and IDBC (125), rely on intuitive merging operations on initial windows created
based on distances between binding sites. CIS-ANALYST and MSCAN applied PWMs
to detect TFBSs, which allowed the binding site strengths to vary; whereas SCORE only
used the predicted sites that exactly match the consensus sequences.
The model-based algorithms, including Cister (126), Comet (127), MCAST (128) and
Cluster-Buster (129), apply probabilistic models (e.g. log likelihood ratios) to
discriminate motif clusters from background DNA in a mathematically optimal way
(129). All four methods are based on the Hidden Markov Model (HMM), which views
locating regulatory regions in genomic DNA as a change-point problem, with the
beginning of regulatory and non-regulatory regions corresponding to the change points
(131). A statistical E-value is computed for each detected cluster to indicate its
significance.
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1.5.1.2.1

The Information Density-based Clustering Algorithm

The Information Density-Based Clustering (IDBC) algorithm will be used in Chapter 6 to
effectively detect TFBS clusters by taking into account both the spatial organization (i.e.
intersite distances) and information density (i.e. 𝑅𝑖 values) of TFBSs (125). Its detailed
steps include (Figure 1.8):
① For each binding site 𝑠, calculate the neighborhood information content (𝑛𝑖𝑐) as
being the total of pairwise sums of the information content for 𝑠 and each site lying
within a radius 𝑑 (number of bases) of 𝑠.
② For each site 𝑠 with 𝑛𝑖𝑐 exceeding a threshold 𝐼, create an initial cluster in which 𝑠 is
the center and all binding sites within the radius 𝑑 are included.
③ In the first phase of merging clusters, consider each pair of clusters with centers 𝑐𝑖
and 𝑐𝑗 .
•

If either cluster contains the center of the other cluster, then merge the two
clusters. The center of the new cluster is the stronger one between 𝑐𝑖 and 𝑐𝑗 . If
they have the same 𝑅𝑖 value, the center of the cluster containing more TFBSs
is made the center of the new cluster, whereas the other center is relegated to
being just a site.

•

If 𝑐𝑖 is included in the cluster with 𝑐𝑗 as its center, but 𝑐𝑗 is not included in the
cluster with 𝑐𝑖 as its center, compare the strengths of 𝑐𝑖 and 𝑐𝑗 .
o If 𝑐𝑖 is stronger than 𝑐𝑗 , the overlapping TFBSs are put into the cluster
with 𝑐𝑖 as its center and removed from the cluster with 𝑐𝑗 as its center.
o If 𝑐𝑖 is weaker than 𝑐𝑗 , the overlapping sites are put into the cluster with 𝑐𝑗
as its center and removed from the cluster with 𝑐𝑖 as its center. The
remaining sites in the cluster with 𝑐𝑗 as its center form a cluster in which
the strongest site 𝑐𝑘 is selected as the new center.

This step is iterated until no 𝑐𝑖 occurs in more than one cluster.
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Figure 1.8: The IDBC algorithm. (A) Vertical bars indicate the locations of putative
binding sites upstream of the TSS, and their heights are positively correlated with the
strengths of the binding sites. (B) The initial four clusters are created from the first two
steps of the algorithm. Clusters 1 and 2 share one binding site, and Clusters 3 and 4
contain each other’s center. (C) Step 3 solves the overlap of Clusters 3 and 4 by putting
the center of Cluster 4 into Cluster 3, since the center of Cluster 3 is of the same strength
as that of Cluster 4 and Cluster 3 contains more sites. (D) Step 4 solves the overlapping
site of Clusters 1 and 2 by putting it into Cluster 1. (E) In Step 5, since the single site in
Cluster 4 is not strong enough to be a cluster, finally only three clusters remain.
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④ In the second phase of merging, all binding sites that belong to more than one cluster
are exclusively allocated to the cluster with the stronger center.
⑤ In the re-evaluation phase, a final check is performed to ensure that the information
content of each cluster reaches the threshold I (as in Step 2) after the possible reallocation
of sites in the preceding step. Clusters failing the check are dissolved into individual sites.

1.6 Prediction of Gene Expression Levels
As described above, the gene expression pattern is largely determined by the distribution
and composition of TFBS clusters in the promoter, implying that TFBSs can be used to
explain the variance in the expression level between genes. In fact, previous studies,
based on either TF binding or chromatin structure data, predicted gene expression levels
using a variety of machine learning classifiers and regression models. The TF binding
profiles used to predict tissue-specific absolute gene expression levels were derived from
either in vivo ChIP-seq peaks (132–134) or computationally detected binding sites and
clusters (135). Both achieved similar accuracy (136).
Ouyang et al. (132) applied a principle component regression model based on features
extracted from ChIP-seq peaks of 12 TFs in mouse embryonic stem cells, and found that
these features explained 63.9% of the variance in the gene expression levels. The feature
of each gene for each TF, termed as the TF association strength, was a weighted sum of
signal values of all ChIP-seq peaks, where the weights are the distances of the peaks from
the gene (132). Similarly, Cheng et al. (133) related the binding strengths of 40 TFs to the
expression levels of 57 genes in the K562 cell line, and achieved a 67% predictive
performance. The binding strength of each TF on each gene was computed by averaging
the signal values of ChIP-seq peaks within a 100bp interval centered on the TSS (133).
Smith et al. (135) used the PWMs from the TRANSFAC database (85) to detect TFBSs
and clusters, and applied the MARS algorithm (137) to construct a classification model
for each of 56 human and mouse tissues to distinguish expressed from silent genes. The
classifiers succeeded in 80% of the tissues with a smallest prediction error of 35%. The
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TFBS clusters were formed by combining immediately adjacent two or three binding
sites (135).
Chromatin structure data, including histone modifications (HMs) (e.g. H3K4me3,
H3K9me3 and H3K27me3) and DNase I hypersensitivity, were also used to predict
tissue-specific absolute gene expression levels (133, 134, 136, 138, 139). Similarly, the
feature of a gene for a histone marker was defined as the sum of signal values of ChIPseq peaks of the marker within a fixed-length interval around the TSS.
These studies found that chromatin structure is statistically redundant with TF binding in
explaining tissue-specific mRNA transcript abundance at a genome-wide level, which
was attributed to the heterogeneous distribution of HMs across chromatin domains (134).
Combining these two types of data explained the largest fraction of variance in gene
expression levels in multiple cell lines (133, 134), suggesting that either contributes
unique information to gene expression that cannot be compensated for by the other.
These previous studies successfully related TF binding profiles and chromatin structure
data to gene expression levels. However, they have several limitations:
1) Because signal values of ChIP-seq peaks are not strictly proportional to TFBS
strengths contained in the peaks (2), representing TF binding strengths by ChIP-seq
signals may not be appropriate.
2) The clustering algorithm used in (135) arbitrarily limits the number of binding sites
contained in a module, which is inflexible. It does not consider the information densities
of binding sites and clusters either.
3) When detecting TFBSs the PWMs in (135) are used to compute log likelihood ratio
scores which are not Shannon information theory-based. These scores are not
quantitatively related to the amount of dissipated heat energy by Equation 1.6, so that
they are unable to quantify binding site strengths as accurately as 𝑅𝑖 values.
4) The machine learning models in (135) are tissue-specific; each of the 56 tissues has a
different classifier trained from genes expressed in the specific tissue. Thus each
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classifier can only be applied to one single tissue, resulting in an excess of
ungeneralizable models.

1.7 Prediction of Transcription Factor Target Genes
As described above, TF binding to target sites in the promoter results in the effective
regulation of the gene expression level; however, not every binding event can alter the
expression level. Cusanovich et al. (140) found that the number of genes directly bound
by a TF significantly exceeds the number of genes whose expression levels significantly
change upon knockdown of the TF. They performed siRNA-based knockdown
experiments of 59 TFs in the GM19238 cell line, and measured the changes in the
expression levels of 8,872 genes. They also indicated whether the promoters of these
genes display evidence of binding to TFs by intersecting with ChIP-seq peaks in the
GM12838 cell line, and observed that only a small subset of genes whose promoters
overlap ChIP-seq peaks were differentially expressed (DE) after TF knockdown (140).
Similarly, by perturbing expression of 10 TF genes with the CRISPR technique in K562
cells and performing single cell RNA sequencing, the regulatory effects of each TF on
22,046 genes were dissected with a regularized linear computational model (141), which
accurately revealed DE targets and new functions of individual TFs.
Using the siRNA-generated knockdown data as the gold standard, correlation between
TFBS counts and gene expression levels across 10 different cell lines were found to be
more predictive of DE targets than setting a minimum threshold on TFBS counts (142).
Machine learning classifiers have also been applied in a small number of gene instances
to predict targets of a single TF using features extracted from n-grams derived from
consensus binding sequences (143), or from TFBSs and homotypic binding site clusters
(125).
These previous studies successfully used TF binding data to predict TF target genes.
However, they also have a number of limitations.
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1) In the correlation-based approach (142), TFBS counts were defined as the number of
ChIP-seq peaks overlapping the promoter, though it was unknown how many binding
sites were present in these peaks.
2) In the correlation-based approach (142), positives might not be direct targets in the TF
regulatory cascade, as the promoters of these targets were not intersected with ChIP-seq
peaks.
3) The machine learning approaches (125, 143) were applied on a small scale, rather than
on the genome-wide set of target genes of multiple TFs identified from knockdown
experiments.
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Chapter 2

2

Thesis Overview

In this chapter, we will describe the objectives of this thesis, our methods to achieve these
objectives, and the motivations for our methods.

2.1 Thesis Objectives
The objective of this thesis is to improve the current computational modelling of the
transcriptional regulation of human genes. The ultimate goal of the transcriptional
regulation is to mediate the accurate regulation of expression levels of TF target genes
through the underlying physical interactions between TFs and their binding sites. Thus
we dissected the transcriptional regulation into three levels; the lowest level is the
individual binding site and its association with the TF protein, the intermediate level is
the TFBS cluster and the cooperation between individual sites within it, and the highest
level is the promoter and the cooperation between individual clusters within it.
Accordingly, we dissected the objective into five sub-objectives on these three levels.
The two sub-objectives on the lowest level are to improve the derivation of TFBS motifs
from ChIP-seq datasets, and to improve the detection of TFBS variants related to
hereditary breast and ovarian cancer (HBOC) and the prediction of their effects using the
iPWMs derived from these binding site motifs. The sub-objective on the intermediate
level is to improve the modelling of the relationship between individual binding sites and
the cluster in terms of composition and variation. The two sub-objectives on the highest
level are to improve the modelling of the relationship between individual clusters and the
promoter in terms of composition and variation, and to improve the prediction of gene
expression patterns and TF target genes.

2.2 Our Methods
We proposed to conduct the following Study 1 to achieve the first sub-objective on the
lowest level, Study 2 to achieve the second sub-objective on the lowest level, and Study 3
to achieve the remaining three sub-objectives.
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1) In Chapter 3, when initially analyzing ChIP-seq datasets with Bipad, we noticed that it
may return cofactor or noise motifs instead of primary motifs. This is attributable to the
fact that Bipad was originally designed to analyze bacterial genomes, which contain few
low-complexity sequences in contrast with human genomes. Thus we first aimed to
improve the ability of Bipad to reveal primary motifs from human ChIP-seq datasets by
recursively masking motifs found in previous iterations to discover additional conserved
motifs from the same dataset, resulting in the Maskminent software. In the Maskminent
motif discovery pipeline, we further sought to improve the detection of primary motifs
and obtain the most accurate iPWMs by using the half-interval search to find the
minimum threshold peak strength for inclusion of the maximum number of top peaks that
can produce the primary motif. By applying the pipeline to ENCODE ChIP-seq peak
datasets, we expected to obtain the iPWMs for sequence-specific TFs that enable
prediction of TFBSs and mutation analyses on TFBS variants, and proposed to evaluate
the accuracy of these iPWMs by detecting experimentally confirmed binding sites and
explaining effects of experimentally characterized SNPs. We also expected to discover
cofactor motifs, which support new TF-TF interactions and complexes.
2) In Chapters 4 and 5, we aimed to apply the iPWMs from Study 1 to detect TFBS
variants in genes harboring known mutations that increase the risk of HBOC. We sought
to prioritize these variants based on the extent of changes in the 𝑅𝑖 values of binding sites
caused by them.
3) In Chapter 6, we sought to apply the Bray-Curtis similarity metric to measure the
similarity between genes in the tissue-wide expression profile. We further sought to
develop a general machine learning framework that predicts genes with similar tissuewide expression profiles to a given gene and predicts DE direct TF targets by combining
information theory-based TF binding profiles with DNase I hypersensitive regions. We
sought to derive TF binding features from clusters detected by the IDBC algorithm from
iPWM-detected TFBSs that can effectively capture the spatial organization and
informational composition of these clusters in the promoter. We also proposed to perform
mutation analyses on promoters of target genes to investigate the downstream effects of
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TFBS variants on information-dense clusters, the regulatory state and expression level of
the gene.

2.3 Motivations for Our Methods
The methods proposed above aimed to overcome the limitations of the previous studies
experimentally and computationally deriving TFBS motifs that were respectively
described in Sections 1.3.1 and 1.3.2.3 of Chapter 1. Specifically, we sought to overcome
Limitation 1 of both experimental and computational approaches by the fact that Bipad is
capable of deriving bipartite binding site motifs from ChIP-seq datasets and generating
bipartite iPWMs to accurately describe the binding behavior of dimeric TFs. We sought
to avoid Limitations 2 and 3 of experimental approaches by the use of ChIP-seq datasets.
We also sought to overcome Limitation 2 of computational approaches by analyzing the
maximum number of top peaks that can produce the primary motif above the minimum
threshold peak strength found by the half-interval search, Limitation 3 by the fact that
Bipad is able to generate iPWMs, and Limitation 4 by the fact that Bipad does not rely on
the background nucleotide composition and will always return the lowest-entropy motif.
The methods proposed above also aimed to overcome the limitations of the previous
studies predicting gene expression levels and TF target genes that were respectively
described in Sections 1.6 and 1.7 of Chapter 1. Specifically, we sought to overcome
Limitation 1 of the prior studies predicting gene expression levels by the direct use of 𝑅𝑖
values of binding sites, Limitation 2 by the use of the IDBC algorithm, Limitation 3 by
the use of iPWMs, and Limitation 4 by the definition of the tissue-wide gene expression
profile and application of the Bray-Curtis similarity measure. We also sought to
overcome Limitation 1 of the prior studies predicting TF target genes by the direct use of
iPWM-detected TFBSs, Limitation 2 by the fact that positives are direct targets whose
promoters overlap tissue-specific ChIP-seq peaks, and Limitation 3 by the use of
CRISPR- and siRNA-generated knockdown data.
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Chapter 3

3

Discovery and Validation of Information Theory-based
Transcription Factor and Cofactor Binding Site Motifs

The work presented in this chapter is reproduced from:
Lu,R., Mucaki,E.J., Rogan,P.K. (2017) Discovery and validation of information theorybased transcription factor and cofactor binding site motifs. Nucleic Acids Research,
45(5): e27

3.1 Introduction
Transcription factors (TFs) interact with regulatory elements in genes to mediate positive
or negative regulation of tissue- and stage-specific expression (1, 2). TFs either directly
bind to DNA by recognizing specific sequence motifs, or indirectly interact as partners
(or cofactors) of sequence-specific TFs (3). Interactions between these two types of TFs,
as well as between sequence-specific TFs, abound across the whole genome (3, 4). For
instance, NF-Y extensively coassociates with FOS over all chromatin states, and CTCF
extensively colocalizes with cohesins consisting of SMC1/SMC3 heterodimers and two
non-SMC subunits RAD21 and SCC3 (5, 6). The genome-wide distributions of both
types of bound TFs have been analyzed by sequence analysis of immunoprecipitated
chromatin (ChIP-seq) (7). ChIP-seq can identify the repertoire of binding site sequences
in a genome, and often pull down binding sites of coregulatory cofactors.
Sequence-specific TFs either recognize contiguous sequence motifs, or form
homodimeric or heterodimeric structures that contact half sites separated by gaps that
together comprise bipartite binding sites (8). Although generally the binding sequences of
TFs are well conserved, significant variability at most positions of their binding motifs
characterizes most TFs. Information theory-based position weight matrices (iPWMs) can
quantitatively and accurately describe these base preferences. A contiguous iPWM is
derived from a set of aligned binding sites using Shannon information theory and a
uniform background nucleotide composition (9, 10). This approach may be more
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appropriate for defining binding sites than Relative Entropy because the contacts between
the TF and the nucleotides do not depend on the background genomic composition (10,
11). A bipartite iPWM consists of two contiguous, adjacent iPWMs, each corresponding
to a half site, separated by a range of sequence gaps. The individual information content
(𝑅𝑖 ) of a TF-bound sequence, which represents the affinity of the TF-DNA interaction, is
the dot product between the binary matrix of the sequence and an iPWM of the TF (10).
The 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 value of an iPWM is the mean of the 𝑅𝑖 values of all the binding site
sequences used to compute the iPWM, and represents the average binding affinity (12).
Our laboratory previously developed the Bipad software to generate bipartite (and
contiguous) iPWMs from ChIP-seq data (8).
TF binding motifs have been derived from both experimental evidence and computational
approaches. Weirauch et al. (13) measured TF binding by octanucleotide microarrays to
infer sequence specificity from overlapping bound sequences for >1,000 TFs
encompassing 54 different DNA binding domain (DBD) classes. Jolma et al. (14)
obtained 830 binding profiles representing 411 human and mouse TFs using highthroughput SELEX and ChIP sequencing. The oligonucleotide-based approach does not
account for variable-length spacers in bipartite binding sites, and it may reconstruct
potentially incorrect motifs that cannot be discriminated from correct binding site
sequences. In addition, the set of octamers used in the DNA microarrays may not cover
all possible binding site sequences (>8 nucleotides [nt]) recovered in the genome from
ChIP-seq, and there is no way to discover potential binding sites from TF cofactors.
Wang et al. (3) carried out de novo motif discovery for 119 human TFs from 457 ChIPseq datasets using the MEME-ChIP software suite, and Kheradpour et al. (15) provided a
systematic motif analysis for 427 ChIP-seq datasets of 123 human TFs using five motif
discovery tools. However, these studies did not generate bipartite motifs with half sites
separated by gaps varying in length; more importantly, the derived motifs were only
based upon strongest ChIP-seq signal peaks (top 500 or 250 peaks), effectively
eliminating thousands of intermediate or weak binding events and biasing the resulting
iPWMs toward high-affinity, consensus-like binding sites. This is necessary, as the
sequences contained in the weakest ChIP-seq peaks may contribute low-complexity,
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likely non-functional sequences (i.e. noise) that can obfuscate the detection of true
binding motifs. Extreme peak selection bias in the population of sites distorts the binding
strengths estimated for individual sites (16).
We developed a motif discovery pipeline, Maskminent, by integrating recursive masking
and thresholding the maximum number of ChIP-seq peaks into an entropy minimization
framework. Bipad was modified to incorporate these features, and TF binding motifs
were derived and validated for 765 ENCODE ChIP-seq datasets (1275 replicates)
consisting of 207 human TFs. 93 primary and 23 cofactor binding motifs were
successfully recovered and refined for 127 TFs. Reanalysis of the same data using the
masking and thresholding techniques revealed many known and previously unreported
TF cofactors; however, frequently our approach revealed cofactor motifs directly. These
primary motifs were validated by comparing predicted with experimentally-detected true
binding sites, explaining effects of characterized SNPs on binding site strengths, and
through comparisons to an independent motif database.

3.2 Materials and Methods
3.2.1

ENCODE ChIP-seq datasets

The ENCODE Consortium conducted ChIP-seq assays for human TFs and generated
initial peak datasets for each replicate of each assay using a uniform peak calling pipeline
(7, 17). For some assays, these analyses produced optimal and conservative IDRthresholded peaks after applying the IDR (Irreproducible Discovery Rate) framework to
the initial datasets to improve consistency of motifs obtained from multiple biological
replicates. In addition, Factorbook (3, 18) also reports motifs from refined datasets
(limited to the top 500 peaks) generated by the SPP peak calling software (19).
We started with the IDR-thresholded peak datasets, because we found that these data are
more likely to produce primary or cofactor motifs than the initial (i.e. unprocessed)
datasets; they contain greater numbers of ChIP-seq peaks (and thus more binding sites)
than the truncated SPP datasets. The initial, unfiltered datasets were examined if neither
IDR-thresholded nor SPP datasets were available.
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3.2.2

The Maskminent motif discovery pipeline

Initially, iPWMs from ChIP-seq reads were derived by entropy minimization with Bipad
(Appendix B.1). However, we noted that these iPWMs sometimes exhibited cofactor or
noise motifs, rather than the expected primary motifs. In order to improve detection of
primary motifs, the Maskminent software, which implements a generalization of the
objective function used in Bipad, enables new motif discovery by recursively masking
sequences detected by previous analyses of a ChIP-seq dataset while defining thresholds
for inclusion of the maximum number of top peaks to eliminate peaks with lower signal
intensities whose inclusion can result in emergence of noise over primary or cofactor
motifs (Appendix B.1). Multiple ChIP-seq datasets from distinct cell lines for the same
TF, if available, were examined for enriched sequence motifs to assess whether this
approach was reproducible, and discover tissue-specific sequence preferences between
these sources.
This masking technique, which contrasts with the likelihood approach used by MEME
(20), provides a means of discovering additional conserved motifs adjacent to primary TF
binding sites within the same datasets. The sequences detected by motifs found in
previous iterations are masked and the next lowest entropy motif is derived. The
coordinates of all the predicted binding sites in a dataset scanned with prior iPWMs are
recorded and skipped in the subsequent reanalysis. The specified parameters include the
length of the motif, number of Monte Carlo cycles used in entropy minimization, a motif
masking file for recursion, and for bipartite binding sites, the lengths of the left and right
motifs and the gap length range between the half sites (Appendix B.1). Once a motif is
generated, another program, Scan, is used to detect binding sites in a DNA sequence and
determine their respective information contents, or binding strengths.
To eliminate noisy patterns that suppress the expected TF binding motifs due to ChIP-seq
peaks with low signal strengths (i.e. read counts), the dataset is truncated based on signal
strengths as follows (Figure 3.1). First, all the peaks are ranked in the descending order of
strengths, and the top 200 peaks are selected. If the iPWM derived from the top 200
peaks exhibits the primary/cofactor motif, then the minimum threshold peak strength is
contained within the range from the strength of the 200th peak (i.e. the initial value of G)
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Figure 3.1: One iteration of the half-interval search used to refine the threshold
peak strength. All peaks in the dataset are sorted in the descending order of signal
strengths. 𝑺 is the smaller bound of the current range containing the minimum threshold
that can generate the primary/cofactor motif, and 𝑮 is the greater bound (i.e. the current
threshold). 𝑮 and 𝑺 are respectively initialized to the strength of the 200th peak and the
strength of the last peak. 𝑴 is the strength of the peak at the mean (rounding to the
nearest multiple of 500) of the number of top peaks above 𝑮 and the number of top peaks
above 𝑺. 𝒊𝑷𝑾𝑴𝑮 , 𝒊𝑷𝑾𝑴𝑺 , 𝒊𝑷𝑾𝑴𝑴 are respectively the iPWMs derived from the top
peaks above 𝑮, 𝑺, 𝑴. 𝒅(𝒊𝑷𝑾𝑴𝑮 , 𝒊𝑷𝑾𝑴𝑴 ) is the Euclidean distance between 𝒊𝑷𝑾𝑴𝑮
and 𝒊𝑷𝑾𝑴𝑴 , and 𝒅(𝒊𝑷𝑾𝑴𝑺 , 𝒊𝑷𝑾𝑴𝑴 ) is the Euclidean distance between 𝒊𝑷𝑾𝑴𝑺 and
𝒊𝑷𝑾𝑴𝑴 . If 𝒅(𝒊𝑷𝑾𝑴𝑮 , 𝒊𝑷𝑾𝑴𝑴 ) is greater than 𝒅(𝒊𝑷𝑾𝑴𝑺 , 𝒊𝑷𝑾𝑴𝑴 ), 𝒊𝑷𝑾𝑴𝑴
exhibits the noise motif and the minimum threshold is contained in the subrange from 𝑮
to 𝑴; if 𝒅(𝒊𝑷𝑾𝑴𝑮 , 𝒊𝑷𝑾𝑴𝑴 ) is smaller than 𝒅(𝒊𝑷𝑾𝑴𝑺 , 𝒊𝑷𝑾𝑴𝑴 ), 𝒊𝑷𝑾𝑴𝑴 exhibits
the primary/cofactor motif and the minimum threshold is contained in the subrange from
𝑴 to 𝑺. When the number of peaks contained in the range does not exceed 500, this halfinterval search is stopped. The approximately minimum threshold that is returned is 𝑮 of
the final range.

58

to the peak with the weakest signal (i.e. the initial value of S). A half-interval search
iterated over sets of progressively weaker peaks narrows this range until the number of
peaks contained in the range is ≤500. The value of G is the threshold peak signal strength
above which the top peaks can still produce the primary/cofactor motif. The minimum
threshold obtained for G (i.e. the final value of G) defines the approximate peak set
containing the maximum number of top peaks that can produce the primary/cofactor
motif.

3.2.3

Binding site motif validation

The methods used to evaluate the accuracy of our iPWMs include:
1) To detect experimentally proven binding sites in known target genes, derived iPWMs
were used to evaluate the 𝑅𝑖 value of each site;
2) To predict changes in binding site strength, characterized variants were evaluated with
the corresponding iPWMs. The predicted changes were compared with experimentally
supported effects on TF binding or gene expression;
3) The iPWMs were compared with the corresponding annotated motifs in the CIS-BP
database (13) based on their normalized Euclidean distances;
4) To distinguish true binding motifs from noise motifs, we delineated the relationship
between 𝑅𝑖 values of binding sites discovered by the iPWM and their corresponding
binding energy (i.e. higher 𝑅𝑖 values have lower binding energies) (Appendix B.1).
Primary/cofactor motifs are expected to demonstrate this relationship, whereas noise
motifs are not; that is, for primary/cofactor motifs, the linear regression fit between 𝑅𝑖
values and binding energy are expected to have slopes well below 0 which is the
expected slope for noise motifs. After applying F-tests to evaluate this relationship, F
values for the two categories of motifs were compared using a Mann-Whitney U test.

3.3 Results
The derived iPWMs displayed primary motifs for 93 TFs (Appendix B.2), as well as 23
cofactor motifs for 127 primary TFs (Appendix B.3). We also describe 6 high-confidence
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novel motifs that have not been previously annotated in these ChIP-seq data (Appendix
B.4).
The initial iPWMs directly exhibited primary motifs for 76 TFs and 18 cofactor motifs
for 107 primary TFs. Thresholding the datasets revealed 31 primary motifs and 14
cofactors for 38 primary TFs. We used the masking technique to discover an additional 4
primary motifs; 7 cofactor motifs were also found in 21 datasets (Appendix B.2&B.3).
For each TF ChIP-seq dataset with a derived primary motif (n=367), we determined the
false positive detection rate from the null 𝑅𝑖 distribution, which is approximately
Gaussian (12). The iPWM was used to scan for binding sites in a random 10,000
nucleotide sequence that conserved the mono- and dinucleotide composition as the
dataset (Appendix B.2). The means of all null distributions range from -97.5 to -12.3 bits
with standard deviations from 6.9 to 22.5 bits. The probabilities of observing a potentially
functional binding site, i.e. with 𝑅𝑖 >0, in these sequences range from 1.2E-7 to 0.06.
Similarly, the independence of contributions of each position in a binding site to the
overall information content was analyzed for one iPWM of each primary motif. The total
mutual information, which measures the interdependence between individual positions in
the same binding site, was determined by summing the pairwise mutual information at
each position (Appendix B.2). Then, the percentage of the total mutual information
relative to the average information, 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 , was determined. For 83 TFs (~89.2%),
<10% of the information present in the iPWM is dependent, and for 62 TFs (~66.7%),
<5% is dependent. Neglecting the interactions between positions introduces a minimal
error into the calculation of 𝑅𝑖 values of binding sites, and would be expected to have
little impact on assessment of the mutations in these sequences.

3.3.1
3.3.1.1

Primary binding motifs
Contiguous iPWMs

Correct iPWMs were successfully derived for 65 TFs with contiguous binding motifs,
which are concordant with published descriptions of these motifs (3). All of these motifs
can be characterized as degenerate and do not correspond to published consensus
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sequences. Consensus sequences miss TF binding sites of weak or intermediate strength
(16). We determined the frequencies of such sequences appearing on a genome scale for
10 TFs by counting the peaks containing these sequences in their respective datasets
(Figure 3.2 - panel A). Surprisingly, only 0.015%-7.3% of all peaks contain binding sites
with these sequences, demonstrating that these sites are extremely rare in ChIP-seq
datasets. Thus, intermediate and low-affinity TF-DNA interactions are the most prevalent
in vivo and are able to regulate gene expression (21).

3.3.1.2

Bipartite iPWMs

For 19 TFs, bipartite iPWMs were successfully derived, and were in agreement with
previously reported motifs. The following examples illustrate key insights that can be
taken from bipartite modeling:
1) El Marzouk et al. (22) demonstrated that ESR1 is able to recognize binding sites with
half sites separated by nucleotide spacer lengths from 0 - 4nt, in which sites containing a
3nt spacer are most common and have the highest binding affinities. We allowed the
spacer length to vary from 0 to 5nt in bipartite iPWMs derived from the T47D cell line
data. The resultant iPWMs show the documented predominant sequences and are
palindromic. The bipartite iPWM exceeds the average information content of the
corresponding contiguous iPWM prepared from the same dataset, and the dominant gap
between half sites is 3nt (Figure 3.2 - panel B). Nevertheless, 333 binding sites (~9%) in
this iPWM exhibit a 5nt spacer, implying that ESR1 may be capable of binding to sites
that were not previously detected. The symmetry between the half sites exhibited by the
bipartite iPWMs suggests that dimeric ESR1 may bind a narrow range of sequences with
similar half site affinities.
2) The palindromic predominant sequence of the AP2 family is 5’-GCCN3GGC-3’, and
other binding sequences confirmed in an in vitro binding-site selection assay include 5’GCCN4GGC-3’ and 5’-GCCN3/4GGG-3’. Another binding site 5’-CCCCAGGC-3’ was
also found in the SV40 enhancer (23). The spacer lengths in the bipartite iPWMs for
AP2A and AP2C range from 2 – 4nt, which is representative of the genome-wide pool of
true binding sites (Figure 3.2 – panel B). We also noted that the two outermost positions
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are the most variable, and that adenine (instead of the consensus guanine) can also appear
at the first position of the right half site. These bipartite iPWMs exhibit similar
conservation levels across all the individual positions, suggesting that these binding sites
of the two AP2 members may exhibit similar degrees of binding affinity, though iPWMs
can recognize different sequences.
3) The predominant spacer length separating half sites recognized by STAT1 is 3nt;
however, previous reports describe sites with a 2nt gap, but not those separated by 4nt
(24). However, the STAT1 bipartite iPWM is based on 1709 binding sites (~18%) with a
4nt spacer, with most half sites separated by 2 or 3 nt (Figure 3.2 – panel B). The leftand rightmost nucleotides are nearly invariant, whereas the inner 2 nucleotide contacts in
each half site are variable.
4) NFE2 and BACH1 heterodimerize with the MAF family (MAFF, MAFG and MAFK),
and recognize two types of bipartite palindromic motifs, defined by the predominant
binding sites TGCTGA(C)TCAGCA and TGCTGA(CG)TCAGCA (25). The previously
reported binding motifs (3) are contiguous, and do not account for the dimeric interaction
that gives rise to this bipartite binding pattern. The bipartite iPWMs indicate that the
inner 6 positions surrounding the dominant 1nt spacer exhibit higher information contents
than the outer 6 positions (Figure 3.2 – panel B).

3.3.1.3

Comparing iPWMs for the same TF in distinct cell lines

Cell-type-specific differences between iPWMs of the same TF were evident for certain
contiguous and bipartite motifs. For instance, among the three contiguous iPWMs of
ESR1 derived from the ECC1 steroid-responsive endometrial cell line, conservation
levels in the respective half sites are asymmetric, whereas the average information of
these half sites are much more symmetric in iPWMs derived from T47D, a breast tumor
cell line (Figure 3.3 – panel A). For the TFs MAFF and MAFK, the discrepancy between
the bipartite iPWMs from K562 and HepG2 cells is evident: the outer 6 positions show a
greater degree of conservation than the internal 6 positions in HepG2, but in K562 the
opposite trend is illustrated (Figure 3.3 – panel A). The MAFK iPWM derived from
ChIP-seq data of IMR90 cells resembles the HepG2 iPWMs, whereas the iPWMs from
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Figure 3.2: Sequence logos of contiguous (A) and bipartite (B) iPWMs. The TF name, and the cell line from which the iPWM was
derived, and the number of binding sites that the iPWM is based upon are displayed. In (B), each of the first four rows includes a
contiguous (left) iPWM and a bipartite (right) iPWM of one TF from the same dataset. The last row includes the bipartite iPWMs of
NFE2 and BACH1. The bipartite search patterns, which are denoted by l<a,b>r (l and r are the lengths of the left and right half sites
respectively, a and b are the minimum and maximum spacer lengths respectively), are 6<0,5>6, 3<2,4>3, 3<2,4>3, 3<2,4>3, 6<1,2>6
and 6<1,2>6 from top to bottom, respectively.

63

Figure 3.3: Comparison between iPWMs from different cell lines and novel motifs. (A) Each row includes sequence logos of two
iPWMs of the same TF from two different cell lines. The bipartite iPWMs for MAFF and MAFK used the search pattern 6<1,2>6. (B)
The high-confidence novel motifs (“NM1” – “NM6”). The logos of the NM1, NM2 and NM3 motifs come from the datasets of
BAF155, NANOG and ESRRA, respectively.
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HeLa-S3 and H1-hESC datasets resemble the K562 iPWMs. The compositions of binding
sites (i.e. different target genes for the same TF in different tissues) account for these
differences because TFs can display distinct cell-type-specific DNA sequence
preferences (26). Consistent iPWMs between replicate datasets makes it unlikely that the
skewed base conservation between ChIP-seq datasets for the same TF in different cell
lines arises from sampling differences; however, this possibility cannot be excluded.

3.3.2

Cofactor binding motifs

Discovery of the binding motif of a cofactor in the same ChIP-seq dataset for a primary
TF implies that the two TFs transcriptionally co-regulate this set of common target genes.
This could be accomplished either by formation of a physical complex on the promoter,
or by synergistic or antagonistic cis-regulatory effects. De novo motif discovery from
ChIP-seq datasets provides an effective approach for confirming or predicting statistically
significant TF interactions on a genome-wide scale; by contrast, the abundant, existing
literature overwhelmingly documents gene-by-gene evidence about such interactions
which constrains arguments supporting their generalizability. Figure 3.4 illustrates TFcofactor interactions revealed by the Maskminent pipeline.

3.3.2.1

Confirmation of known cofactors

The derived iPWMs confirmed genome-wide interactions between 22 cofactors and 102
primary TFs (Table 3.1), which were supported by the previous studies (3, 5, 6, 15, 2793) . For example, the interaction between SP1 and multiple members of the ETS and
AP1 families has been well characterized (94–99). ELK1 and SRF can recruit each other
to form a ternary complex on CArG-ETS elements (100). TEAD-AP1 cooperation with
SRC coactivators drives downstream gene transcription to regulate cancer cell migration
and invasion (101), and STAT1, STAT2 and IRF9 form a heterotrimer that regulates
transcription of genes containing IFN-stimulated response elements (ISREs) (102).
Consistent with previous reports (15), the existence of a YY1-THAP1 complex is
predicted from co-segregation of their binding motifs in the K562 dataset of THAP1.
Similarly, we predict that the SOX2-OCT4 complex colocalizes with BCL11A, similar to
Wang et al (3). A DNA-binding complex consisting of GATA1, TAL1, E2A, LMO2 and
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Figure 3.4: Network graph of TF-cofactor interactions revealed by the Maskminent pipeline. A yellow ellipse denotes a cofactor
and a white ellipse denotes a primary TF. A hexagon denotes a TF family with dash lines connecting its members. For a TF family
only members for which ENCODE provides peak datasets are shown. A red rectangle denotes a known or predicted TF complex with
black or blue dotted lines indicating its components, respectively. An undirected line denotes the interaction between a primary TF
and a cofactor which may be a complex or a TF family. A directed line links two cofactors, denoting that in a dataset of the starting
TF, the ending TF was discovered as a cofactor. Black lines denote known interactions and blue lines denote the newly discovered
interactions.
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Table 3.1: Cofactors revealed by iPWMs and their corresponding primary TFs
Primary TFs*
Cofactors
Sequence-specific
AP1

GATA2, MYC, SRF, STAT3, TEAD4

CEBPB
CTCF
ETS family

Non-sequence-specific
BAF155, BAF170, BCL3, BRG1, P300
P300

ZNF143

RAD21, SMC3

MAX, SRF1, TR4

DIDO12

GATA family RUNX12

BRG12, SIRT62

GATA1-TAL1 NR2F22, STAT5A2, TAL12, TEAD42

P3002, PML2, RCOR12, TBL1XR12

FOXA family ARID3A3, GATA3, GATA43, NFIC3, TCF123, TEAD43

HDAC23, MBD43, P300

HNF4 family

SP13
PGC1A3

HSF family
IRF family

ATF12, BCL11A1, CEBPB1, CREM1, ETV61, FOXM11, FOXP2, IKZF11, EED1, EZH21, MTA31, P3001,
MEF2A1, MEF2C1, NFE21, NFKB1, OCT21, RUNX31, STAT12, STAT22, TBL1XR11
STAT31, STAT5A1, TCF71, ZBED11
KDM5A4

NFKB
NFY

FOS, IRF3

NRSF

SP23, TEAD4

SIN3A4
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RUNX family BCL11A1, CEBPB1, IRF41, MEF2A1, MEF2C1
SP family

EED1, P3001

ATF24, ATF3, CEBPD3, CREB1, CREM1, DEAF12, E2F1, E2F4, E2F6,

BCLAF1, BRCA1, CBX13, CCNT22,

ELF1, ELK1, ETS1, FOS, FOSL14, FOXP2, GABPA, GATA43, IRF12,

CHD1, CHD2, DIDO12, EZH2,

IRF3, JUND, KLF132, MAX, MITF2, MXI1, MYC, NFE21, NFKB1,

GTF2B2, HDAC12, HMGN32, INI1,

NFYA, NRF1, NRSF3, OCT21, PAX51, PBX3, RFX5, SMAD5, SREBF13, KAT2A, KDM5B2, P3004, PHF82,

SOX2

SREBF23, SRF, STAT11, SUZ12, TBP, TCF4, TCF72, THAP12, TR4,

PML, RBBP5, RCOR13, RPB1,

UBTF2, YY1, ZBED12, ZBTB33, ZBTB7A2, ZHX23

SAP302, SIN3A, TAF1, TAF7

NANOG4

SOX2-OCT4

BCL11A4, OCT44

TEAD family

GATA2, MYC, STAT3

TFIIIC
YY family

HSF13, TBP, TCF12

BDP1, BRF1, RPC155, RPC32

CREB32, IRF92, PTTG12, TEAD22, THAP12

DDX202, ID32, ILK2, KDM5A4,
PTRF2, PYGO22, TAF72

USF

ATF3, NFE21

ZBTB33

ETS11

BRCA1

ZNF143

ETS1, DEAF12

SIX5

* The underlined or normal font denotes known or newly discovered interactions between cofactors and primary TFs, respectively.
1,2,3,4

The cofactor was revealed in the GM12878-related, K562, HepG2 or H1-HESC cell lines, respectively. Otherwise the cofactor

appeared in other or multiple cell lines.
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LDB1 is present in the erythroid cell lineage (103). Based on the proximity and
coprecipitation of these binding sequences, we and others (3, 104) find that this complex,
in which GATA1 and TAL1 contact DNA, coordinately binds with TEAD4 and other
non-DNA binding proteins (P300, PML, RCOR1 and TBL1XR1). The GATA1-TAL1
and SOX2-OCT4 complexes emerged from the datasets of TAL1 and OCT4 as primary
motifs, respectively, which implies the formation of the two complexes being necessary
for binding of TAL1 and OCT4.

3.3.2.2

Discovery of novel cofactors

Maskminent revealed a number of previously unrecognized cofactor motifs (n=10) for 46
primary TFs (Table 3.1), which supports novel TF cobinding and interactions. This
includes possible associations between the IRF and RUNX families, and their further
cooperation with BCL11A, MEF2A, MEF2C, CEBPB, EED and P300 in GM12878 cells
(Table 3.1; Figure 3.4). Similarly, the TEAD-AP1 complex is predicted to recruit MYC,
STAT3 and GATA2 in multiple cell lines. The finding that NR2F2 and STAT5A motifs
are in close proximity to sequences recognized by the GATA1-TAL1 complex suggests
these factors may coordinately regulate target genes. Many cofactors were also
discovered among datasets of non-sequence-specific primary TFs, which is consistent
with the possibility that these primary TFs are recruited to gene promoters through their
association with DNA-binding cofactors (Table 3.1).

3.3.2.3

Cofactor binding sites

To validate the predicted cobinding between cofactors and primary TFs, we determined
the intersite distance distributions by scanning the individual ChIP-seq intervals with the
derived iPWMs for each (Figure 3.5; Appendix B.5). A minimum information threshold
was applied to the 𝑅𝑖 values of predicted binding sites in order to remove the relatively
large number of weak binding sites that are likely to be low-complexity sequences (e.g.
𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 [or 0.5 * 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 , if too many cofactor binding sites were eliminated at the
higher threshold]). The SOX2-OCT4 complex was used as a primary negative control, as
it is primarily expressed in the H1-hESC cell line and is unlikely to be a cofactor for
primary TFs in other cell lines. A large percentage of peaks have short intersite distances
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Figure 3.5: Distributions of intersite distances between primary TFs and discovered
cofactors versus negative controls. The minimum threshold on information contents of
predicted binding sites is 𝑹𝒔𝒆𝒒𝒖𝒆𝒏𝒄𝒆 . Each graph illustrates a much higher frequency of
short (< 20nt) intersite distances between primary TFs and cofactors (blue) compared to
the negative control (SOX2-OCT4; red).
between the primary TF and the corresponding cofactor binding sites (e.g. <20nt),
whereas there is no such a trend for the negative control sequences and the primary TF.
The same difference is observed between the distribution for the documented TEAD4AP1 pair and for the negative control. Consistent with previous reports (4), the binding
sites of cofactors and primary TFs in peak datasets were physically overlapped between
the IRF and RUNX motifs, between the TEAD4 and AP1 motifs, and between USF and
ATF3 (AP1) recognition motifs.

3.3.2.4

Tissue-specific preferences of predicted cofactors relative
to primary TFs

Several cofactors were recurrently associated with different primary TF partners, notably
in specific cell lines. One possible explanation is that these cofactors are coordinately
regulated with different primary TFs preferentially in specific cell types. For example, the
datasets of 25 primary TFs in which the IRF family was discovered as a cofactor were all
derived from lymphoblastoid (e.g. GM12878) cell lines, with 4 exceptions (Table 3.1).
Regulation by the IRF family is central to B-lymphocyte expression programs (105). All
the datasets of 11 primary TFs from which the GATA and GATA1-TAL1 motifs
emerged as cofactors were derived from K562 erythrocytic leukemia cells (Table 3.1),
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which is consistent with the activation role that the GATA family exhibits in
hematopoietic lineage gene expression (106, 107). Similarly, FOXA family members
bind to the same sequences as 7 primary TFs in the HepG2 cell line derived from
hepatocellular carcinoma cells (Table 3.1), which is consistent with the fact that FOXA
proteins regulate the initiation of liver development (108). Datasets of GATA3 and P300
from the T47D breast cancer cell line are also linked to FOXA. Another TF family
known to be a key factor regulating hepatocyte differentiation and liver-specific functions
is HNF4 (109), which was discovered as a cofactor of SP1 in a HepG2 dataset. SOX2 and
the SOX2-OCT4 complex were unveiled as cofactors only in datasets of 3 primary TFs
from the H1-hESC cell line representing embryonic stem cells (Table 3.1), which is
supported by the requirement for SOX2, OCT4 and NANOG to maintain pluripotency
(110). Interestingly, all the datasets (n=12) in which YY was revealed as a cofactor were
from K562 cells, with one exception (Table 3.1). Unlike the GATA TFs, the YY family
is ubiquitously distributed and not known to play an especially central role in erythroid
lineage development, although YY1 is known to act as a developmental repressor of the
ε-globin gene along with GATA1 (111).
Not surprisingly, the SP family was found to be capable of interacting with the maximum
number of TFs, which is consonant with its role in constitutive transcriptional activation.
Similarly, the ubiquitously expressed AP1 interacts with 10 TFs in multiple cell lines,
and these interactions do not show any preference in cell type.
A number of primary TFs exhibit an extensive capability of interacting with multiple
cofactors in different tissues. The unique distribution of these cofactors across multiple
cell lines suggests the tissue-specific functions of the primary TFs. For instance, TEAD4
was found to coimmunoprecipitate with GATA1-TAL1 in K562 cells, NRSF in A549
cells, FOXA in HepG2 cells, and AP1 in multiple cell types. Cofactors of P300 include
IRF-RUNX in GM12878 cells, SP in H1-hESC cells, AP1 and CEBPB in HeLa-S3 cells,
FOXA in HepG2 and T47D cells and GATA1-TAL1 in K562 cells. Cosegregation
analysis revealed interactions between BCL11A and IRF-RUNX in GM12878 cells, and
SOX2-OCT4 in H1-hESC cells. STAT5A and TBL1XR1 cosegregated with members of
the IRF family in GM12878 cells and with GATA1-TAL1 in K562 cells.
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3.3.2.5

Discordance between iPWMs derived from the same ChIPseq assay

We noticed some discrepancies between IDR-thresholded datasets and SPP datasets from
the same ChIP-seq assay. For example, for the primary TF BRG1, iPWMs exclusively
from SPP datasets exhibit motifs of GATA1 and AP1; IDR-thresholded BRG1 data
produced only noisy low information content motifs. We also noticed that the motifs
derived from different biological replicates of the same ChIP-seq assay were sometimes
inconsistent. One replicate of the TEAD4 ChIP-seq assay from the A549 cell line
revealed only the NRSF binding motif, whereas both the cofactor AP1 and the primary
motif were derived from the other replicate.

3.3.3

Novel binding motifs

We uncovered 6 high-confidence novel motifs that have not been previously annotated
(Figure 3.3 – panel B). The “NM1” motif was considerably enriched in the datasets of
BAF155 and BRG1 (which do not bind DNA directly) from HeLa-S3 cells and the
“NM2” motif was highly conserved in the datasets of BCL11A and NANOG from H1hESC cells. The “NM3” motif was revealed in the ESRRA and SREBF2 datasets from
GM12878 cells, in the MAX dataset from HCT116, in the CREB1 and GTF3C2 datasets
from K562, and in the non-DNA-binding RCOR1 dataset from IMR90 cells. The
Euclidean distances between these novel motifs and primary motifs are dissimilar,
ranging from 3.1 to 3.4 bits/nt. The “NM4”, “NM5” and “NM6” motifs were discovered
in the datasets of GATA3, MXI1 and FOSL1 from MCF-7, SK-N-SH, and H1-hESC
cells, respectively, with distances ranging from 2.9 to 3.4 bits/nt.
We investigated whether these novel motifs were enriched in hallmarks of open
chromatin, based on the co-occurrence with DNase I hypersensitive sites and near
H3K4me and H3K27ac histone modifications (112). After scanning the complete genome
with these iPWMs, the proportions of sites detected within these corresponding
ENCODE chromatin tracks were determined for the respective cell lines (Table 3.2).
These proportions (5%-35%) are consistent with previously reports of binding sites for
other TFs (113). The frequencies of sites detected with the NM2 and NM6 motifs within
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Table 3.2: Percentages of binding sites from novel motifs (NM) that overlap DNase I
hypersensitive intervals and/or regions of specific histone modifications
ENCODE Genome Browser Track
Novel motif

✝

DNase I HS

H3K4me1

H3K4me2

H3K4me3

H3K27ac

NM1✝

4.50%

17.63%

15.52%

16.23%

11.44%

NM2✝

7.06%

33.63%

14.39%

9.61%

34.05%

NM3✝

4.21%

21.19%

16.89%

13.75%

12.25%

NM4

3.18%

N/A*

N/A*

1.04%

2.22%

NM5

2.31%

N/A*

N/A*

1.21%

N/A*

NM6

6.16%

32.37%

13.58%

9.36%

34.10%

The iPWMs of the NM1, NM2 and NM3 motifs used to scan the hg19 genome

assembly come from the datasets of BAF155, NANOG and ESRRA, respectively.
* The histone modification data for the specific cell line used to derive the iPWM is
unavailable.
the H3K4me1 and H3K27ac peaks are significantly higher than those found after
intersection of each NM binding site with the H3K4me2 and H3K4me3 tracks,
respectively. The co-occurence of NM2 and NM6 with the H3K4me1 and H3K27ac
epigenetic marks supports the assignment of these motifs as components of
transcriptional enhancer elements, because these histone modifications are present in
nucleosomes flanking enhancer elements (114). Additionally, the co-occurence of these
two motifs within DNase I hypersensitive intervals exhibit the highest among all the 6
motifs. The remaining motifs could represent binding motifs of currently unknown TFs
or other non-annotated functional elements.

3.3.4
3.3.4.1

Binding site motif validation
Detection of true binding sites with iPWMs

803 experimentally-confirmed, previously published binding sites were verified for the
93 TFs whose primary binding motifs had been identified (Appendix B.6). We detected
these sites with the derived iPWMs by scanning promoters of known TF target genes for
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binding elements with positive 𝑅𝑖 values. There was complete concordance between
these true binding sites and those detected with the iPWMs, both in terms of their
locations and relative strengths. For example, an EMSA analysis of the SERPINA3
promoter proved that the nucleotide sequence starting at GRCh38 (chr14:94612260)
contains a stronger binding site of STAT1 than the one starting at GRCh38
(chr14:94612291) (Appendix B.6) (115); the binding site (5'-TTCTGGTAA-3' with 𝑅𝑖 =
9.02 bits; Row 781) detected by the bipartite iPWM is indeed 22.13 (or 4.38) fold
stronger than the other site (5'-TTCTCGGA-3' with 𝑅𝑖 = 6.89 bits; Row 782) detected in
this promoter.

3.3.4.2

Correspondence between functionally characterized SNPs
and changes in information content

Based on the change in the 𝑅𝑖 value of a binding site, the effect of a SNP on the binding
site strength can be predicted with iPWMs (10,12). For 153 SNPs within the binding sites
of 29 TFs, we determined 𝑅𝑖 values of the variant sequence for the corresponding iPWM
and compared the predicted consequence to observed TF binding, and if available,
published changes in expression (Appendix B.7). For 130 SNPs (~85.0%) affecting
binding sites of 27 TFs, the predictions of the iPWMs and the experimental observations
are completely concordant. For 16 SNPs (~10.5%) affecting binding sites of 10 TFs, the
predicted and observed experimental findings are concordant, but the extents of these
changes differ (e.g. TF binding is predicted to only be weakened, but binding or
expression was completely abolished). For 7 SNPs (~4.6%) altering binding sites of 3
TFs, the predicted and observed experimental changes were discordant. iPWMs for 2
(CEBPB and SP1) of these 3 TFs were validated for other SNPs.

3.3.4.3

Comparison between iPWMs and other binding motifs

Binding motifs of eukaryotic TFs in the CIS-BP database were previously reconstructed
from oligonucleotide binding selection assays (13); these motifs represent another type of
ground truth reflecting the genuine sequence preferences of these TFs. For 133 TFs, we
quantitatively compared the iPWMs with these motifs by determining the normalized
Euclidean distances between them, and classified the distances into three categories. We

74

observed that the iPWMs derived in this study and the reconstructed motifs are nearly
identical (<1 bit/nt) for 75 TFs, or only differ at 1 or 2 positions (1-2 bits/nt) for 18 TFs.
The discovery of cofactors was the predominant explanation for large distances (>2
bits/nt) for 39 of these TFs.

3.3.4.4

Statistical analyses on iPWMs

To distinguish true binding motifs from noise motifs, the relationship between 𝑅𝑖 values
and binding energy was evaluated by performing F tests on all binding sites in all of the
contiguous iPWMs that we derived (674 primary/cofactor, 312 noise). The F values are
plotted as a histogram to illustrate probability density distributions (Figure 3.6; data
available in Appendix B.2&B.3). The histogram shows that most F values between 0 and
100 were significantly enriched for noise motifs. In general, the F values of
primary/cofactor motifs significantly exceed those derived from noise. The
primary/cofactor motif and noise motif distributions are different (Mann-Whitney U test;
p = 3.1E-57 at 1% significance level). We note that only primary and cofactor motifs
exhibit F values >1000, which comprise 37.2% (251 of 674) of all iPWMs. The iPWMs
with F values <1000 remain valid based on the other criteria described above.

3.4 Discussion
In this study, we derived and validated TF binding motifs from ChIP-seq datasets using
an information theory-based approach, also revealing TF cofactor binding sites and other
novel motifs. The primary TF motifs were validated by comparison with motifs derived
independently from binding studies, by analysis of gene variants known to alter TF
binding affinities, and by comparing the locations of binding sites predicted by iPWMs
with those of true sites previously determined in published binding and expression
studies. In addition to contiguous iPWMs, bipartite iPWMs with variable-length spacers
were also derived. These iPWMs more precisely reflect the binding behavior of dimeric
TFs, as they incorporate intermediate and often weak binding sites that are often excluded
from consensus sequence-based (strong) binding site sets (3). This enables these iPWMs
to accurately quantify binding site strengths across a broad range of affinities (Appendix
B.6). To test this, the iPWMs were applied to mutation analyses of regulatory SNPs
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Figure 3.6: F-test results evaluating the relationship between Ri values and binding
energy. The proportion of F values within the first bin for primary/cofactor motifs is
much higher than that for noise motifs. A minimum threshold of 1,000 correctly classifies
all the noise motifs and 37.2% (251/674) of primary/cofactor motifs.
(Appendix B.7). We have recently used this approach to identify and prioritize variants
affecting TF binding in 20 risk genes of 287 hereditary breast and ovarian cancer patients
(116) and 7 genes from 102 such patients (117). In present study, the iPWMs were also
used to delineate known and novel TF-cofactor interactions.
TF binding sites across the genome have been predicted from promoter accessibility
analyses with high-throughput DNase-seq assays. For each of 20 TFs, Yardımcı et al.
(118) obtained a set of true binding sites by intersecting ChIP-seq peaks with the 50,000
strongest binding sites predicted by JASPAR and TRANSFAC PWMs in the genome.
The FLR (Footprint Log-likelihood Ratio), which is defined as the logarithm of the ratio
between probabilities that a DNase I footprint is produced by either a true binding site or
a background sequence, was determined at these sites. We attempted to detect these true
sites using the derived iPWMs. For these 20 TFs, all of these sites (ranging from n=31 to
21550, depending on the TF) were successfully detected by the iPWMs (𝑅𝑖 > 0). By
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contrast, the FLR identified 35%-85% of the verified binding sites (Appendix B.8). As
weak binding sites tend not to generate footprints and thus not to be discovered by
DNase-seq, the expectation is that the sites detected by DNase-seq would be stronger
than those that evade detection. In fact, this trend was observed for only 10 TFs and the
average strengths of these classes of these binding sites were not significantly different.
In the Maskminent pipeline, the weak peaks below the threshold signal intensity do not
necessarily contain weak or are missing binding sites; in fact, the distribution of 𝑅𝑖 values
of binding sites in these bottom peaks is similar to that in the top peaks used to derive the
iPWM (Appendix B.1). Thresholding the dataset is required in order to ensure that the
iPWM for the primary motif consists of binding sites from as many peaks as possible,
while preventing alternative motifs from dominating the objective function used in
Maskminent.
We also compared results produced by the Maskminent pipeline with other motif
discovery tools from two perspectives of revealing primary and cofactor binding motifs
(Appendix B.9). MEME-ChIP was previously used to derive motifs for 457 ChIP-seq
datasets (119) and SeqGL (120) was used to analyze 105 datasets. Among the sequencespecific TFs (n=98) investigated by both tools, Maskminent and MEME-ChIP discovered
primary motifs for 80 (~81.6%) and 92 (~93.9%) TFs, respectively. Among the 59 TF
datasets analyzed by Maskminent, MEME-ChIP, SeqGL and HOMER (121), primary
motifs were revealed for 45 (~76.3%), 51 (~86.4%), 49 (~83.1%) and 47 (~79.7%)
datasets, respectively. The cofactor motifs that Maskminent found (which MEME-ChIP
and SeqGL failed to detect) primarily comprise the SP family. Since MEME and SeqGL
discriminate binding sites from background sequences using nucleotide frequencies
computed from all input sequences, binding motifs with compositions similar to the
background may fail to be discovered, such as the SP motif; in contrast, Maskminent
does not rely on background compositions and will always return the lowest entropy
motif. While MEME-ChIP and SeqGL revealed a greater number of cofactor motifs,
selecting only the top 500 or 2000 peaks increases the likelihood that those cofactors
appeared by chance. This is because MEME-ChIP and SeqGL were configured to report
multiple motifs, whereas the main objective of Maskminent was to discover primary
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motifs (i.e. if the initial iPWM derived from a dataset exhibits the primary motif, the
masking and thresholding techniques will no longer be used, unless it is explicitly
masked). Finally, the ability of Maskminent, MEME-ChIP, SeqGL to reveal binding
motifs was compared on the 105 datasets (120). Each tool discovers cofactor motifs that
others do not recognize.
Arvey et al. (26) trained support vector machines (SVMs) that use flexible k-mer patterns
to capture DNA sequence signals more accurately from 286 ChIP-seq experiments than
traditional motif approaches, and these SVMs can also integrate histone modifications
and DNase accessibility to significantly more accurately predict TF occupancy than
simpler approaches. However, the SVM approach does not provide any insight into
binding strength. Even though accessible constrains increase the accuracy of binding site
detection, it is not possible to compare binding site strengths once the designated sites are
combined with DNase I hypersensitivity profiles and other chromatin accessibility marks.
In fact, the number of TFs for which cofactor motifs were revealed exceeds the number
of TFs whose primary binding motifs were discovered, partially because only cofactor
motifs can be found in the datasets of TFs which exhibit little or no sequence specificity
(e.g. CCNT2, INI1 and P300). For 11 primary TFs, the binding site sequences were
extremely variable; that is, the overall conservation levels of their binding motifs contain
less information than noisy, low complexity sequences or cofactor motifs. For 18 primary
TFs associated with cofactors, which themselves physically contact DNA, the primary TF
motif was not enriched. The inability of the software to discover such primary motifs is a
limitation of this approach. Interactions between the primary TFs and a subset of the
cofactors which are known to cooperate with them were detected, since the association
has to occur with a prevalence sufficient to produce a recognizable motif (usually >0.5
bit/nt over the entire site). Nevertheless, the algorithm may not find cofactors with
weakly conserved motifs or those that overlap with other conserved motifs.
While unable to discover cofactors nor identify bipartite motifs of variable spacing, the
oligonucleotide microarray technique adopted by Weirauch et al. (13) and Jolma et al.
(14) theoretically is able to determine binding specificities for all the sequence-specific
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TFs, because contiguous binding sites of TFs are reconstructed from overlapping
oligonucleotide sequences by directly detecting complexes with the TF. This eliminates
interference of noisy sequences or cofactors which may emerge as false minimum
entropies using our method.
The Maskminent pipeline can be applied to other ChIP-seq data not included in
ENCODE. The quality control criteria we described are capable of ensuring that the userbuilt iPWMs are accurate and can be used for binding site detection. The first and second
criteria are particularly important, because they provide a straightforward assessment of
iPWM performance. The recursively thresholded feature is crucial for guaranteeing that
the discovered cofactors do not appear by chance, because the greater the number of
peaks from which a cofactor is derived, the higher the confidence that the cofactor indeed
interacts with the primary factor.
In summary, we comprehensively investigated and implemented a new approach to
define TF binding specificities based on the ChIP-seq TF data that ENCODE has
released. This allowed us to mine and quantify both known and previously unrecognized
TF binding motifs and cofactor interactions on a genome scale. This information expands
the granularity of the current knowledge on TF interaction with DNA and points out
potential directions for future experimental study on interaction between TFs.
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Chapter 4

4

A Unified Analytic Framework for Prioritization of Noncoding Variants of Uncertain Significance in Heritable
Breast and Ovarian Cancer

The work presented in this chapter is reproduced from:
Mucaki,E.J., Caminsky,N.G., Perri,A.M., Lu,R., Laederach,A., Halvorsen,M.,
Knoll,J.H.M., Rogan,P.K. (2016) A unified analytic framework for prioritization of noncoding variants of uncertain significance in heritable breast and ovarian cancer. BMC
Med. Genomics, 9, 19

4.1 Background
Advances in next-generation sequencing (NGS) have enabled panels of genes, whole
exomes, and even whole genomes to be sequenced for multiple individuals in parallel.
These platforms have become so cost-effective and accurate that they are beginning to be
adopted in clinical settings, as evidenced by recent FDA approvals [1, 2]. However, the
overwhelming number of gene variants revealed in each individual has challenged
interpretation of clinically significant genetic variation [3–5].
After common variants, which are rarely pathogenic, are eliminated, the number of
variants of uncertain significance (VUS) in the residual set remains substantial.
Assessment of pathogenicity is not trivial, considering that nearly half of the unique
variants are novel, and cannot be resolved using published literature and variant
databases [6]. Furthermore, loss-of-function variants (those resulting in protein truncation
are most likely to be deleterious) represent a very small proportion of identified variants.
The remaining variants are missense and synonymous variants in the exon, single
nucleotide changes, or in frame insertions or deletions in intervening and intergenic
regions. Functional analysis of large numbers of these variants often cannot be
performed, due to lack of relevant tissues, and the cost, time, and labor required for each
variant. Another problem is that in silico protein coding prediction tools exhibit
inconsistent accuracy and are thus problematic for clinical risk evaluation [7–9].
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Consequently, many HBOC patients undergoing genetic susceptibility testing will receive
either an inconclusive (no BRCA variant identified) or an uncertain (BRCA VUS) result.
The former has been reported in up to 80% of cases and depends on the number of genes
tested [10]. The occurrence of uncertain BRCA mutations varies greatly (as high as 46%
in African American populations and as low as 2.1%) among tested individuals
depending on the laboratory and the patient’s ethnicity [11–13]. The inconsistency in
diagnostic yield is significant, considering that HBOC accounts for 5-10% of all
breast/ovarian cancer [14, 15].
One strategy to improve variant interpretation in patients is to reduce the full set of
variants to a manageable list of potentially pathogenic variants. Evidence for
pathogenicity of VUS in genetic disease is often limited to amino acid coding changes
[16, 17], and mutations affecting splicing, transcriptional activation, and mRNA stability
tend to be underreported [18–24]. Splicing errors are estimated to represent 15% of
disease-causing mutations [25], but may be much higher [26, 27]. The impact of a single
nucleotide change in a recognition sequence can range from insignificant to complete
abolition of a protein binding site. Aberrant splicing events causing frameshifts often
disrupt of protein function; in-frame changes are dependent on gene context. The
complexity of interpretation of non-coding sequence variants benefits from
computational approaches [28] and direct functional analyses [29–33] that may each
support evidence of pathogenicity.
Ex vivo transfection assays developed to determine the pathogenicity of VUS predicted to
lead to splicing aberrations (using in silico tools) have been successful in identifying
pathogenic sequence variants [34, 35]. Information technology (IT)-based analysis of
splicing variants has proven to be robust and accurate (as determined by functional assays
for mRNA expression or binding assays) at analyzing splice site (SS) variants, including
splicing regulatory factor binding sites (SRFBSs), and in distinguishing them from
polymorphisms in both rare and common diseases [36–39]. However, IT can be applied
to any sequence recognized and bound by another factor [40], such as with transcription
factor binding sites (TFBSs) and RNA-binding protein binding sites (RBBSs). IT is used
as a measure of sequence conservation and is more accurate than consensus sequences
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[41]. The individual information (𝑅𝑖 ) of a base is related to thermodynamic entropy, and
therefore free energy of binding, and is measured on a logarithmic scale (in bits). By
comparing the change in information (∆𝑅𝑖 ) for a nucleotide variation of a bound
sequence, the resulting change in binding affinity is ≥ 2∆𝑅𝑖 , such that a 1 bit change in
information will result in at least a 2-fold change in binding affinity [42].
IT measures nucleotide sequence conservation and does not provide information on
effects of variants on mRNA secondary (2°) structure, nor can it accurately predict effects
of amino acid sequence changes. Associations of structural changes in untranslated
regions of mRNA (UTR) with disease justifies including predicted effects of these
changes on 2° structure in the comprehensive analysis of sequence variants [43]. Other in
silico methods have attempted to address these deficiencies. For example, Halvorsen et
al. (2010) introduced an algorithm called SNPfold, which computes the potential effect of
a single nucleotide variant (SNV) on mRNA 2° structure [20]. Predictions made by
SNPfold can be tested by the SHAPE assay (Selective 2’-Hydroxyl Acylation analyzed
by Primer Extension) [44], which provides evidence for sequence variants that lead to
structural changes in mRNA by detection of covalent adducts in mRNA.
The implications of improved VUS interpretation are particularly relevant for HBOC due
to its incidence and the adoption of panel testing for these individuals [45, 46]. It has
been suggested that patients with a high risk profile receiving uninformative results
would imply that deleterious variants lie in untested regions of BRCA1/2, untested genes,
or are unrecognized [47, 48]. This is also supported by studies where families with
linkage to BRCA1/2 had no detectable pathogenic mutation (however it is noteworthy that
detection rates of BRCA mutations in families with documented linkage to these loci
appears to vary by ascertainment, inclusion criteria, and technology used to identify the
mutations) [49, 50]. The concept of non-BRCA gene association has been demonstrated
by the identification of low-to-moderate risk HBOC genes, and variants within coding
and non-coding regions affecting splicing and regulatory factor binding [51, 52].
Consequently, VUS, which include rare missense changes, other coding and non-coding
changes in all of these genes, greatly outnumber the catalog of known deleterious
mutations [53].
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Here, we develop and evaluate IT-based models to predict potential non-coding sequence
mutations in SSs, TFBSs, and RBBSs in 7 genes sequenced in their entirety. These
models were used to analyze 102 anonymous HBOC patients who did not exhibit known
BRCA1/2 coding mutations at the time of initial testing, despite meeting the criteria for
BRCA genetic testing. The genes are: ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2,
and TP53, and have been reported to harbor mutations that increase HBOC risk [54–76].
We apply these IT-based methods to analyze variants in the complete sequences of
coding, non-coding, and up- and downstream regions of the 7 genes. In this study, we
established and applied a unified IT-based framework, first filtering out common
variants, then to “flag” potentially deleterious ones. Then, using context-specific criteria
and information from the published literature, we prioritized likely candidates.

4.2 Methods
4.2.1

Design of Tiled Capture Array for HBOC Gene Panel

Nucleic acid hybridization capture reagents designed from genomic sequences generally
avoid repetitive sequence content to avoid cross hybridization [77]. Complete gene
sequences harbor numerous repetitive sequences, and an excess of denatured C0t-1 DNA
is usually added to hybridization to prevent inclusion of these sequences [78].
RepeatMasker software completely masks all repetitive and low-complexity sequences
[79]. We increased sequence coverage in complete genes with capture probes by
enriching for both single-copy and divergent repeat (> 30% divergence) regions, such
that, under the correct hybridization and wash conditions, all probes hybridize only to
their correct genomic locations [77]. This step was incorporated into a modified version
of Gnirke and colleagues’ (2009) in-solution hybridization enrichment protocol, in which
the majority of library preparation, pull-down, and wash steps were automated using a
BioMek® FXP Automation Workstation (Beckman Coulter, Mississauga, Canada) [80].
Genes ATM (RefSeq: NM_000051.3, NP_000042.3), BRCA1 (RefSeq: NM_007294.3,
NP_009225.1), BRCA2 (RefSeq: NM_000059.3, NP_000050.2), CDH1 (RefSeq:
NM_004360.3, NP_004351.1), CHEK2 (RefSeq: NM_145862.2, NP_665861.1), PALB2
(RefSeq: NM_024675.3, NP_078951.2), and TP53 (RefSeq: NM_000546.5,
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NP_000537.3) were selected for capture probe design by targeting single copy or highly
divergent repeat regions (spanning 10 kb up- and downstream of each gene relative to the
most upstream first exon and most downstream final exon in RefSeq) using an ab initio
approach [77]. If a region was excluded by ab initio but lacked a conserved repeat
element (i.e. divergence > 30%) [79], the region was added back into the probe-design
sequence file. Probe sequences were selected using PICKY 2.2 software [81]. These
probes were used in solution hybridization to capture our target sequences, followed by
NGS on an Illumina Genome Analyzer IIx (Appendix C.1).
Genomic sequences from both strands were captured using overlapping oligonucleotide
sequence designs covering 342,075 nt among the 7 genes (Figure 4.1). In total, 11,841
oligonucleotides were synthesized from the transcribed strand consisting of the complete,
single copy coding, and flanking regions of ATM (3,513), BRCA1 (1,587), BRCA2
(2,386), CDH1 (1,867), CHEK2 (889), PALB2 (811), and TP53 (788). Additionally,
11,828 antisense strand oligos were synthesized (3,497 ATM, 1,591 BRCA1, 2,395
BRCA2, 1,860 CDH1, 883 CHEK2, 826 PALB2, and 776 TP53). Any intronic or
intergenic regions without probe coverage are most likely due to the presence of
conserved repetitive elements or other paralogous sequences.
For regions lacking probe coverage (of ≥ 10 nt, N = 141; 8 in ATM, 26 in BRCA1, 10 in
BRCA2, 29 in CDH1, 36 in CHEK2, 15 in PALB2, and 17 in TP53), probes were selected
based on predicted Tms similar to other probes, limited alignment to other sequences in
the transcriptome (< 10 times), and avoidance of stable, base-paired 2° structures (with
unaFOLD) [82, 83]. The average coverage of these sequenced regions was 14.1-24.9%
lower than other probe sets, indicating that capture was less efficient, though still
successful.

4.2.2

HBOC Samples for Oligo Capture and High-Throughput
Sequencing

Genomic DNA from 102 patients previously tested for inherited breast/ovarian cancer
without evidence of a predisposing genetic mutation, was obtained from the Molecular
Genetics Laboratory (MGL) at the London Health Sciences Centre in London, Ontario,

98

Figure 4.1: Capture probe coverage over sequenced genes. The genomic structure of
the 7 genes chosen are displayed with the UCSC Genome Browser. Top row for each
gene is a custom track with the “dense” visualization modality selected with black
regions indicating the intervals covered by oligonucleotide capture reagent. Regions
without probe coverage contain conserved repetitive sequences or correspond to
paralogous sequences that are unsuitable for probe design.
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Canada. Patients qualified for genetic susceptibility testing as determined by the Ontario
Ministry of Health and Long-Term Care BRCA1 and BRCA2 genetic testing criteria [84]
(see Appendix C.2). The University of Western Ontario research ethics board (REB)
approved this anonymized study of these individuals to evaluate the analytical methods
presented here. BRCA1 and BRCA2 were previously analyzed by Protein Truncation Test
(PTT) and Multiplex Ligation-dependent Probe Amplification (MLPA). The exons of
several patients (N = 14) had also been Sanger sequenced. No pathogenic sequence
change was found in any of these individuals. In addition, one patient with a known
pathogenic BRCA variant was re-sequenced by NGS as a positive control.

4.2.3

Sequence Alignment and Variant Calling

Variant analysis involved the steps of detection, filtering, IT-based and coding sequence
analysis, and prioritization (Figure 4.2). Sequencing data were demultiplexed and aligned
to the specific chromosomes of our sequenced genes (hg19) using both CASAVA
(Consensus Assessment of Sequencing and Variation; v1.8.2) [85] and CRAC (Complex
Reads Analysis and Classification; v1.3.0) [86] software. Alignments were prepared for
variant calling using Picard [87] and variant calling was performed on both versions of
the aligned sequences using the UnifiedGenotyper tool in the Genome Analysis Toolkit
(GATK) [88]. We used the recommended minimum phred base quality score of 30, and
results were exported in variant call format (VCF; v4.1). A software program was
developed to exclude variants called outside of targeted capture regions and those with
quality scores < 50. Variants flagged by bioinformatic analysis (described below) were
also assessed by manually inspecting the reads in the region using the Integrative
Genomics Viewer (IGV; version 2.3) [89, 90] to note and eliminate obvious false
positives (i.e. variant called due to polyhomonucleotide run dephasing, or PCR duplicates
that were not eliminated by Picard). Finally, common variants (≥ 1% allele frequency
based on dbSNP 142 or > 5 individuals in our study cohort) were not prioritized.

4.2.4

IT-Based Variant Analysis

All variants were analyzed using the Shannon Human Splicing Mutation Pipeline, a
genome-scale variant analysis program that predicts the effects of variants on mRNA
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Figure 4.2: Framework for the identification of potentially pathogenic variants. Integrated laboratory processing and
bioinformatic analysis procedures for comprehensive complete gene variant determination and analysis. Intermediate datasets
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resulting from filtering are represented in yellow and final datasets in green. Non-bioinformatic steps, such as sample preparation are
represented in blue and prediction programs in purple. Sequencing analysis yields base calls for all samples. CASAVA [85] and
CRAC [86] were used to align these sequencing results to hg19. GATK [88] was used to call variants from this data against GRCh37
release of the reference human genome. Variants with a quality score < 50 and/or call confidence score < 30 were eliminated along
with variants falling outside of our target regions. SNPnexus [112–114] was used to identify the genomic location of the variants.
Nonsense and indels were noted and prediction tools were used to assess the potential pathogenicity of missense variants. The
Shannon Pipeline [91] evaluated the effect of a variant on natural and cryptic SSs, as well as SRFBSs. ASSEDA [38] was used to
predict the potential isoforms as a result of these variants. PWMs for 83 TFs were built using an information weight matrix generator
based on Bipad [106]. Mutation Analyzer evaluated the effect of variants found 10 kb upstream up to the first intron on protein
binding. Bit thresholds (𝑹𝒊 values) for filtering variants on software program outputs are indicated. Variants falling within the UTR
sequences were assessed using SNPfold [20], and the most probable variants that alter mRNA structure (p < 0.1) were then processed
using mFold to predict the effect on stability [83]. All UTR variants were scanned with a modified version of the Shannon Pipeline,
which uses PWMs computed from nucleotide frequencies for 28 RBPs in RBPDB [109] and 76 RBPs in CISBP-RNA [110]. All
variants meeting these filtering criteria were verified with IGV [89, 90]. * Sanger sequencing was only performed for protein
truncating, splicing, and selected missense variants
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splicing [91, 92]. Variants were flagged based on criteria reported in Shirley et al. (2013):
weakened natural site ≥ 1.0 bits, or strengthened cryptic site (within 300 nt of the nearest
exon) where cryptic site strength is equivalent or greater than the nearest natural site of
the same phase [91]. The effects of flagged variants were further analyzed in detail using
the Automated Splice Site and Exon Definition Analysis (ASSEDA) server [38].
Exonic variants and those found within 500 nt of an exon were assessed for their effects,
if any, on SRFBSs [38]. Sequence logos for splicing regulatory factors (SRFs) (SRSF1,
SRSF2, SRSF5, SRSF6, hnRNPH, hnRNPA1, ELAVL1, TIA1, and PTB) and their
𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 values (the mean information content [93]) are provided in Caminsky et al.
(2015) [36]. Because these motifs occur frequently in unspliced transcripts, only variants
with large information changes were flagged, notably those with a) ≥ 4.0 bit decrease, i.e.
at least a 16-fold reduction in binding site affinity, with 𝑅𝑖,𝑖𝑛𝑖𝑡𝑖𝑎𝑙 ≥ 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 for the
particular factor analyzed, or b) ≥ 4.0 bit increase in a site where 𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 ≥ 0 bits.
ASSEDA was used to calculate 𝑅𝑖,𝑡𝑜𝑡𝑎𝑙 , with the option selected to include the given SRF
in the calculation. Variants decreasing 𝑅𝑖,𝑡𝑜𝑡𝑎𝑙 by < 3.0 bits (i.e. 8-fold) were predicted to
potentially have benign effects on expression, and were not considered further.
Activation of pseudoexons through creating/strengthening of an intronic cryptic splice
site was also assessed [94]. Changes in intronic cryptic sites, where ∆𝑅𝑖 > 1 bit and
𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 ≥ (𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 – 1 standard deviation [S.D.] of 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 ), were identified. A
pseudoexon was predicted if a pre-existing cryptic site of opposite polarity (with 𝑅𝑖 >
[𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 - 1 S.D.]) and in the proper orientation for formation of exons between 10-250
nt in length was present. In addition, the minimum intronic distance between the
pseudoexon and either adjacent natural exon was 100 nt. The acceptor site of the
pseudoexon was also required to have a strong hnRNPA1 site located within 10 nt (𝑅𝑖 ≥
𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 ) [38] to ensure accurate proofreading of the exon [37].
Next, variants affecting the strength of SRFs were analyzed by a contextual exon
definition analysis of ∆𝑅𝑖,𝑡𝑜𝑡𝑎𝑙 . The context refers to the documented splicing activity of
an SRF. For example, TIA1 has been shown to be an intronic enhancer of exon
definition, so only intronic sites were considered. Similarly, hnRNPA1 proofreads the 3'
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SS (acceptor) and inhibits exon recognition elsewhere [95]. Variants that lead to
redundant SRFBS changes (i.e. one site is abolished and another proximate site [≤ 2 nt]
of equivalent strength is activated) were assumed to have a neutral effect on splicing. If
the strength of a site bound by PTB (polypyrimidine tract binding protein) was affected,
its impact on binding by other factors was analyzed, as PTB impedes binding of other
factors with overlapping recognition sites, but does not directly enhance or inhibit
splicing itself [96].
To determine effects of variants on transcription factor (TF) binding, we first established
which TFs bound to the sequenced regions of the gene promoters (and first exons) in this
study by using ChIP-seq data from 125 cell types (Appendix C.1) [97]. We identified 141
TFs with evidence for binding to the promoters of the genes we sequenced, including cMyc, C/EBPβ, and Sp1, shown to transcriptionally regulate BRCA1, TP53, and ATM,
respectively [98–100]. Furthermore, polymorphisms in TCF7L2, known to bind enhancer
regions of a wide variety of genes in a tissue-specific manner [101], have been shown to
increase risk of sporadic [102] and hereditary breast [103], as well as other types of
cancer [104, 105].
IT-based models of the 141 TFs of interest were derived by entropy minimization of the
DNase accessible ChIP-seq subsets [106]. Details are provided in Lu R, Mucaki E, and
Rogan PK (BioRxiv; http://dx.doi.org/10.1101/042853). While some data sets would
only yield noise or co-factor motifs (i.e. co-factors that bind via tethering, or histone
modifying proteins [107]), techniques such as motif masking and increasing the number
of Monte Carlo cycles yielded models for 83 TFs resembling each factor’s published
motif. Appendix C.3 contains the final list of TFs and the models we built (described
below) [108].
These TFBS models (N = 83) were used to scan all variants called in the promoter
regions (10 kb upstream of transcriptional start site to the end of IVS1) of HBOC genes
for changes in 𝑅𝑖 . Binding site changes that weaken interactions with the corresponding
TF (to 𝑅𝑖 ≤ 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 ) are likely to affect regulation of the adjacent target gene. Stringent
criteria were used to prioritize the most likely variants and thus only changes to strong
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TFBSs (𝑅𝑖,𝑖𝑛𝑖𝑡𝑖𝑎𝑙 ≥ 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 ), where reduction in strength was significant (∆𝑅𝑖 ≥ 4.0
bits), were considered. Alternatively, novel or strengthened TFBSs were also considered
sources of dysregulated transcription. These sites were defined as having𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 ≥
𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 and as being the strongest predicted site in the corresponding genomic interval
(i.e. exceeding the 𝑅𝑖 values of adjacent sites unaltered by the variant). Variants were not
prioritized if the TF was known to a) enhance transcription and IT analysis predicted
stronger binding, or b) repress transcription and IT analysis predicted weaker binding.
Two complementary strategies were used to assess the possible impact of variants within
UTRs. First, SNPfold software was used to assess the effect of a variant on 2° structure
of the UTR (Appendix C.1) [20]. Variants flagged by SNPfold with the highest
probability of altering stable 2° structures in mRNA (where p-value < 0.1) were
prioritized. To evaluate these predictions, oligonucleotides containing complete wild-type
and variant UTR sequences (Appendix C.4) were transcribed in vitro and followed by
SHAPE analysis, a method that can confirm structural changes in mRNA [44].
Second, the effects of variants on the strength of RBBSs were predicted. Frequencybased, position weight matrices (PWMs) for 156 RNA-binding proteins (RBPs) were
obtained from the RNA-Binding Protein DataBase (RBPDB) [109] and the Catalog of
Inferred Sequence Binding Preferences of RNA binding proteins (CISBP-RNA) [110,
111]. These were used to compute information weight matrices (based on the method
described by Schneider et al. 1984; N = 147) (see Appendix C.1) [40]. All UTR variants
were assessed using a modified version of the Shannon Pipeline [91] containing the
RBPDB and CISBP-RNA models. Results were filtered to include a) variants with |∆𝑅𝑖 |
≥ 4.0 bits, b) variants creating or strengthening sites (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 ≥ 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 and the 𝑅𝑖,𝑖𝑛𝑖𝑡𝑖𝑎𝑙
< 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 ), and c) RBBSs not overlapping or occurring within 10 nt of a stronger, preexisting site of another RBP.

4.2.5

Exonic Protein-Altering Variant Analysis

The predicted effects of all coding variants were assessed with SNPnexus [112–114], an
annotation tool that can be applied to known and novel variants using up-to-date dbSNP
and UCSC human genome annotations. Variants predicted to cause premature protein
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truncation were given higher priority than those resulting in missense (or synonymous)
coding changes. Missense variants were first cross referenced with dbSNP 142 [115].
Population frequencies from the Exome Variant Server [116] and 1000Genomes [117]
are also provided. The predicted effects on protein conservation and function of the
remaining variants were evaluated by in silico tools: PolyPhen-2 [118], Mutation
Assessor (release 2) [119, 120], and PROVEAN (v1.1.3) [121, 122]. Default settings
were applied and in the case of PROVEAN, the “PROVEAN Human Genome Variants
Tool” was used, which includes SIFT predictions as a part of its output. Variants
predicted by all four programs to be benign were less likely to have a deleterious impact
on protein activity; however this did not exclude them from mRNA splicing analysis
(described above in IT-Based Variant Analysis). All rare and novel variants were crossreferenced with general mutation databases (ClinVar [123, 124], Human Gene Mutation
Database [HGMD] [125, 126], Leiden Open Variant Database [LOVD] [127–134],
Domain Mapping of Disease Mutations [DM2] [135], Expert Protein Analysis System
[ExPASy] [136] and UniProt [137, 138]), and gene-specific databases (BRCA1/2: the
Breast Cancer Information Core database [BIC] [139] and Evidence-based Network for
the Interpretation of Germline Mutant Alleles [ENIGMA] [140]; TP53: International
Agency for Research on Cancer [IARC] [141]), as well as published reports to prioritize
them for further workup.

4.2.6

Variant Classification

Flagged variants were prioritized if they were likely to encode a dysfunctional protein
(indels, nonsense codon > 50 amino acids from the C-terminus, or abolition of a natural
SS resulting in out-of-frame exon skipping) or if they exceeded established thresholds for
fold changes in binding affinity based on IT (see Methods above). In several instances,
our classification was superseded by previous functional or pedigree analyses (reported in
published literature or databases) that categorized these variants as pathogenic or benign.

4.2.7

Positive control

We identified the BRCA1 exon 17 nonsense variant c.5136G>A (chr17:41215907C>T;
rs80357418; 2-5A) [142] in the sample that was provided as a positive control. This was

106

the same mutation identified by the MGL as pathogenic for this patient. We also
prioritized another variant in this patient (Table 4.1) [143].

4.2.8

Variant Validation

Protein-truncating, prioritized splicing, and selected prioritized missense variants were
verified by Sanger sequencing. Primers of PCR amplicons are indicated in Appendix C.5.

4.2.9
4.2.9.1

Deletion Analysis
Junctional Read Detection

Potential large rearrangements were detected with BreakDancer software [144], which
identifies novel genomic rearrangements based on the respective orientation and distance
between ends of the same read (and exceeding the lengths of NGS library inserts. This
approach can, in theory, approximately localize deletions, duplications, or other types of
breakpoints within exons, introns, and regulatory regions (eg. promoters) that could affect
gene expression and function. We required at least 4 reads per suspected rearrangement
in a sample separated by >700 nt, with each end mapping to proximate genomic reference
coordinates to infer a potential deletion. Synthetic and cost limitations in the maximum
genomic real estate covered by the capture reagent led to a tradeoff between extending
the span of captured genomic intervals and higher tiling densities over shorter sequences,
ie. exons, to achieve the level of coverage to reliably detect deletions based on read
counts alone.

4.2.9.2

Prioritization based on Potential Hemizygosity

Our complete gene enrichment strategy with independent capture of both genomic
strands enabled and facilitated development of a new algorithm to identify potential
hemizygous genomic intervals in these individuals. In each subject, we first searched for
contiguous long stretches (usually >> 1 kb) of non-polymorphic segments with
diminished repetitive element content (<10%), which is consistent with the possibility of
these regions harboring a deletion. Then, we determined the likelihood of homo- or
hemizygosity by comparing the degree of heterozygosity of variants in each of these
intervals in for an individual with all of the other individuals sequenced with this protocol
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Table 4.1: Prioritized variants in the positive control
Gene

BRCA1

mRNA

rsID (dbSNP 142)

Protein

Allele Frequency (%)†

c.5136G>A
p.Trp1712Ter

rs80357418

Category

Consequence

Ref

Nonsense

151 AA short

[142]

Repressor action of hnRNPA1 at this site abolished
SRFBS

(5.2 to 0.4 bits). Blocking action of PTB removed as
site is abolished (5.5 to -7.5 bits) and may uncover
binding sites of other SRFs.
Listed in ClinVar as conflicting interpretations (likely
benign, unknown) and in BIC as unknown clinical

BRCA2

c.3218A>G
p.Gln1073Arg

rs80358566

Missense

importance. 2 in silico programs called deleterious.
The variant occurs between repeat motifs BRC1 and
BRC2 of BRCA2, a region in which pathogenic
missense mutations have not yet been identified.
Repressor action of hnRNPA1 at this site abolished

SRFBS

(5.2 to 0.4 bits). Blocking action of PTB removed as
site is abolished (5.5 to -7.5 bits) and may uncover
binding sites of other SRFs.

[143]
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in this population. Regions containing haplotype blocks in strong linkage disequilibrium
(LD; from HapMap [145]) were then excluded as candidate deletion intervals. Some
individuals without a deletion are expected to be non-polymorphic, because detection of
heterozygosity depends on genomic length of the region, marker informativeness, and the
level of LD for those markers. We required that > 80% of the control individuals be
heterozygous for at least two well-distributed loci within these intervals. Highly
informative SNPs with a random genomic distribution in the controls (and other public
databases) and which were non-polymorphic in the individual with the suspected deletion
were weighted more heavily in inferring potential hemizygosity. This analysis was
implemented using a Perl script that identified the most likely intervals of hemizygosity,
which were then crossreferenced with the corresponding genomic intervals in HapMap.

4.3 Results
4.3.1

Capture, Sequencing, and Alignment

The average coverage of capture region per individual was 90.8x (range of 53.8 to 118.2x
between 32 samples) with 98.8% of the probe-covered nucleotides having ≥ 10 reads.
Samples with fewer than 10 reads per nucleotide were re-sequenced and the results of
both runs were combined. The combined coverage of these samples was, on average,
48.2x (± 36.2).
The consistency of both library preparation and capture protocols was improved from
initial runs, which significantly impacted sequence coverage (Appendix C.1). Of the 102
patients tested, 14 had been previously Sanger sequenced for BRCA1 and BRCA2 exons.
Confirmation of previously discovered SNVs served to assess the methodological
improvements introduced during NGS and ultimately, to increase confidence in variant
calling. Initially, only 15 of 49 SNVs in 3 samples were detected. The detection rate of
SNVs was improved to 100% as the protocol progressed. All known SNVs (N = 157)
were called in subsequent sequencing runs where purification steps were replaced with
solid phase reversible immobilization beads and where RNA bait was transcribed the
same day as capture. To minimize false positive variant calls, sequence read data were

109

aligned with CASAVA and CRAC, variants were called for each alignment with GATK,
and discrepancies were then resolved by manual review.
GATK called 14,164 unique SNVs and 1,147 indels. Only 3777 (15.3%) SNVs were
present in both CASAVA and CRAC-alignments for at least one patient, and even fewer
indel calls were concordant between both methods (N = 110; 6.2%). For all other SNVs
and indels, CASAVA called 6871 and 1566, respectively, whereas CRAC called 13,958
and 110, respectively. Some variants were counted more than once if they were called by
different alignment programs in two or more patients. Intronic and intergenic variants
proximate to low complexity sequences tend to generate false positive variants due to
ambiguous alignment, a well known technical issue in short read sequence analysis [146,
147], contributing to this discrepancy. For example, CRAC correctly called a 19 nt
deletion of BRCA1 (rs80359876; also confirmed by Sanger sequencing) but CASAVA
flagged the deleted segment as a series of false-positives (Appendix C.6). For these
reasons, all variants were manually reviewed.

4.3.2
4.3.2.1

IT-Based Variant Identification and Prioritization
Natural SS Variants

The Shannon Pipeline reported 99 unique variants in natural donor or acceptor SSs. After
technical and frequency filtering criteria were applied, 12 variants remained (Appendix
C.7). IT analysis allowed for the prioritization of 3 variants, summarized in Table 4.2.
First, the novel ATM variant c.3747-1G>A (chr11:108,154,953G>A; sample number 74F) abolishes the natural acceptor of exon 26 (11.0 to 0.1 bits). ASSEDA reports the
presence of a 5.3 bit cryptic acceptor site 13 nt downstream of the natural site, but the
effect of the variant on a pre-existing cryptic site is negligible (~0.1 bits). The cryptic
exon would lead to exon deletion and frameshift (Figure 4.3A). ASSEDA also predicts
skipping of the 246 nt exon, as the 𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 of the natural acceptor is now below
𝑅𝑖,𝑚𝑖𝑛𝑖𝑚𝑢𝑚 (1.6 bits), altering the reading frame. Second, the novel ATM c.6347+1G>T
(chr11:108188249G>T; 4-1F) abolishes the 10.4 bit natural donor site of exon 44 (∆𝑅𝑖 = 18.6 bits), and is predicted to cause exon skipping. Finally, the previously reported
CHEK2 variant, c.320-5A>T (chr22:29121360T>A; rs121908700; 4-2B) [148] weakens

110

Table 4.2: Variants prioritized by IT analysis
Information Change
rsID (dbSNP 142)
Patient ID

Gene

mRNA

Ri,initial Ri,initial

ΔRi or Ri

Allele Frequency (%)d
(bits)

(bits)

(bits)

e

Consequencef or Binding
Factor Affected

Abolished Natural SS
7-4F

ATM

c.3747-1G>Aa

Novel

11.0

0.1

-10.9

4-1F

ATM

c.6347+1G>Tb

Novel

10.4

-8.3

-18.6

4.1

-2.7

Exon skipping and use of
alternative splice forms
Exon skipping

Leaky Natural SS
rs121908700
4-2B

CHEK2

c.320-5T>A

a

6.8
0.08

Leaky splicing with intron
inclusion

Activated Cryptic SS
Cryptic site not expected to
rs117281398
7-3E

BRCA1

c.548-293G>A

-12.1

2.6

14.7

0.74

be used. Total information
for natural exon is stronger
than cryptic exon.

7-4A

BRCA2

c.7618-269_7618-

Novel

3.9

9.4

5.5

Cryptic site not expected to
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260del10

be used. Total information
for natural exon is stronger
than cryptic exon.

Pseudoexon formation due to activated acceptor SS
7-3F

BRCA2

c.8332-805G>A

Novel

-9.3

5.4

5.6e

6,065/211/592f

-6.6

4.3

6.5 e

61,236/224/1,798f

7.3

8.5

5.0e

1,175/50/124f

rs184740925
7-3D

CDH1

c.164-2023A>G
0.3
rs565488866

5-3H

CDH1

c.2296-174T>A
0.02

Pseudoexon formation due to activated donor SS
rs189352191
3-6A

BRCA1

4.1

6.7

5.2e

186/63/1,250f

4.7

7.2

7.7e

2,589/103/5,272f

10.9

-0.2

-11.1

GATA-3 (GATA3)

c.212+253G>A
0.08
rs367890577

5-2G

BRCA2

c.7007+2691G>A
0.02
Affected TFBSs

7-4B

BRCA1

c.-8895G>A

Novel

112

5-3E

rs5030874
CDH1

c.-54G>C

7-4E

1.7

12.0

10.4

E2F-4 (E2F4)

12.1

-1.3

-13.4

GABPα (GABPA)

-6.3

10.9

17.2

RUNX3 (RUNX3)

rs113451673

5.1

12.3

7.2

E2F-4 (E2F4)

0.4

8.0

12.9

4.8

Sp1 (SP1)

9.8

-19.9

-29.7

RBFOX

-20.3

9.6

29.9

SF3B4

8.2

1.8

-6.4

CELF4

10.9

3.7

-7.2

BX511012.1

0.16
rs552824227

5-2B

PALB2

c.-291C>G
0.1
rs17882863

7-2F

TP53

c.-28-3132T>C
0.3

4-1A

TP53

c.-28-1102T>C
Affected RBBSs
c.-244T>A

7-4G

c.-744T>A

rs539948218

c.-1929T>A

0.04

ATM
c.-3515T>A

5-3C
7-2E

CDH1
CHEK2

c.*424T>A
c.-588G>A

Novel
rs141568342
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4-3C.5-4G

CHEK2

3-1A

c.-345C>Tc

rs137853007

c.-107T>C

rs113530090

TP53
4-1H

c.-188T>C

3.3

11.4

8.2

SF3B4

10.5

4.5

-6.0

ELAVL1

10.7

4.1

-6.6

KHDRBS1

0.72

c.*1175A>C
4-2H

rs78378222
TP53

c.*1376A>C

7-2F

0.26
c.*1464A>C

a

Confirmed by Sanger sequencing

b

Ambiguous Sanger sequencing results

c

Prioritized under missense and was therefore verified with Sanger sequencing. Variant was confirmed

d

If available

e

𝑅𝑖 of site of opposite polarity in the pseudoexon

f

Consequences for pseudoexon formation describe how the intron is divided: “new intron A length/pseudoexon length/new exon B”

length.
None of the variants have been previously reported by other groups with the exception of CHEK2 c.320-5T>A [148].
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Figure 4.3: Predicted isoforms and relative abundances as a consequence of ATM
splice variant c.3747-1G>A. Intronic ATM variant c.3747-1G>A abolishes (11.0 to 0.1
bits) the natural acceptor of exon 26 (total of 63 exons). A) ASSEDA predicts skipping of
the natural exon (𝑹𝒊,𝒊𝒏𝒊𝒕𝒊𝒂𝒍 from 14.5 to 3.6 bits [an 1910 fold decrease in exon strength];
isoform 7) and/or activation of a preexisting cryptic acceptor site 13 nt downstream
(𝑹𝒊,𝒕𝒐𝒕𝒂𝒍 for cryptic exon = 9.0 bits; isoform 1) of the natural site leading to exon
truncation. The reading frame is altered in both mutant isoforms. The other isoforms use
weak, alternate acceptor/donor sites leading to cryptic exons with much lower total
information. B) Before the mutation, isoform 7 is expected to be the most abundant splice
form. C) After the mutation, isoform 1 is predicted to become the most abundant splice
form and the wild-type isoform is not expected to be expressed.
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the natural acceptor of exon 3 (6.8 to 4.1 bits), and may active a cryptic acceptor (7.4
bits) 92 nt upstream of the natural acceptor site which would shift the reading frame
(Figure 4.4). A constitutive, frameshifted alternative isoform of CHEK2 lacking exons 3
and 4 has been reported, but skipping of exon 3 alone is not normally observed.
Variants either strengthening (N = 4) or slightly weakening (∆𝑅𝑖 < 1.0 bits; N = 4) a
natural site were not prioritized. In addition, we rejected the ATM variant (c.1066-6T>G;
chr11:108119654T>G; 4-1E and 7-2B), which slightly weakens the natural acceptor of
exon 9 (11.0 to 8.1 bits). Although other studies have shown leaky expression as a result
of this variant [149], a more recent meta-analysis concluded that this variant is not
associated with increased breast cancer risk [150].

4.3.3

Cryptic SS Activation

Two variants produced information changes that could potentially impact cryptic
splicing, but were not prioritized for the following reasons (Table 4.2). The first variant,
novel BRCA2 deletion c.7618-269_7618-260del10 (chr13:32931610_32931619del10; 74A) strengthens a cryptic acceptor site 245 nt upstream from the natural acceptor of exon
16 (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = 9.4 bits, ∆𝑅𝑖 = 5.5 bits). Being 5.7-fold stronger than the natural site (6.9
bits), two potential cryptic isoforms were predicted, however the exon strengths of both
are weaker than the unaffected natural exon (𝑅𝑖,𝑡𝑜𝑡𝑎𝑙 = 6.6 bits) and thus neither were
prioritized. The larger gap surprisal penalties explain the differences in exon strength.
The natural donor SS may still be used in conjunction with the abovementioned cryptic
SS, resulting in an exon with 𝑅𝑖,𝑡𝑜𝑡𝑎𝑙 = 3.5 bits. Alternatively, the cryptic site and a weak
donor site 180 nt upstream of the natural donor (𝑅𝑖 = 0.7 vs 1.4, cryptic and natural
donors, respectively) result in an exon with 𝑅𝑖,𝑡𝑜𝑡𝑎𝑙 = 6.5 bits. The second variant,
BRCA1 c.548-293G>A (chr17:41249599C>T; 7-3E), creates a weak cryptic acceptor
(𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = 2.6 bits, ∆𝑅𝑖 = 6.2 bits) 291 nt upstream of the natural acceptor for exon 8
(∆𝑅𝑖 = 0.5). Although the cryptic exon is strengthened (final 𝑅𝑖,𝑡𝑜𝑡𝑎𝑙 = 6.9 bits, ∆𝑅𝑖 =
14.7 bits), ASSEDA predicts the level of expression of this exon to be negligible, as it is
weaker than the natural exon 𝑅𝑖,𝑡𝑜𝑡𝑎𝑙 = 8.4 bits) due to the increased length of the
predicted exon (+291 nt) [38].
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Figure 4.4: Predicted isoforms and relative abundances as a consequence of CHEK2
splice variant c.320-5T>A. Intronic CHEK2 variant c.320-5T>A weakens (6.8 to 4.1
bits) the natural acceptor of exon 3 (total of 15 exons). A) ASSEDA reports the
weakening of the natural exon strength (𝑹𝒊,𝒕𝒐𝒕𝒂𝒍 reduced from 13.2 to 10.5 bits), which
would result in reduced splicing of the exon otherwise known as leaky splicing. A preexisting cryptic acceptor exists 92 nt upstream of the natural site, leading to a cryptic
exon with similar strength to the mutated exon (𝑹𝒊,𝒕𝒐𝒕𝒂𝒍 = 10.0 bits). This cryptic exon
would contain 92 nt of the intron. B) Before the mutation, isoform 1 is expected to be the
only isoform expressed. C) After the mutation, isoform 1 (wild-type) is predicted to
become relatively less abundant and isoform 2 is expected to be expressed, although less
abundant in relation to isoform 1.
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4.3.4

Pseudoexon Formation

The Shannon Pipeline initially reported 1583 unique variants creating or strengthening
intronic cryptic sites. We prioritized 5 variants, 1 of which is novel (BRCA2 c.8332805G>A; 7-3F), that were within 250 nt of a pre-existing complementary cryptic site and
have an hnRNPA1 site within 5 nt of the acceptor (Table 4.2). If used, 3 of these
pseudoexons would lead to a frameshifted transcript.

4.3.5

SRF Binding

Variants within 500 nt of an exon junction and all exonic variants (N = 4015) were
investigated for their potential effects on affinity of sites to corresponding SRFs [38]. IT
analysis flagged 54 variants significantly altering the strength of at least one binding site
(Appendix C.8). A careful review of the variants, the factor affected, and the position of
the binding site relative to the natural SS, prioritized 36 variants (21 novel), of which 4
are in exons and 32 are in introns. As an example, a novel CHEK2 exon 2 variant
c.69C>A (p.Gly23=) is predicted to increase the strength of an hnRNP A1 site (0.7 to 5.3
bits) and decrease total exon strength (∆𝑅𝑖,𝑡𝑜𝑡𝑎𝑙 = -5.7 bits). A similar type of exonic
variant in FANCM, which was predicted to create exonic hnRNP A1 site by IT, has been
shown to bind this exonic repressor and induce exon skipping [37].

4.3.6

TF Binding

We assessed SNVs with models of 83 TFs experimentally shown to bind (Appendix C.3)
upstream or within the first exon and intron of our sequenced genes (N = 2177). Thirteen
variants expected to significantly affect TF binding were flagged (Appendix C.9). The
final filtering step considered the known function of the TF in transcription, resulting in 5
prioritized variants (Table 4.2) in 6 patients (one variant was identified in two patients).
Four of these variants have been previously reported (rs5030874, rs552824227,
rs17882863, rs113451673) and one is novel (c.-8895G>A; 7-4B).

4.3.7

UTR Structure and Protein Binding

There were 364 unique UTR variants found by sequencing. These variants were
evaluated for their effects on mRNA 2° structure (including that of splice forms with
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alternate UTRs in the cases of BRCA1 and TP53) through SNPfold, resulting in 5 flagged
variants (Table 4.3), all of which have been previously reported.
Analysis of three variants using mFOLD [83] revealed likely changes to the UTR
structure (Figure 4.5). Two variants with possible 2° structure effects were common
(BRCA2 c.-52A>G [N = 26 samples] and c.*532A>G [N = 40]) and not prioritized. The
5’UTR CDH1 variant c.-71C>G (chr16:68771248C>G; rs34033771; 7-4C) disrupts a
double-stranded hairpin region to create a larger loop structure, thus increasing binding
accessibility (Figure 4.5A and B). Analysis using RBPDB and CISBP-RNA-derived IT
models suggests this variant affects binding by NCL (Nucleolin, a transcription
coactivator) by decreasing binding affinity 14-fold (𝑅𝑖,𝑖𝑛𝑖𝑡𝑖𝑎𝑙 = 6.6 bits, ∆𝑅𝑖 = -3.8 bits)
(Appendix C.10). This RBP has been shown to bind to the 5’ and 3’ UTR of p53 mRNA
and plays a role in repressing its translation [151].
In addition, the TP53 variant c.*485G>A (NM_000546.5: chr17:7572442C>T;
rs4968187) is found at the 3’UTR and was identified in two patients (4-2E and 5-4A). In
silico mRNA folding analysis demonstrated this variant disrupts a G/C bond of a loop in
the highest ranked potential mRNA structure (Figure 4.5C and D). Also, SHAPE analysis
showed a difference in 2° structure between the wild-type and mutant (data not shown).
IT analysis with RBBS models indicated that this variant significantly increases the
binding affinity of SF3B4 by > 48-fold (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = 11.0 bits, ∆𝑅𝑖 = 5.6 bits) (Appendix
C.10). This RBP is one of four subunits comprising the splice factor 3B, which binds
upstream of the branch-point sequence in pre-mRNA [152].
The third flagged variant also occurs in the 3’UTR of TP53 (c.*826G>A;
chr17:7,572,101C>T; rs17884306), and was identified in 6 patients (2-1A, 7-1B, 5-2A.71D, 7-2B, 7-2F, and 7-4C). It disrupts a potential loop structure, stabilizing a doublestranded hairpin, and possibly making it less accessible (Figure 4.5E and F). Analysis
using RBPDB-derived models suggests this variant could affect the binding of both
RBFOX2 and SF3B4 (Appendix C.10). A binding site for RBFOX2, which acts as a
promoter of alternative splicing by favoring the inclusion of alternative exons [153], is
created (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = 9.8 bits; ∆𝑅𝑖 = -6.5 bits). This variant is also expected to
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Table 4.3: Variants predicted by SNPfold to affect UTR structure
Classa

Patient ID

Gene

mRNA

F

In 26 patients

BRCA2b

c.-52A>G

UTR

rsID (dbSNP 142)

position

Allele Frequency (%)d

5’ UTR

Ranke

p-value

2/900

0.002

239/2700

0.089

69/600

0.115

169/4500

0.038

371/4500

0.082

rs206118
14.86

F

In 40 patients

BRCA2b

c.*532A>G

3’ UTR

rs11571836
19.75

P

7-4C

CDH1c

c.-71C>G

5’ UTR

rs34033771
0.56

4-2E

F

5-4A
2-1A, 7-1B, 5-2A, 7-

F

1D, 7-2B, 7-2F, 7-4C

a

F:Flagged; P:Prioritized

b

Long Range UTR SNPfold Analysis

c Local

TP53b

c.*485G>A

3’ UTR

rs4968187
5.11

TP53b

c.*826G>A

3’ UTR

rs17884306
5.71

Range SNPfold Analysis

d

If available

e

Rank of the SNP, in terms of how much it changes the mRNA structure compared to all other possible mutations.
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Figure 4.5: Predicted alteration in UTR structure using mFOLD for variants
flagged by SNPfold. Wild-type and variant structures are displayed, with the variant
indicated by a red arrow. A) Predicted wild-type structure of CDH1 5’UTR surrounding
c.-71. B) Predicted CDH1 5’UTR structure due to c.-71C>G variant. C) Predicted wildtype TP53 3’UTR structure surrounding c.*485. D) Predicted TP53 5’UTR structure due
to c.*485G>A variant. E) Predicted wild-type TP53 3’UTR structure surrounding c.*826.
F) Predicted TP53 5’UTR structure due to c.*826G>A variant. §SHAPE analysis revealed
differences in reactivity between mutant and variant mRNAs, confirming alterations to 2°
structure.
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simultaneously abolish a SF3B4 binding site (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = -20.3 bits; ∆𝑅𝑖 = -29.9 bits).
RBPDB- and CISBP-RNA-derived information model analysis of all UTR variants
resulted in the prioritization of 1 novel, and 5 previously-reported variants (Table 4.2).
No patient within the cohort exhibited more than one prioritized RBBS variant.
To evaluate the background rate of prioritizing variants flagged by this method, all 5' and
3' UTR SNVs in dbSNP144 for the 7 genes sequenced (excluding those already flagged
in Table 4.3) were evaluated by SNPfold and our RBP information models. Of 1207
SNVs, only 10 were prioritized with both methods, which results in a background rate of
0.83%.

4.3.8

Exonic Variants Altering Protein Sequence

Exonic variants called by GATK (N = 245) included insertions, deletions, nonsense,
missense, and synonymous changes.

4.3.8.1

Protein-Truncating Variants

We identified 3 patients with different indels (Table 4.4). One was a PALB2 insertion
c.1617_1618insTT (chr16:23646249_23646250insAA; 5-3A) in exon 4, previously
reported in ClinVar as pathogenic. This mutation results in a frameshift and premature
translation termination by 626 residues, abolishing domain interactions with RAD51,
BRCA2, and POLH [137]. We also identified two known frameshift mutations in
BRCA1: c.4964_4982del19 in exon 15 (chr17:41222949_41222967del19; rs80359876; 51B) and c.5266_5267insC in exon 19 (chr17:41209079_41209080insG; rs397507247; 53C) [148, 154]. Both are indicated as pathogenic and common in the BIC Database due to
the loss of one or both C-terminal BRCT repeat domains [137]. Truncation of these
domains produces instability and impairs nuclear transcript localization [155], and this
bipartite domain is responsible for binding phosphoproteins that are phosphorylated in
response to DNA damage [156, 157].
We also identified 4 nonsense mutations, one of which was novel in exon 4 of PALB2
(c.1042C>T; chr16:23646825G>A; 4-4D). Another in PALB2 has been previously
reported (c.1240C>T; chr16:23646627G>A; rs180177100; 7-3A) [58]. As a
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Table 4.4: Variants resulting in premature protein truncation
Patient
ID

Gene

Exon

mRNA

rsID (dbSNP 142)

Protein

Allele Frequency

(%)c

ClinVard,e,f

Details

Ref

Insertions/Deletions
6d; Pathogenic/likely

5-1B

BRCA1

15 of 23

c.4964_4982del19

pathogenice; Familial

a

rs80359876

p.Ser1655Tyrfs

STOP at

breast and breast-ovarian

p.1670

cancer, Hereditary cancer-

193 AA short

-

predisposing syndromef.
13d; Pathogenic, risk
factore; Familial breast,
5-3C

BRCA1

19 of 23

c.5266_5267insCa
p.Gln1756Profs

rs397507247

breast-ovarian, and
pancreatic cancer,
Hereditary cancer-

STOP at
p.1788
75 AA short

[148,
154]

predisposing syndromef.

5-3A

PALB2

4 of 13

c.1617_1618insTT
p.Asn540Leufs

1d; Pathogenice; Hereditary

a

-

cancer-predisposing
syndromef.

Stop Codons

STOP at
p.561
626 AA short

-
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5d; Pathogenice; Familial
7-1G

BRCA2

15 of 27

c.7558C>Tb
p.Arg2520Ter

rs80358981

breast, and breast-ovarian
cancer, Hereditary cancer-

899 AA short [158]

predisposing syndromef.

4-4A

BRCA2

25 of 27

c.9294C>G

3d; Pathogenice; Familial

a

p.Tyr3098Ter

rs80359200

breast and breast-ovarian

321 AA short [159]

cancerf.
3d; Pathogenice; Familial

7-3A

PALB2

4 of 13

c.1240C>Ta
p.Arg414Ter

rs180177100

breast cancer, Hereditary
cancer-predisposing

773 AA short

[58]

839 AA short

-

syndromef.
4-4D

PALB2

4 of 13

c.1042C>Ta
p.Gln348Ter

a

Confirmed by Sanger sequencing

b

Not confirmed by Sanger sequencing

c

If available

d

Number of submissions

e

Clinical significance

f

Condition(s)

Novel

-
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consequence, functional domains of PALB2 that interact with BRCA1, RAD51, BRCA2,
and POLH are lost [137]. Two known nonsense mutations were found in BRCA2,
c.7558C>T in exon 15 [158] and c.9294C>G in exon 25 [159]. The first
(chr13:32930687C>T; rs80358981; 7-1G) causes the loss of the BRCA2 region that
binds FANCD2, responsible for loading BRCA2 onto damaged chromatin [160]. The
second (chr13:32968863C>G, rs80359200; 4-4A) does not occur within a known
functional domain, however the transcript is likely to be degraded by nonsense mediated
decay [161].

4.3.8.2

Missense

GATK called 61 missense variants, of which 18 were identified in 6 patients or more and
19 had allele frequencies > 1.0% (Appendix C.11). The 40 remaining variants (15 ATM, 8
BRCA1, 9 BRCA2, 2 CDH1, 2 CHEK2, 3 PALB2, and 1 TP53) were assessed using a
combination of gene specific databases, published classifications, and 4 in silico tools
(Appendix C.12). We prioritized 27 variants, 2 of which were novel. None of the nonprioritized variants were predicted to be damaging by more than 2 of 4 conservationbased software programs.

4.3.9

Variant Classification

Initially, 15,311 unique variants were identified by complete gene sequencing of 7 HBOC
genes. Of these, 132 were flagged after filtering, and further reduced by IT-based variant
analysis and consultation of the published literature to 87 prioritized variants. Figure 4.6
illustrates the decrease in the number of unique variants per patient at each step of our
identification and prioritization process. The distribution of prioritized variants by gene is
34 in ATM, 13 in BRCA1, 11 in BRCA2, 8 in CDH1, 6 in CHEK2, 10 in PALB2, and 5 in
TP53 (Appendix C.13), which are categorized by type in Table 4.5.
Three prioritized variants have multiple predicted roles: ATM c.1538A>G in missense
and SRFBS, CHEK2 c.190G>A in missense and UTR binding, and CHEK2 c.433C>T in
missense and UTR binding. Of the 102 patients that we sequenced, 72 (70.6%) exhibited
at least one prioritized variant, and some patients harbored more than one prioritized
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Figure 4.6: Ladder plot representing variant identification and prioritization. Each line is representative of a different sample in
each sequencing run (A-E), illustrating the number of unique variants at important steps throughout the variant prioritization process.
The left-most point indicates the total number of unique variants. The second point represents the number of unique variants
remaining after common (> 5 patients within cohort and/or ≥ 1.0% allele frequency) and false-positive variants were removed. The
right-most point represents the final number of unique. No variants were prioritized in the following patients: 2-1A, 2-5A, 2-6A, 3-2A,
3-3A, 3-4A, 3-5A, 3-8A, 4-1B, 4-2C, 4-2F, 4-3B, 4-3D, 4-4B, 4-4E, 5-1G, 5-1H, 5-3D, 5-4C, 5-4D, 5-4F, 5-4G, 5-4H, 7-1B, 7-1C, 71D, 7-1H, 7-2B, 7-2C, 7-2H, 7-3H, 7-4A, 7-4D, 7-4H. The average number of variants per patient at each step is indicated in a table
below each plot, along with the percent reduction in variants from one step to another.
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Table 4.5. Summary of prioritized variants by gene
Indel

Nonsense Missense

Natural

Cryptic

Splicing Splicing

Pseudoexon

SR
Factor

TF

UTR

UTR

Structure Binding

Total

ATM

0

0

14

2

0

0

18

0

0

1

34a

BRCA1

2

0

2

0

0

1

7

1

0

0

13

BRCA2

0

2

3

0

0

2

4

0

0

0

11

CDH1

0

0

2

0

0

2

1

1

1

1

8

CHEK2

0

0

2

1

0

0

3

0

0

2

6a

PALB2

1

2

3

0

0

0

3

1

0

0

10

TP53

0

0

1

0

0

0

0

2

0

2

5

Total

3

4

27

3

0

5

36

5

1

6

Three variants were prioritized under multiple categories: ATM chr11:108121730A>G (missense and SRFBS), CHEK2
chr22:29121242G>A (missense, UTR binding), and CHEK2 chr22:29130520C>T (missense, UTR binding).
a

Counts represent the number of unique variants identified (i.e. a variant is not counted twice if it appeared in multiple individuals).
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variant (N = 33; 32%). Appendix C.14 presents a summary of all flagged and prioritized
variants for patients with at least one prioritized variant.

4.3.10

Prioritization of Potential Deletions

Using BreakDancer, none of the individuals analyzed exhibited large rearrangements that
met the level of stringency required, but a small intragenic rearrangement in BRCA1 was
identified and confirmed by Sanger sequencing. Attempts to detect deletions with
BreakDancer only flagged single, non-contiguous paired-end reads, rather than a series of
reads clustered within the same region within the same individual, which would be
necessary to indicate the presence of a true deletion or structural rearrangement.
After prioritizing individuals for potential hemizygosity in the sequenced regions,
potential deletions were detected in BRCA2 and CDH1. Patient UWO5-4D exhibited a
non-polymorphic 32.1 kb interval in BRCA2 spanning introns 1 to 13 that was absent
from all of the other individuals (chr13:32890227-32922331). Haploview (hapmap.org)
showed very low levels of linkage disequilibrium in this region. The potential deletion
may extend further downstream, however the presence of a haploblock covering the
entire sequenced interval beyond exon 11 with significant LD precludes delineation of
the telomeric breakpoint. We also flagged a non-polymorphic 2.6 kb interval near the 3’
end of CDH1 in 6 individuals (UWO3-5, UWO4-2C, UWO4-4E, UWO4-4F, UWO4-2G,
UWO5-2H). This is a low LD region spanning chr16:68861286-68863887 that includes
exons 14 and 15, and is polymorphic in all of the other individuals sequenced. CDH1
mutations are characteristically present in families with predisposition to gastric cancer,
however breast cancer frequently co-occurs [69]. A study of CDH1 deletions in inherited
gastric cancer identified two families with deletions that overlap the intervals prioritized
in the present study [162].

4.3.11

Comparison to Combined Annotation Dependent Depletion

The analysis and prioritization of non-coding variants can also be accomplished using
Combined Annotation Dependent Depletion (CADD; [163]), which uses known and
simulated variants to compute a C-score, an ad hoc measure of how deleterious is likely
to be. The suggested C-score cutoff is between 10-20, though it is stated that any selected
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cutoff value would be arbitrary (http://cadd.gs.washington.edu/info). This contrasts with
information-based methods, which are based on thermodynamically-defined thresholds.
To directly compare methods, CADD scores were obtained for all prioritized or flagged
SNVs. Half of prioritized variants met this cutoff (C>10), while only 28.6% of flagged
variants did the same. All prioritized nonsense variants (4/4) and 26/27 missense variants
had strong C-scores. Prioritized non-coding variant categories that correlated well with
CADD include natural splicing variants (4/4), UTR structure variants (1/1), and RBPs
(4/6).Weakly correlated variants included those affecting SRFBPs (5/36), TFBS (2/5),
and pseudoexon activating variants (0/5). Missense mutations comprised 75% of the
flagged variants with C>10. The aforementioned flagged splicing variant ATM c.10666T>G also exceeded the threshold C value (C = 11.9). Meanwhile, the flagged TP53
variant, shown by SHAPE analysis to alter UTR structure, did not (C = 5.3). Despite
consistency between some variant categories, the underlying assumptions of each
approach probably explain why these results differ for non-coding variants. The limited
numbers validated, deleterious non-coding variants also contributes to the accuracy of
these predictions [163].

4.3.12

Variant Verification

We verified prioritized protein-truncating (N = 7) and splicing (N = 4) variants by Sanger
sequencing (Table 4.2 and Table 4.4, respectively). In addition, two missense variants
(BRCA2 c.7958T>C and CHEK2 c.433C>T) were re-sequenced, since they are indicated
as likely pathogenic/pathogenic in ClinVar (Appendix C.12). All protein-truncating
variants were confirmed, with one exception (BRCA2 c.7558C>T, no evidence for the
variant was present for either strand). Two of the mRNA splicing mutations were
confirmed on both strands, while the other two were confirmed on a single strand (ATM
c.6347+1G>T and ATM c.1066-6T>G). Both documented pathogenic missense variants
were also confirmed.

4.4 Discussion
NGS technology offers advantages in throughput and variant detection [126], but the task
of interpreting the sheer volume of variants in complete gene or genome data can be
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daunting. The whole genome of a Yoruban male contained approximately 4.2 million
SNVs and 0.4 million structural variants [164]. The variant density in the present study
(average 948 variants per patient) was 5.3-fold lower than the same regions in HapMap
sample NA12878 in Illumina Platinum Genomes Project (5029 variants) [165]. The
difference can be attributed primarily to the exclusion of polymorphisms in highly
repetitive regions in our study.
Conventional coding sequence analysis, combined with an IT-based approach for
regulatory and splicing-related variants, reduced the set to a manageable number of
prioritized variants. Unification of non-coding analysis of diverse protein-nucleic acid
interactions using the IT framework accomplishes this by applying thermodynamic-based
thresholds to binding affinity changes and by selecting the most significant binding site
information changes, regardless of whether the motifs of different factors overlap.
Previously, rule-based systems have been proposed for variant severity classification
[166, 167]. Functional validation and risk analyses of these variants are a prerequisite for
classification, but this would not be practical to accomplish without first limiting the
subset of variants analyzed. With the exception of some (but not all [37]) protein
truncating variants, classification is generally not achievable by sequence analysis alone.
Only a minority of variants with extreme likelihoods of pathogenic or benign phenotypes
are clearly delineated because only these types of variants are considered actionable [166,
167]. The proposed classification systems preferably require functional, co-segregation,
and risk analyses to stratify patients. Nevertheless, the majority of variants are VUS,
especially in the case of variants occurring beyond exon boundaries. Of the 5713 variants
in the BIC database, the clinical significance of 4102 BRCA1 and BRCA2 variants are
either unknown (1904) or pending (2198), and only 1535 have been classified as
pathogenic (Class 5) [168]. Our results cannot be considered equivalent to validation,
which usually include expression assays [36] or the use of RNA-seq data [169] (splicing),
qRT-PCR [170] (transcription), SHAPE analysis (mRNA 2° structure) [44], or binding
assays to determine functional effects of variants. Classification of VUS in BRCA1 and
BRCA2 by the ENIGMA Consortium addresses mRNA splicing and missense variants.
Criteria define risk based on whether the variant occurs within a protein structural
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domain, the impact on protein function, and the segregation pattern of variant with
disease in pedigrees [171]. These guidelines cannot be fully implemented here for several
reasons: a) patients were anonymized in this study, precluding segregation analysis, b)
the splicing mutation guideline does not take into account predicted leaky or cryptic
splice site mutations, nor other non-canonical changes that have been demonstrated to
alter the expression of these and numerous other genes, c) conserved domains have not
been identified in regions of the proteins encoded by these genes, especially BRCA2,
where many missense mutations reside, and d) the guidelines are currently silent as to the
potential impact of regulatory variants affecting splicing, RNA stability, and
transcriptional regulation.
While miRNA variant prediction program mrSNP [172] was used to evaluate all of the 3’
UTR variants, 41.4% of the variants were predicted to alter the stability of the miRNAtarget mRNA duplex for at least one miRNA expressed in breast tissue. However, only 2
of these interactions could be confirmed using TarBase [173], and these variants could
not be prioritized for disruption of miRNA regulation. Other post-transcriptional
processes, including miRNA regulation, that were not addressed in this study, may also
be amenable to IT-based modeling. With the proposed approach, functional prediction of
variants could precede or at least inform the classification of VUS.
It is unrealistic to expect all variants to be functionally analyzed, just as it may not be
feasible to assess family members for a suspected pathogenic variant detected in a
proband. The prioritization procedure reduces the chance that significant variants have
been overlooked. Capturing coding and non-coding regions of HBOC-related genes,
combined with the framework for assessing variants, balances the need to
comprehensively detect all variation in a gene panel with the goal of identifying variants
likely to be phenotypically relevant.
The location of variants in relation to known protein domains was documented in this
study, but was not directly incorporated into our prioritization method. The locations and
impact of splicing mutations in BRCA1 and BRCA2 were mapped to the known
functional domains of the encoded proteins [174]. A high concentration of variants
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predicted to result in splicing changes occurred in the BRCT, RING finger, and NLS
domains of BRCA1. However, BRCA2 variants were generally concentrated outside of
known functional domains (aside from the C-terminal domain). Because of these
inconsistencies, domain-mapping was not integrated with IT based prioritization.
However, where adequate information on structure-function relationships is available (eg.
TP53), we suggest that such analysis be carried out subsequent to IT-based variant
prioritization.

4.4.1

Non-coding Variants

Although coding variants are typically the sole focus of a molecular diagnostic laboratory
(with the exception of the canonical dinucleotide positions within splice sites), noncoding mutations have long been known to be disease causing [19, 36, 175–183]. In this
study, variant density in non-coding regions significantly exceeded exonic variants by >
60-fold, which, in absolute terms, constituted 1.6% of the 15,311 variants. This is
comparable to whole genome sequencing studies, which typically result in 3-4 million
variants per individual, with < 2% occurring in protein coding regions [184]. IT analysis
prioritized 3 natural SS, 36 SRFBS, 5 TFBS, and 6 RBBS variants and 5 predicted to
create pseudoexons. Two SS variants in ATM (c.3747-1G>A and c.6347+1G>T) were
predicted to completely abolish the natural site and cause exon skipping. A CHEK2
variant (c.320-5A>T) was predicted to result in leaky splicing.
The IT-based framework evaluates all variants on a common scale, based on bit values,
the universal unit that predicts changes in binding affinity [185]. A variant can alter the
strength of one or a “set” of binding sites; the magnitude and direction of these changes is
used to rank their significance. The models used to derive information weight matrices
take into account the frequency of all observed bases at a given position of a binding
motif, making them more accurate than consensus sequence and conservation-based
approaches [36].
IT has been widely used to analyze natural and cryptic SSs [36], but its use in SRFBS
analysis was only introduced recently [38]. For this reason, we assigned conservative,
minimum thresholds for reporting information changes. Although there are examples of
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disease-causing variants resulting in small changes in 𝑅𝑖 [174, 186–192], the majority of
deleterious splicing mutations that have been verified functionally, produce large
information changes. Among 698 experimentally deleterious variants in 117 studies, only
1.96% resulted in < 1.0 bit change [36]. For SRFBS variants, the absolute information
changes for deleterious variants ranged from 0.2 - 17.1 bits (mean 4.7 ± 3.8). This first
application of IT in TFBS and RBBS analysis, however, lacks a large reference set of
validated mutations for the distribution of information changes associated with
deleterious variants. The release of new ChIP-seq datasets will enable IT models to be
derived for TFs currently unmodeled and will improve existing models [193].
Pseudoexon activation results in disease-causing mutations [194], however such
consequences are not customarily screened for in mRNA splicing analysis. IT analysis
was used to detect variants that predict pseudoexon formation and 5 variants were
prioritized. Previously, we have predicted experimentally proven pseudoexons with IT
(Ref 42: Table 4.2, No #2; and Ref 195: Table 4.2, No #7) [42, 195]. Although it was not
possible to confirm prioritized variants in the current study predicted to activate
pseudoexons because of their low allele frequencies, common intronic variants that were
predicted to form pseudoexons were analyzed. We then searched for evidence of
pseudoexon activation in mapped human EST and mRNA tracks [196] and RNA-seq data
of breast normal and tumour tissue from the Cancer Genome Atlas project [15]. One of
these variants (rs6005843) appeared to splice the human EST HY160109 [197] at the
predicted cryptic splice site and is expressed within the pseudoexon boundaries.
Variants that were common within our population sample (i.e. occurring in > 5
individuals) and/or common in the general population (> 1.0% allele frequency) reduced
the list of flagged variants substantially. This is now a commonly accepted approach for
reducing candidate disease variants [166], based on the principle that the disease-causing
variants occur at lower population frequencies. Variants occurring in > 5 patients all
either had allele frequencies above 1.0% or, as shown previously, resulted in very small
∆𝑅𝑖 values [198].
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The genomic context of sequence changes can influence the interpretation of a particular
variant [36]. For example, variants causing significant information changes may be
interpreted as inconsequential if they are functionally redundant or enhancing existing
binding site function (see IT-Based Variant Analysis for details). Our understanding of
the roles and context of these cognate protein factors is incomplete, which affects
confidence in interpretation of variants that alter binding. Also, certain factors with
important roles in the regulation of these genes, but that do not bind DNA directly or in a
sequence-specific manner (eg. CtBP2 [199]), could not be included. Therefore, some
variants may have been incorrectly excluded.

4.4.2

Prioritization of Potential Deletions

Although individuals can be prioritized based on potential hemizygosity, this does not
definitively identify deletions. Nevertheless, it should be possible to prioritize those
individuals worthy of further detailed diagnostic workup. It has not escaped our attention
that the weighted probabilities obtained from this analysis could be represented and
formalized using the same units of Shannon information (in bits) as the other sequence
changes we have described, analogous to single or multinucleotide gene variants
predicted to affect nucleic acid binding sites. Full development and validation of this
method is in progress.

4.4.3

Coding Sequence Changes

We also identified 4 nonsense and 3 indels in this cohort. In one individual, a 19 nt
BRCA1 deletion in exon 15 causes a frameshift leading to a stop codon within 14 codons
downstream. This variant, rs80359876, is considered clinically relevant. Interestingly,
this deletion overlaps two other published deletions in this exon (rs397509209 and
rs80359884). This raises the question as to whether this region of the BRCA1 gene is a
hotspot for replication errors. DNA folding analysis indicates a possible 15 nt long stemloop spanning this interval as the most stable predicted structure (data not shown). This
15 nt structure occurs entirely within the rs80359876 and rs397509209 deletions and
partially overlaps rs80359884 (13 of 15 nt of the stem loop). It is plausible that the 2°
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structure of this sequence predisposes to a replication error that leads to the observed
deletion.
Missense coding variants were also assessed using multiple in silico tools and evaluated
based on allele frequency, literature references, and gene-specific databases. Of the 27
prioritized missense variants, the previously reported CHEK2 variant c.433G>A
(chr22:29121242G>A; rs137853007) stood out, as it was identified in one patient (43C.5-4G) and is predicted by all 4 in silico tools to have a damaging effect on protein
function. Accordingly, Wu et al. (2001) demonstrated reduced in vitro kinase activity and
phosphorylation by ATM kinase compared to the wild-type CHEK2 protein [200],
presumably due to the variant’s occurrence within the forkhead homology-associated
domain, involved in protein-phosphoprotein interactions [201]. Implicated in LiFraumeni syndrome, known to increase the risk of developing several types of cancer
including breast [202, 203], the CHEK2: c.433G>A variant is expected to result in a
misfolded protein that would be targeted for degradation via the ubiquitin-proteosome
pathway [204]. Another important missense variant is c.7958T>C
(chr13:32,936,812T>C; rs80359022; 4-4C) in exon 17 of BRCA2. Although classified as
being of unknown clinical importance in both BIC and ClinVar, it has been classified as
pathogenic based on posterior probability calculations [205].
It is unlikely that all prioritized variants are pathogenic in patients carrying more than one
prioritized variant. Nevertheless, a polygenic model for breast cancer susceptibility,
whereby multiple moderate and low-risk alleles contribute to increased risk of HBOC
may also account for multiple prioritized variants [206, 207]. There was a significant
fraction of patients (29.4%) in whom no variants were prioritized. This could be due to a)
the inability of the analysis to predict a variant affecting the binding sites analyzed, b) a
pathogenic variant affecting a function that was not analyzed or in a gene that was not
sequenced, c) a large rearrangement/deletion where both breakpoints occur beyond the
captured genomic intervals (which is unlikely, as this would have been observed as an
extended non-polymorphic sequence), or d) the significant family history was not due to
heritable, but instead to shared environmental influences.
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BRCA coding variants were found in individuals who were previously screened for
lesions in these genes, suggesting this NGS protocol is a more sensitive approach for
detecting coding changes. However, previous testing of a number of these patients had
been predominantly based on PTT and MLPA, which have lower sensitivity for detecting
mutations than sequence analysis. Nevertheless, we identified 2 BRCA1 and 2 BRCA2
variants predicted to encode prematurely truncated proteins. Fewer non-coding BRCA
variants were prioritized (15.7%) than expected by linkage analysis [49], however this
presumes at least 4 affected breast cancer diagnoses per pedigree, and, in the present
study, the number of affected individuals per family was not known.
Prioritization of a variant does not equate with pathogenicity. Some prioritized variants
may not increase risk, but may simply modify a primary unrecognized pathogenic
mutation. A patient with a known BRCA1 nonsense variant, used as a positive control,
was also found to possess an additional prioritized variant in BRCA2 (missense variant
chr13:32911710A>G), which was flagged by PROVEAN and SIFT as damaging, as well
as flagged for changing an SRFBS for abolishing a PTB site (while simultaneously
abolishing an exonic hnRNPA1 site). This variant has been identified in cases of early
onset prostate cancer and is considered a VUS in ClinVar [143]. Similarly, variants
prioritized in multiple patients may act as risk modifiers rather than pathogenic
mutations. A larger cohort of patients with known pathogenic mutations would be
necessary to calculate a background/basal rate of falsely flagged variants.
Other groups have attempted to develop comprehensive approaches for variant analysis,
analogous to the one proposed here [208–210]. While most employ high-throughput
sequencing and classify variants, either the sequences analyzed or the types of variants
assessed tend to be limited. In particular, non-coding sequences have not been sequenced
or studied to the same extent, and none of these analytical approaches have adopted a
common framework for mutation analysis.
Our published oligonucleotide design method [77] produced an average sequence
coverage of 98.8%. The capture reagent did not overlap conserved highly repetitive
regions, but included divergent repetitive sequences. Nevertheless, neighboring probes
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generated reads with partial overlap of repetitive intervals. As previously reported [147],
we noted that false positive variant calls within intronic and intergenic regions were the
most common consequence of dephasing in low complexity, pyrimidine-enriched
intervals. This was not alleviated by processing data with software programs based on
different alignment or calling algorithms. Manual review of all intronic or intergenic
variants became imperative. As these sequences can still affect functional binding
elements detectable by IT analysis (i.e. 3’ SSs and SRFBSs), it may prove essential to
adopt or develop alignment software that explicitly and correctly identifies variants in
these regions [147]. Most variants were confirmed with Sanger sequencing (10/13), and
those that could not be confirmed are not necessarily false positives. A recent study
demonstrated that NGS can identify variants that Sanger sequencing cannot, and
reproducing sequencing results by NGS may be worthwhile before eliminating such
variants [211].

4.5 Conclusions
Through a comprehensive protocol based on high-throughput, IT-based and
complementary coding sequence analyses, the numbers of VUS can be reduced to a
manageable quantity of variants, prioritized by predicted function. While exonic variants
corresponded to a small fraction of prioritized variants, there is considerably more
evidence for their pathogenicity because clinical sequencing has concentrated in these
regions. Our sequencing approach illustrates the importance of sequencing non-coding
regions of genes to establish pathogenic mutations not already evident from changes in
the amino acid based genetic code [212]. We suggest our approach for variant flagging
and prioritization bridges the phase between high-throughput sequencing, variant
detection with the time-consuming process of variant classification, including pedigree
analysis and functional validation. Subsequent to completion of the present study, ethics
approval was obtained for a similar analysis of consented patients with clinical
information. This work will be described elsewhere [212].
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Chapter 5

5

Prioritizing Variants in Complete Hereditary Breast and
Ovarian Cancer Genes in Patients Lacking Known
BRCA Mutations

The work presented in this chapter is reproduced (with permission, Appendix D.1) from:
Caminsky,N.G., Eliseos,J.M., Perri,A.M., Lu,R., Knoll,J.H.M., Rogan,P.K. (2016)
Prioritizing variants in complete Hereditary Breast and Ovarian Cancer genes in patients
lacking known BRCA mutations. Hum. Mutat., 37, 640–652

5.1 Introduction
Currently, the lifetime risk for a woman to develop breast cancer (BC) is 12.3% and 1.3%
in the case of ovarian cancer (OC [Howlander et al., 2014]). Approximately 5-10% of all
BC cases are hereditary in nature, versus 25% for OC, where relative risk (RR) of BC or
OC with one affected 1st degree family member is estimated at 2.1 and 3.1, respectively
[Stratton et al., 1998; Walsh et al., 2011]. Two highly penetrant genes, BRCA1 and
BRCA2, are associated with a large proportion of HBOC cases. However, the estimated
rate of linkage to these genes is significantly higher than the proportion of pathogenic
mutations identified in HBOC families [Ford et al., 1998], suggesting unrecognized or
unidentified variants in BRCA1/2.
Clinical BRCA1/2 testing is restricted primarily to coding regions. Limitations on how
variants can be interpreted, lack of functional validation, and mutations in other genes
contribute to uninformative results. The heritability that is not associated with BRCA
genes is likely due to other genetic factors rather than environmental causes, specifically
moderate- and low-risk susceptibility genes [Antoniou and Easton, 2006]. Hollestelle et
al. (2010) point out the challenges in estimating increased risks associated with mutations
in these genes, as the disease patterns are often incompletely penetrant, and require large
pedigree studies to confidently assess pathogenicity.
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Next-generation sequencing (NGS) of gene panels for large cohorts of affected and
unaffected individuals has become an increasingly popular approach to confront these
challenges. Numerous HBOC gene variants have been catalogued, including cases in
which RR has been determined; however the literature is also flooded with variants
lacking a clinical interpretation [Cassa et al., 2012]. It is not feasible to functionally
evaluate the effects all of the VUS identified by NGS and in silico assessment of variants
is often limited to structural changes or concerns evolutionary conservation among
species. Several approaches have been developed to better assess variants from exome
and genome-wide NGS data [Duzkale et al., 2013; Kircher et al., 2014]. Nevertheless,
there is an unmet need for other methods that quickly and accurately bridge variant
identification and classification.
To begin to address this problem, we sought to provide potentially novel interpretations
of noncoding sequence changes, based on disruption or acquisition of interactions with
proteins that recognize nucleic acid binding sites. Information theory (IT) based analysis
predicts changes in sequence binding affinity, and it has been applied and validated for
use in the analysis of splice sites (SSs), SRBSs [Rogan et al., 1998, 2003; Mucaki et al.,
2013; Caminsky et al., 2015] and TFBSs [Gadiraju et al., 2003]. A unified framework
based on IT requires binding genome-scale site data devoid of consensus sequence bias
[Schneider, 1997], for example, photoactivatable-ribonucleotide-enhanced cross-linking
and immunoprecipitation (PAR-CLIP), ChIP-Seq, and a comprehensive, validated set of
SSs. Although these data sources are heterogeneous, the IT models and binding site
affinities derived from them are uniformly scaled (in units of bits). Thus, binding
interactions involving disparate proteins or other recognition molecules can be measured
and directly compared.
We have described a unified IT framework for the identification and prioritization of
variants in coding and noncoding region s of BRCA1, BRCA2, and five other HBOC
genes (ATM, CDH1, CHEK2, PALB2, and TP53 [Mucaki et al., 2016]. This approach
was applied to a cohort of 102 individuals lacking BRCA mutations with a history of
HBOC. This distinguished prioritized variants from flagged alleles conferring small
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changes to regulatory protein binding site sequences in 70.6% of cases [Mucaki et al.,
2016].
In the present study, we have sequenced 13 additional genes that have been deemed
HBOC susceptibility loci (BARD1, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH,
NBN, PMS2, PTEN, RAD51B, STK11, and XRCC2 [Minion et al., 2015]). These genes
encode proteins with roles in DNA repair, surveillance, and cell cycle regulation (Figure
5.1; for further evidence supporting this gene set see Appendix D.2 [Apostolou and
Fostira 2013; Al Bakir and Gabra 2014]), and are associated with specific disease
syndromes that confer an increased risk of BC and OC, as well as many other types of
cancer (Appendix D.3). High-risk genes confer > 4-times increased risk of BC compared
to the general population. BRCA1 and BRCA2 are estimated to increase risk 20-fold
[Antoniou et al., 2003]. Pathogenic variants in other high-risk genes, CDH1, PTEN,
STK11, and TP53, are rarely seen outside of their associated syndromes, and account for
< 1% of hereditary BC cases [Maxwell and Domchek, 2013]. EPCAM, MLH1, MSH2,
MSH6, and PMS2 have also been proposed to harbor high-risk BC alleles, but the RR is
still controversial [Maxwell and Domchek, 2013]. Genes with moderate-risk alleles,
ATM, CHEK2, and PALB2, cause between a 2- and 4-fold increased risk of BC
[Apostolou and Fostira, 2013; Maxwell and Domchek, 2013]. The remaining genes
(BARD1, MRE11A, MUTYH, NBN, RAD51B, and XRCC2) are newly identified and
currently associated with unknown risks for HBOC (Figure 5.1).
We report NGS of hybridization-enriched, complete genic and surrounding regions of
these genes, followed by variant analysis in 287 consented patients from Southwestern
Ontario, Canada with previously uninformative HBOC test results. (Except for 6
individuals, these patients were different from our submitted study). We then reduced the
set of potentially pathogenic gene variants in each individual by prioritizing the results of
coding and IT-analyses. After applying a frequency-based filter, the IT-based framework
prioritizes variants based on their predicted effect on the recognition of sequence
elements involved in mRNA splicing, transcription, and untranslated region (UTR)
binding, combined with UTR secondary structure and coding variant analysis. Our
approach integrates disparate sources of information, including bioinformatic analyses,
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Figure 5.1: Common genomic pathways among 20 HBOC genes, including risk and
relevant literature. The left, top, and right circles indicate sequenced genes that play
important roles in the mismatch repair (MMR), Fanconi anemia, and DNA double-strand
break repair pathways, respectively. The bottom circle contains genes involved in cell
cycle control. Genes considered to present a high risk of breast and/or ovarian cancer
when mutated are bolded, moderate-risk genes are underlined, and low-risk genes are in
normal font. The estimated number of articles listing a gene’s association with breast or
ovarian cancer (based on a systematic search in PubMed [performed June 2015]) is
indicated in superscript. ∗∗ MUTYH is only high risk in the case of bi-allelic mutations. ∗
EPCAM is not involved in any pathways, but is associated with hereditary nonpolyposis
colorectal cancer (HNPCC) by virtue of the fact that 3’ deletions of EPCAM can cause
epigenetic silencing of MSH2, causing Lynch syndrome protein. See Appendix D.1 for
citations and further evidence supporting this gene set.
likelihood ratios based on familial segregation, allele frequencies, and published findings
to prioritize disease-associated mutation candidates.
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5.2 Methods
5.2.1 Ethics and Patient Recruitment
Recruitment and consent of human participants was approved by the University of
Western Ontario Research Ethics Board (Protocol 103746). Patients were enrolled from
January, 2014 through March, 2015 at London Health Sciences Centre (LHSC). Patients
met the following criteria: male or female, aged between 25 and 75 years, > 10% risk of
having an inherited mutation in a breast/ovarian cancer gene, diagnosed with BC and/or
OC, and previously receiving uninformative results for a known, pathogenic BRCA1 or
BRCA2 variant in either the patient or other relatives (by Protein Truncation Test [PTT]
and/or Multiplex Ligation-dependent Probe Amplification [MLPA]).
The median age of onset for patients (N = 287; Appendix D.5-Supp. Fig. S1) with BC
was 48 (N = 277), and 46 for OC (N = 17), and 7 were diagnosed with both BC and OC.
Furthermore, 31 patients had bilateral BC (98 patients at diagnosis; 23 developed tumors
on the opposite side after the initial occurrence), 1 had bilateral OC, and 13 have had
recurrent BC in the same breast. There was a single case of male BC (Appendix D.4).

5.2.2

Probe Design, Sample Preparation, and Sequencing

Probes for sequence capture were designed by ab initio single copy analysis, as described
in Mucaki et al. [2016] and Dorman et al. [2013]. The probes covered1,103,029 nt across
the 21 sequenced genes, including the negative control gene ATP8B1 (see Appendix D.5
for gene names, GenBank accession numbers, and OMIM reference numbers). This set of
genes was proposed for evaluation at the evidence-based network for the Interpretation of
Germline Mutant Alleles (ENIGMA) Consortium Meeting (2013). Other genes that have
been found to be mutated in HBOC could not be included (e.g. BRIP1, RAD50, RAD51C,
RAD51D [Heikkinen et al. 2003; Seal et al. 2006; Janatova et al. 2015]).
Patient DNA extracted from peripheral blood was either obtained from the initial genetic
testing at LHSC Molecular Genetics Laboratory or isolated from recent samples. NGS
libraries were prepared using modifications to a published protocol (Gnirke et al., 2009)
described in Mucaki et al. [2016], and all post-capture pull-down steps were automated
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(Appendix D.5). An Illumina Genome Analyzer IIx instrument in our laboratory was
used for sequencing.
Library preparation and re-sequencing were repeated for samples with initial average
coverage below our minimum threshold (< 30x). To ensure that the proper sample was
re-sequenced, the variant call format (VCF) files from each run were compared to all
others in the run using VCF-compare (http://vcftools.sourceforge.net/). VCF files from
separate runs for the re-sequenced patient were concordant, except for minor differences
in variant call rates due to differences in coverage. The aligned reads from both runs were
then merged (with BAMtools; http://sourceforge.net/projects/bamtools/).
Samples were demultiplexed and aligned using CASAVA (Consensus Assessment of
Sequencing and Variation; v1.8.2 [DePristo et al. 2011]) and CRAC (Complex Reads
Analysis & Classification; v1.3.0; http://crac.gforge.inria.fr/). Aligned BAM files were
then pre-processed for variant calling with Picard [v.1.109;
http://broadinstitute.github.io/picard/] (MarkDuplicates, AddorReplaceReadGroups,
FixMateInformation). The Genome Analysis Toolkit (GATK v3.1;
http://www.broadinstitute.org/gatk/) was then used for variant calling using the modules
‘Indel realigner’ and the ‘Unified Genotyper’. Variants flagged by bioinformatic analysis
[see Variant Analysis below] were also assessed by manual inspection with the
Integrative Genome Viewer v2.3 (IGV; http://www.broadinstitute.org/igv/). Variants in
this study are written in HGVS notation, are based on cDNA sequence, and comply with
journal guidelines.

5.2.3

Information Models

Models for natural splice sites (SSs) and splicing regulatory factors (SRFs) are described
in Mucaki et al. [2013]. These models were used to predict deleterious effects on natural
splicing, the activation of cryptic SSs, and changes to binding of splicing enhancers and
silencers. In addition, using a combination of cryptic site activation and hnRNPA1 site
prediction, pseudoexon formation was also assessed.
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We previously built models for TFBSs (N = 83) using ENCODE ChIP-seq data
[ENCODE Project Consortium, 2012; Mucaki et al., 2016]. Due to the inclusion of the
additional genes, eight additional transcription factors (TFs) were identified from the
literature and ENCODE ChIP-seq data from BC cell lines with evidence of binding and
potentially regulating these genes. However, models for three of these TFs passed our
quality control criteria (TFIIIB150 [BDP1], PBX3 and ZNF274; described in Lu et al.
[2017]. Appendix D.6 contains the full list of TFs (N = 86) and indicates which genes
exhibit evidence of promoter or other binding events. Noise models (N = 5), reflecting
motifs of interacting cofactors or sequence-specific histone modifying events, were
excluded (Appendix D.5).
Information weight matrices, 𝑅𝑖 (𝑏, 𝑙), for sequences bound by RNA-binding proteins
(RBPs) were derived from frequency matrices published in the Catalog of Inferred
Sequence Binding Preferences of RNA binding protein (CISBP-RNA; http://cisbprna.ccbr.utoronto.ca/) and RNA-Binding Protein Database (BPDB;
http://rbpdb.ccbr.utoronto.ca/). These 𝑅𝑖 (𝑏, 𝑙)s were used to compute changes in binding
affinity due to SNVs, using conservative minimum information thresholds described in
Mucaki et al. [2016]. Finally, predicted changes in UTR structure resulting from variants
were determined using SNPfold
[http://ribosnitch.bio.unc.edu/snpfold/;Halvorsenetal.,2010]. Significant changes in UTR
structure and stability were represented using mfold (http://unafold.rna.albany.edu/?q =
mfold).

5.2.4

Variant Analysis

Information analysis has been used in the interpretation of variant effects on binding sites
containing these changes, whether this involves the creation or strengthening, or the
abolition or weakening of a site [Rogan et al., 1998]. This analysis was applied to all
variants identified by NGS. Changes in information are directly related to changes in
thermodynamic entropy and thus binding affinity [Rogan et al., 1998]. For example, a 1.0
bit change in information corresponds to at least a twofold change in binding affinity.
Information theoretical analysis of SSs and SRF binding sites has been extensively used
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and proven to be reliable and robust (85.2% accuracy when compared to variants
validated by expression studies) [Caminsky et al., 2015].
Information analysis was automated and thresholds for changes were applied
programmatically based on our previously validated criteria [Rogan et al., 1998, 2003;
von Kodolitschetal., 2006; Dorman et al., 2014]. This reduced manual review of
prioritized variants, databases, and the literature. A minimum 1.0 bit threshold was set for
variants predicted to affect natural SSs or that activate a cryptic SS by exceeding the
strength of cognate natural sites. Variants affecting splicing regulatory, transcription, and
RBP binding sites were assessed more stringently and had a minimum threshold of 4.0
bits, i.e. ≥ 16-fold, in order to be flagged for further assessment. A population frequency
filter was also applied to variants with allele frequencies >1% (in the NCBI Short Genetic
Variations database (dbSNP)) or >5% of our patient cohort. Such variants were
eliminated from further consideration.
To assess coding changes affecting predicted protein chain length or amino acid(s)
composition, we used SNPnexus (http://hsnpnexus.org/). Insertion/deletions (indels) and
nonsense mutations were noted, and missense variants were further assessed with in
silico tools (Mutation Assessor, http://mutationassessor.org/; PolyPhen2,
http://genetics.bwh.arvard.edu/pph2/; PROVEAN/SIFT, http://provean.jcvi.org/) by
referencing the published literature and consulting mutation databases (listed in Appendix
D.7; see Mucaki et al. [2016] for more details on variant analysis). Variants remained
prioritized unless there was clear evidence (co-segregation analysis or functional assays)
supporting the nonpathogenicity of the variant.
EPCAM mutations in familial cancer are limited to 3’ deletions causing epigenetic
silencing of MSH2, and there is currently no evidence of other types of variants that alter
its mRNA transcript or protein product [Ligtenberg et al., 2009]. Therefore, with the
exception of indels, none of the variants flagged in EPCAM were prioritized. We chose to
prioritize variants in MUTYH using the same framework as all other genes, despite
MUTYH pathogenicity resulting from biallelic variants [Jones et al., 2002], because it is
possible that a second MUTYH mutation remains unrecognized.
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All protein truncating (nonsense and indels) as well as potentially pathogenic splicing and
missense mutations were Sanger sequenced for confirmation (details in Appendix D.8).

5.2.5

Negative Control

Variants present in the ATP8B1 gene were used as negative controls for our variant
analysis framework. Initially, it was included in the list of prioritized HBOC genes
provided by ENIGMA, but evidence for its association with HBOC is lacking in the
published literature. Furthermore, it is not a known susceptibility gene for any type of
cancer (mutations in ATP8B1 cause progressive familial intrahepatic cholestasis
[Gonzales et al., 2014]) and is infrequently mutated in breast tumors in several studies
(e.g., see Cancer Genome Atlas Network [2012]).

5.2.6

Likelihood Ratios

Patients with prioritized coding and/or splicing variants, which we consider the most
likely to be pathogenic, were selected for co-segregation analysis (N = 24) using an
online tool that calculates the likelihood of a variant being deleterious based on pedigree
information (https://www.msbi.nl/cosegregation/; Mohammadi et al. [2009]). Genotypes
were assigned based on phenotype such that family members with breast or OC at any
age were assigned the same genotype as the patient in our study (“carrier”) and family
members affected by other cancers, other diseases, or who are disease free were assigned
the “noncarrier” genotype. Because the penetrance parameters cannot be altered from the
settings given for BRCA1 or BRCA2, the BRCA2 option was selected for patients with
prioritized variants in non-BRCA genes. Penetrance in BRCA2 is known to be lower than
BRCA1 values [Mohammadi et al., 2009]. Current evidence suggests that mutations in
non-BRCA genes may be less penetrant than those in the BRCA genes [Apostolou and
Fostira, 2013]; however, the penetrance of many of these variants remains unknown
(Appendix D.5).
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5.3 Results
5.3.1

Variant Analysis

We identified 38,372 unique variants among 287 patients (26,636 intronic, 7,287
intergenic, and 714 coding), on average 1,975 variants per patient, before any filtering
criteria were applied. The extensive span of sequences captured in this study, that is,
complete genes and flanking regions, constrained the genomic density and sequence
coverage that could be achieved; this precluded accurate copy number estimation based
solely on read counts.

5.3.1.1

Natural Site Variants

The Shannon Human Splicing Mutation Pipeline (http://www.mutationforecaster.com;
Shirley et al. [2013]) was used to predict the effect of the 14,458 variants that could
potentially affect splicing, of which 244 reduced natural SS strength. Further stringent
filtering of the natural SS based on information content changes and allele frequency
resulted in seven flagged variants (Appendix D.9). Henceforth, allele frequency of known
variants can be found in their associated supplemental table (where available).
Four of these variants were prioritized (Table 5.1). A novel synonymous variant in exon 2
of RAD51B, c.84G>A (p.Gln28 = ), is predicted to increase exon skipping by weakening
the natural splice donor (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = 5.2 bits, ∆𝑅𝑖 = –3.0 bits). A known ATM variant,
c.6198+1G>A (8-1D.9-1B [Stankovic et al., 1998]), abolishes the natural donor SS of
constitutively spliced exon 42 (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = –13.7 bits, ∆𝑅𝑖 = –18.6 bits). There is no
evidence in public databases for appreciable alternative splicing of this exon in normal
breast tissues. The variant will either lead to exon skipping or activation of a preexisting
cryptic site (Figure 5.2). An ataxia-telangiectasia patient with this variant exhibited low
expression, protein truncation, and abolished kinase activity of ATM [Reiman et al.,
2011]. MLH1 c.306+4A>G causes increased exon skipping (and a decrease in wild-type
exon relative expression) due to the weakening (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = 6.0 bits, ∆𝑅𝑖 = –2.6 bits) of the
exon 3 natural donor. Tournier et al. [2008] assessed this variant using an ex vivo splicing
assay and observed cryptic site activation and exon 3 skipping. MRE11A c.2070+2A>T is
indicated in ClinVar as likely pathogenic and abolishes the natural donor site of exon 19
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Table 5.1: Prioritized Variants Predicted by IT to Affect Natural and Cryptic Splicing
Information Change
Gene

Variant

rsID (dbSNP142)

Consequence

Ri,initial

Ri,final

ΔRi

(bits)

(bits)

(bits)

-

4.9

-13.7

-18.6

Abolished naturald,g

-

7.6

-11

-18.6

Abolished naturald,g

rs267607733

8.6

6

-2.6

Weakened naturale

Novel

8.2

5.2

-3

Weakened naturald

Novel

-2.7

4.4

7.1

Created cryptice

rs373676607

-1.3

5.7

7

Created crypticf,h

Novel

-0.6

4.3

4.9

Created cryptice

Allele Frequency (%)c

NM_000051.3:c.6198+1G>A
ATM

[Stankovic et al., 1998;
Reiman et al., 2011]

MRE11A
MLH1

RAD51B

BARD1
BRCA1

NM_005591.3:c.2070+2A>Ta
NM_000249.2:c.306+4A>Ga
[Tournier et al., 2008]
NM_002877.4:c.84G>Aa
p.Gln28=
NM_000465.2:c.1454C>Ta
p.Ala485Val
NM_007294.2:c.5074+107C>T
NM_004360.3:c.1223C>Ga

CDH1

p.Ala408Gly
[Schrader et al. 2011]
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RAD51B

NM_002877.4:c.958-29A>Tb

STK11

NM_000455.4:c.375-194GT>AC

XRCC2

NM_005431.1:c.122-154G>T

a

Confirmed by Sanger sequencing

b

Ambiguous Sanger sequencing results

c

If available

d

Exon skipping

e

Exon truncation

f

Intron retention

g

Use of alternate isoform

h

Reduced expression of natural isoform

rs34436700
0.78
rs35113943 17.61
rs117211142 0.80
Novel

2.2

4.4

2.2

Strengthened crypticf

7.5

8.8

1.3

Strengthened crypticf

8.1

10

1.9

Strengthened crypticf
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Figure 5.2: Predicted isoforms and relative abundance as a consequence of ATM
natural splice variant c.6198+1G>A. (A) Intronic ATM variant c.6198+1G>A abolishes
the natural donor of exon 42 (𝑹𝒊,𝒊𝒏𝒊𝒕𝒊𝒂𝒍 = 4.9 bits, ∆𝑹𝒊 = –18.6 bits), and would either
result in exon skipping (causing a frame-shift; isoform 15 after mutation), or possibly
activate a downstream cryptic site (isoform 1 maintains reading frame, isoform 2 would
not). (B) The peaks in plot display the predicted abundance (Y-axis) of a splice isoform
(X-axis) relative to another predicted isoform (Z-axis). In the wild-type mRNA, the
natural exon (isoform 15) has the highest predicted relative abundance. Before mutation,
it is predicted to be approximately fivefold stronger than isoform 1 and 2. (C) After
mutation, isoform 1 and 2 is now > 100,000-fold stronger than isoform 15 (abolished
wild-type exon). Isoform 2 to be slightly less abundant than 1.
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(𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = –11.0 bits, ∆𝑅𝑖 = –18.6 bits), while strengthening a cryptic site 5 nt upstream
of the splice junction (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = 8.1 bits, ∆𝑅𝑖 = 0.6 bits). Either cryptic SS activation or
complete exon skipping are predicted.
The BRCA2 variant c.68-7T>A was not prioritized, as its pathogenicity has not been
proven. While there is evidence that this variant induces (in-frame) exon skipping [Théry
et al., 2011], it did not segregate with disease in HBOC pedigrees, where abnormal
splicing was not seen [Santos et al., 2014]. The ATM variant c.1066-6T>G, previously
reported in Mucaki et al. [2016], was also not prioritized as the variant does not correlate
with BC risk [Ding et al., 2011].

5.3.1.2

Activation of Cryptic Splicing

The Shannon Pipeline identified 9,480 variants that increased the strength of at least one
cryptic site, of which nine met or exceeded the defined thresholds for information
change. Six of these were prioritized (Table 5.1). A novel BARD1 variant in exon 6
(c.1454C>T; p.Ala485Val) creates a donor SS (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = 4.4 bits, ∆𝑅𝑖 = 7.1 bits), which
would produce a 58 nt frame shifted exon if activated. The natural donor SS of exon 6,
116 nt downstream of the variant, is stronger (5.5 bits), but the Automated Splice Site and
Exon Definition Analysis (ASSEDA, http://mutationforecaster.com) server predicts equal
levels of expression of both natural and cryptic exons. A BRCA1 mutation 5074+107C>T
downstream of exon 16 is predicted to extend the exon by 105 nt and be slightly more
abundant than the natural exon (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 of 8.6 and 8.1 bits, respectively). CDH1
c.1223C>G (p.Ala408Gly), previously reported in a BRCA-negative lobular BC patient
with no family history of gastric cancer [Schrader et al., 2011], creates a cryptic donor
site (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = 4.3 bits, ∆𝑅𝑖 = 4.9 bits) in exon 9, 97 nt downstream of the natural
acceptor. While residual splicing of the normal exon is still expected, the cryptic is
predicted to become the predominant splice form (~twice as abundant).
STK11 c.375-194GT>AC (rs35113943 and rs117211142) and the novel XRCC2 c.122154G>T both strengthen strong preexisting cryptic sites exceeding the 𝑅𝑖,𝑡𝑜𝑡𝑎𝑙 values of
their respective natural exons. Finally, a known RAD51B variant 29 nt upstream of exon
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10: c.958-29A>T strengthens a cryptic acceptor site (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = 4.4 bits, ∆𝑅𝑖 = 2.2 bits)
that, if activated, would produce a transcript retaining 21 intronic nucleotides.
The remaining cryptic site variants (Appendix D.9) were not prioritized. The novel
BRCA2 c.7618-269_7618-260del10 variant is predicted to create a cryptic site with an
exon having a lower 𝑅𝑖,𝑡𝑜𝑡𝑎𝑙 value (5.2 bits) than the natural exon (6.6 bits). PMS2
c.1688G>T (p.Arg563Leu; rs63750668; three patients) does not segregate with disease.
Drost et al. [2013] demonstrated that this variant does not impair DNA repair activity.
Finally, RAD51B c.728A>G (p.Lys243Arg; rs34594234; 7 patients) predicts an increase
in the abundance of the cryptic exon; however, the natural exon remains the predominant
isoform.

5.3.1.3

Pseudoexon Activation

Pseudoexons arise from creation or strengthening of an intronic cryptic SS in close
proximity to another intron site of opposite polarity. Our analysis detected 623 variants
with such intronic cryptic sites, of which 17 were prioritized (among nine genes),
occurring within 250 nt of a preexisting site of opposite polarity, with an hnRNPA1 site
within 5 nt of the acceptor of the predicted pseudoexon (Appendix D.10). Three are novel
(BRCA2 c.7007+824C>T, BRCA2 c.8332-1130G>T, and PTEN c.802-796C>A) and the
remainder were present in dbSNP. Seven of these variants (BARD1 c.1315-168C>T,
BRCA2 c.631+271A>G, MLH1 c.1559-1732A>T, MRE11A c.1783+2259A>G, MSH6
c.260+1758G>A, PTEN c.79+4780C>T, and RAD51B c.1037-1012C>A), although rare,
occur in multiple patients, and one patient had predicted pseudoexons in both BARD1 and
RAD51B.

5.3.1.4

SRF Binding

Variants within exons or within 500 nt of a natural SS (N = 9,998) were assessed for their
potential effect on SRF binding sites (SRFBSs). Initially 216 unique variants were
flagged (Appendix D.11), but after considering each in the context of the SRF function
and location within the gene [Caminsky et al., 2015], we prioritized 148, of which 57 are
novel. Some prioritized variants affect distant SRFs that may activate cryptic sites, but
were not predicted to affect natural splicing. Of the 88 suitable prioritized variants for
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which exon definition analysis was performed (where initial 𝑅𝑖,𝑡𝑜𝑡𝑎𝑙 of the exon > SRF
gap surprisal value), 55 were predicted to induce or contribute to increased exon
skipping. For example, an uncommon ATM missense variant within exon 41, c.6067G>A
(p.Gly2023Arg; rs11212587), strengthens an hnRNPA1 site (𝑅𝑖,𝑓𝑖𝑛𝑎𝑙 = 5.2 bits, ∆𝑅𝑖 = 4.7
bits) 30 nt from the natural donor, and is predicted to induce exon 41 skipping (∆𝑅𝑖,𝑡𝑜𝑡𝑎𝑙
= –9.5 bits).

5.3.1.5

TF Binding

To assess potential changes to TFBSs, variants occurring from 10 kb upstream of the start
of transcription through the end of the first intron were analyzed by IT, flagging 88 (of
4,530 identified; Appendix D.12). Considering the gene context of each TFBS and extent
of information change, we prioritized 36 variants. The following example illustrates the
rationale for highlighting these variants: BRCA1 c.-19-433A>G abolishes a binding site
for HSF 1 (𝑅𝑖,𝑖𝑛𝑖𝑡𝑖𝑎𝑙 = 5.5 bits, ∆𝑅𝑖 = –7.8 bits). While HSF 1 is known to be a
transcriptional activator associated with poor BC prognosis [Santagata et al., 2011], the
specific effect of reduced HSF 1 binding to BRCA1 has not been established. Similarly,
MLH1 c.-4285T>C (rs115211110; five patients) significantly weakens a C/EBPβ site
(𝑅𝑖,𝑖𝑛𝑖𝑡𝑖𝑎𝑙 = 10.1 bits, ∆𝑅𝑖 = –6.3 bits), a TF that has been shown to play a role in BC
development and progression [Zahnow, 2009]. Another MLH1 variant, c.-6585T>C
(novel), greatly decreases the binding strength (𝑅𝑖,𝑖𝑛𝑖𝑡𝑖𝑎𝑙 = 12.5 bits, ∆𝑅𝑖 = –10.8 bits) of
the NF-κB p65 subunit, which is activated in ER-negative breast tumors [Biswas et al.,
2004]. Two prioritized variants (PMS2 c.-9059G>C and XRCC2 c.-163C>A) weaken
PAX5 binding sites, a TF which when overexpressed can result in mammary carcinoma
cells regaining epithelial cell characteristics [Vidal et al., 2010].

5.3.1.6

Alterations to mRNA Structure

A total of 1,355 variants were identified in the 5’ and 3’ UTRs of the patients. Analysis
of these variants with SNPfold flagged three unique variants (P < 0.05) in BRCA1,
BARD1, and XRCC2 (Table 5.2). The predicted mRNA 2° structures of the reference and
variant sequences are shown in Figure 5.3 (generated with mfold). The BRCA1 variant
occurs in the 3’ UTR of all known transcript isoforms (NM_007294.3:c.∗1332T>C;
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Table 5.2: Variants Predicted by SNPfold to Significantly Affect UTR Structure
Gene

Variant

UTR

rsID (dbSNP142)

Position

Allele Frequency (%)a

XM_005246728.1:
c.-53G>T

BARD1

5'UTR

(c.33G>T p.Gln11His)

rs143914387
0.04

Rank

pvalue

6/600

0.01

13/450

0.03

3/300

0.01

NM_007294.3:c.*133
BRCA1

2T>C
NM_007299.3:c.*143

3'UTR

rs8176320
0.42

8T>C
XRCC2
a

NM_005431.1:c.76C>T

5'UTR

rs547538731
0.08

If known.

rs8176320; 3 patients). The most likely inferred structure consisting of a short arm and a
larger stem loop is destabilized when the variant nucleotide is present (Figure 5.3A and
B). The BARD1 variant falls within the 5’ UTR of a rare isoform (XM_005246728.1:c.53G>T; rs143914387; five patients) and is within the coding region of a more common
transcript (NM_000465.2:c.33G>T; p.Gln11His). While the top ranked isoform
following mutation is similar to the wild-type structure, the second-ranked isoform (∆𝐺 =
+1.88kcal/mol) is distinctly different, creating a loop in a long double-stranded structure
(Figure 5.3C and D). The XRCC2 variant is within its common 5’ UTR
(NM_005431.1:c.-76C>T) and is located 11 nt downstream from the 5’ end of the
mRNA. The variant nucleotide disrupts a potential GC base pair, leading to a large stemloop that could allow access for binding of several RBPs (Figure 5.3E and F). The variant
simultaneously strengthens PUM2 (𝑅𝑖,𝑖𝑛𝑖𝑡𝑖𝑎𝑙 = 2.8 bits, ∆𝑅𝑖 = 4.4 bits, positions 11–17)
and RBM28 sites (𝑅𝑖,𝑖𝑛𝑖𝑡𝑖𝑎𝑙 = 4.0, ∆𝑅𝑖 = 3.6bits, positions10–13); however, there is a
stronger NCL site (8.3 bits, positions 20–31) in the area that is not affected and may
compete for binding.
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Figure 5.3: Predicted RNA structure change due to variants flagged by SNPfold
using mfold. Wild-type (A, C, and E) and variant (B, D, and F) structures are displayed.
The variant nucleotide is marked with an arrow. (A) Predicted wild-type structure of
BRCA1 3’ UTR surrounding c.∗1332G>A. (B) BRCA1 3’ UTR structure due to c.∗1332A
variant, extending arm length while reducing hairpin size. (C) BARD1 5’ UTR structure
of rare isoform (XM_005246728.1:c.-53G>T). Two overlapping preexisting RBP sites
(SRSF7 [outer box] and SRSF2 [inner box]) are predicted and either could occupy this
location if accessible. (D) 2° BARD1 5’ UTR structure of the region predicted only with
sequence containing the c.-53T mutation. The primary predicted c.-53T structure is
identical to wild type (with one disrupted C-G bond leading to a 4.1 kcal/mol lower ∆𝑮).
The variant both weakens and abolishes the preexisting SRSF7 and SRSF2 sites,
respectively. (E) XRCC2 structure within common 5’ UTR surrounding c.-76C>T
variant. (F) XRCC2 5’ UTR structure predicted from c.-76T sequence, containing a
hairpin not found in wild type. This hairpin may allow for the binding of previously
inaccessible nucleotides including the altered nucleotide.
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5.3.1.7

RBP Binding

Using IT models of 76 RBBSs, 33 UTR variants were prioritized (Appendix D.13) from
the initial list of 1,367 UTR variants. Interestingly, one of the three variants that
destabilized the mRNA was also flagged using our RBP scan. The BARD1 c.-53A>C
variant weakens a predicted 8.3 bit SRSF7 site (∆𝑅𝑖 = –3.0 bits) while simultaneously
abolishing a predicted 9.7 bit SRSF2 site (∆𝑅𝑖 = –29.7 bits) (Figure 5.3C and D).

5.3.2
5.3.2.1

Exonic Protein-Altering Variants
Protein Truncating

Of the 714 identified coding variants, six were indels, each of which were found in a
single patient, and two preserved the reading frame. Two indels were novel
(BRCA1:c.3550_3551insA [p.Gly1184Glufs] and CDH1:c.30_32delGCT [p.Leu11del]).
Previously reported indels were detected in CHEK2 and PALB2. In addition, five
nonsense mutations, which have been previously reported by others, were found in six
different patients (Table 5.3; details in Appendix D.14).

5.3.2.2

Missense Variants

Of the 155 unique missense variants (Appendix D.15), 119 were prioritized by consulting
published literature, disease- and gene-specific databases. All are of unknown clinical
significance and 21 have not been previously reported.
Missense variants that have been previously described as detrimental include the ATM
variant c.7271T>G (p.Val2424Gly; rs28904921; two patients), which replaces a
hydrophobic residue by glycine in the conserved FAT domain and confers a ninefold
increase (95% CI) in BC risk [Goldgar et al., 2011]. Functional studies, assessing ATM
kinase activity in vitro with TP53 as a substrate, showed that cell lines heterozygous for
the mutation had less than 10% of wild-type kinase activity, such that this variant is
expected to act in a dominant-negative manner [Chenevix-Trench et al., 2002]. The
CHEK2 variant c.433C>T (p.Arg145Trp; rs137853007; one patient) results in rapid
degradation of the mutant protein [Lee et al., 2001]. Finally, the PMS2 variant c.2T>C
(p.Met1Thr) is listed in ClinVar as pathogenic and would be expected to abrogate correct
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Table 5.3: Variants Resulting in Premature Protein Truncation
Gene

Exon

Variant

rsID (dbSNP142)
Allele Frequency (%)a

Details

Frameshift Insertions/Deletions
BRCA1

PALB2

PALB2

10 of 23

4 of 13

9 of 13

NM_007294.2:c.3550_3551insAb
p.Gly1184Glufs
NM_024675.3:c.757_758delCTc
p.Leu253Ilefs
NM_024675.3:c.2920_2921delAAc
p.Lys974Glufs

Novel

rs180177092

STOP at p.1187
676 AA short
STOP at p.255
932 AA short
STOP at p.979

rs180177126
208AA short

Insertions/Deletions with Conserved Reading Frame

CDH1

CHEK2

1 of 16

4 of 14

NM_004360.3:c.30_32delGCTd
p.Leu11del

NM_007194.3:c.483_485delAGAc
p.Glu161del
Stop Codons

Loss of one AA
Novel

Frame and AA
sequence conserved
Loss of one AA

-

Frame and AA
sequence conserved
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ATM

13 of 63

ATM

62 of 63

BRCA1

23 of 23

PALB2

13 of 13

a

If known.

b

Not confirmed through Sanger sequencing.

c

Confirmed by Sanger sequencing.

d

Ambiguous Sanger sequencing results.

AA: amino acid.

NM_000051.3:c.1924G>Tc
p.Glu642Ter
NM_000051.3:c.8977C>Tc
p.Arg2993Ter
NM_007294.2:c.5503C>Tb
p.Arg1835Ter
NM_024675.3: c.3549C>Gc
p.Tyr1183Ter

-

2415 AA short

-

64 AA short

rs41293465

28 AA short

rs118203998

4 AA short
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initiation of translation. This variant has not been reported in BC families, but is
associated with colorectal cancer (CRC) [Senter et al., 2008].

5.3.3

Variant Prioritization

We prioritized an average of 18.2 variants in each gene, ranging from seven (XRCC2) to
61 (ATM), an average of 0.41 variants/kb, and an average of 0.65 variants/patient (Table
5.4). ATM had the second greatest gene probe coverage (103,511 nt captured), the highest
number of unique prioritized variants, and was among the top genes for number of
prioritized variants per kilobase (0.59).
In total, our framework allowed for the prioritization of 346 unique variants in 246
patients, such that 85.7% of tested patients (N = 287) had at least one prioritized variant.
Most patients (84.7%) harbored fewer than four prioritized variants. The distribution of
patients with prioritized variants was similar across eligibility groups (Table 5.5).
Although Class 5 (91.1% of patients with prioritized variants) and Class 8 (100% with
prioritized variants, with a single patient in this category) deviated to a greater extent
from the mean variants/category, these differences were not significant, 𝜒 2 (4, N = 246) =
0.98, p > 0.90. The distribution of prioritized variants among mutation types is nine
protein truncating, 28 mRNA splicing, 34 affecting RBBS and/or UTR structure, 36
affecting TFBS, 119 missense, and 149 affecting SRFBS, of which 29 were prioritized
into multiple categories (Appendix D.16 and D.17 show this information by gene and
patient, respectively).
All prioritized protein-truncating (N = 10), and selected splicing (N = 7) and missense (N
= 5) variants were verified by bidirectional Sanger sequencing as they were more likely
to be pathogenic (taking into account available published studies). Of the proteintruncating variants, four nonsense, one indel with a conserved reading frame, and two
frameshifts were confirmed (Table 5.3). Six splicing variants and all missense were
confirmed (Table 5.1 and Appendix D.15). An additional 145 prioritized variants,
including 88 noncoding variants, were confirmed upon resequencing of patient gDNA.
Of the 57 resequenced coding variants, 13 were prioritized for their noncoding effects (12
SRFBS, two cryptic site strengthening; one variant prioritized for both). These variants
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Table 5.4: Comparing Counts of Prioritized Variants
Unique
Gene

prioritized
variants

Unique

Gene probe

Prioritized

Prioritized

patients

coverage (nt)

variants/patient

variants/kb

ATM

61

102

103511

0.60

0.59

ATP8B1

21

37

94793

0.57

0.22

BARD1

17

46

73735

0.37

0.23

BRCA1

19

24

52075

0.79

0.36

BRCA2

24

28

73332

0.86

0.33

CDH1

21

32

61312

0.66

0.34

CHEK2

12

13

28372

0.92

0.42

MLH1

18

25

50553

0.72

0.36

MRE11A

17

31

64713

0.55

0.26

MSH2

18

17

112437

1.06

0.16

MSH6

19

23

25216

0.83

0.75

MUTYH

8

16

21439

0.50

0.37

NBN

11

21

57067

0.52

0.19
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PALB2

26

46

25319

0.57

1.03

PMS2a

8

15

11726

0.53

0.68

PTENb

15

23

86059

0.65

0.17

RAD51Bc

22

47

62465

0.47

0.35

STK11

12

20

28373

0.60

0.42

TP53

11

30

23544

0.37

0.47

XRCC2

7

10

19942

0.70

0.35

a

Homologous to other genomic regions, thus fewer probes designed within gene.

b

PTENhas pseudogene PTENP1, thus fewer probes covering exonic regions.

c

Probes limited to 1,000 nt surrounding all exons, and 10,000 nt up- and downstream of gene.

187

Table 5.5: Distribution of Recruited Patients among Eligibility Groups
Number of

Number of Patients

Patients within

with Prioritized

Eligibility Group

Variants

68

62

37

32

72

59

1

1

Three or more cases of breast or

109

92

ovarian cancer at any age (10).

287

246

Eligibility Groupa

Breast cancer <60 year, and a first or
second-degree relative with ovarian
cancer or male breast cancer (5).
Breast and ovarian cancer in the same
individual, or bilateral breast cancer
with the first case <50 years (6).
Two cases of ovarian cancer, both
<50 years, in first or second-degree
relatives (7).
Two cases of ovarian cancer, any age,
in first or second-degree relatives (8).

The risk categories for individuals eligible for screening for a genetic susceptibility to
breast or ovarian cancers are determined by the Ontario Ministry of Health and Long
Term-Care Referral Criteria for Genetic Counseling.
a

Numbers in parentheses correspond to eligibility group designation.

can be found in Appendix D.17 (where “coverage” column contains two or more
coverage values).

5.3.3.1

Negative Control

ATP8B1 was sequenced and analyzed in all patients as a negative control (Appendix
D.18). We prioritized 21 ATP8B1 variants with an average of 0.22 variants/kb and 0.57
variants/patient. This is lower than the prioritization rate for many of the documented
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HBOC genes. This result illustrates that the proposed method represents a screening
rather than a diagnostic approach, as some variants may be incorrectly prioritized.

5.3.4

Pedigree Analysis

Pathogenic BRCA2 variants within a region of exon 11 have been associated with a high
incidence of OC. We therefore verified whether there were a high number of OC cases in
the families of patients prioritized with exon 11 BRCA2 variants (N = 3). The family of
the patient with BRCA2 variant c.4828G>A (p.Val1610Met; diagnosed with BC at 65)
has three reported cases of BC/OC, one of which is OC (diagnosed at 74), two degrees of
separation from the proband. The patient with BRCA2:c.6317T>C (p.Leu2106Pro;
diagnosed with BC at 52) has three other affected family members, two with OC and one
with BC. Finally, four patients found to have the BRCA2 variant c.5199C>T (p.Ser1733 =
) do not have any family members with reported cases of OC.
We also selected patients with prioritized mismatch repair variants (N = 8 in 10 patients)
to assess the incidence of reported CRC cases in these families. Notably, the patient with
mutation MSH2:c.1748A>G (p.Asn583Ser) had five relatives with CRC. A similar
analysis of prioritized CDH1 variants did not reveal any patients with a family history of
gastric cancer.

5.3.5

LR Analyses

We carried out co-segregation analysis of 25 patients with prioritized pathogenic variants
(four nonsense, four frameshift, two in-frame deletions, six missense, four natural
splicing, and six cryptic splicing; including a patient who exhibited prioritized natural
and cryptic SS variants). We compared these findings with those from patients (N = 25)
harboring moderate-priority variants (variants prioritized through IT analysis only) and
those in whom no variants were flagged or prioritized (N = 14). In instances where
disease alleles could be transmitted through either founder parent, the lineage with the
highest likelihood ratio (LR) was reported. For patients with likely pathogenic variants,
the LRs ranged from 0.00 to 70.96 (Table 5.6 and Appendix D.19). Disease cosegregation was supported (LR > 1.0) in 18 patients, and the remainder were either
neutral (LR < 1.0 [Mohammadi et al., 2009]) or could not be analyzed either due to
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Table 5.6: LR Values for Patients with Prioritized Truncating, Splicing, and Selected Missense Variants
Variant
Genesa

Category

UWO ID

LR

mRNA

Protein

c.1924G>T

p.Glu642Ter

Nonsense

10-2F

7.46MGM,9.61MGF

c.6198+1G>A

-

Natural splicing

8-1D.9-1B

1.00

10-1F

1.44

12-1D

1.96P

ATM
c.7271T>G

BARD1

p.Val2424Gly

Missense

c.8977C>T

p.Arg2993Ter

Nonsense

12-4G.13-5D

5.30P

c.1454C>T

p.Ala485Val

Cryptic splicing

8-1D.9-1B

1.00

c.3550_3551insA

p.Gly1184Glufs

Frameshift indel

11-6H

3.36P

c.5503C>T

p.Arg1835Ter

Nonsense

8-5D.9-5D

41.99

c.10095delCins11

p.Ser3366Asnfs

Frameshift indel

15-4E

3.71

c.30_32delGCT

p.Leu11del

Inframe deletion

10-4A

1.00

c.1223C>G

p.Ala408Gly

Cryptic splicing

15-3G

2.14

12-2G

2.86

c.470T>C

p.Ile157Thr

Missense
15-5G

19.44P

BRCA1
BRCA2
CDH1

CHEK2
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c.433C>T

p.Arg145Trp

Missense

4-3C.5-4G.14-4A

3.48

c.3549C>G

p.Tyr1183Ter

Nonsense

15-1E

1.78

c.757_758delCT

p.Leu253Ilefs

Frameshift indel

10-6F

70.96

c.2920_2921delAA

p.Lys974Glufs

Frameshift indel

8-3A.9-3A

5.03

c.2T>C

p.Met1Thr

Missense

11-4H

16.53P

c.84G>A

p.Gln28=

Leaky splicing

8-1H.9-1E

3.51P

c.958-29A>T

-

Cryptic splicing

10-4B

7.44P

c.375-194GT>AC

-

Cryptic splicing

10-5A

2.67M

PALB2

PMS2
RAD51B
STK11

LR values in favor of neutrality are not shown.
aRefSeq accessions: ATM (NM_000051.3), BARD1 (NM_000465.2), BRCA1 (NM_007294.2), BRCA2 (NM_000059.3), CDH1
(NM_004360.3), CHEK2 (NM_007194.3), PALB2 (NM_024675.3), PMS2 (NM_000535.5), RAD51B (NM_002877.4), STK11
(NM_000455.4).
P, paternal; M, maternal; MGF, maternal grandfather; MGM, maternal grandmother.

191

missing pedigree information or limited numbers of affected individuals in a family.
Patient 10–6F (PALB2: c.757 758delCT) exhibited the highest likelihood (LR = 70.96).
Prioritized variants with neutral evidence include a variant that abolishes a natural SS in
MRE11A, c.2070+2T>A (LR = 0.03), and an in-frame deletion c.483 485delAGA in
CHEK2 (LR = 0.00).

5.4 Discussion
Rare noncoding and/or non-truncating mutations can confer an increased risk of disease
in BC [Tavtigian et al., 2009]. This study determined both coding and noncoding
sequences of 20 HBOC-related genes, with the goal of discovering and prioritizing rare
variants with potential effects on gene expression. This work emphasizes results from the
analysis of noncoding variants, which are abundant in these genes, yet have been
underrepresented in previous HBOC mutation analyses. Nevertheless, alterations to
mRNA binding sites in BRCA, and lower risk or rare HBOC genes, have been shown to
contribute to HBOC (exonic splicing enhancers (ESEs) in ATM [Heikkinen et al., 2005],
BARD1 [Ratajska et al., 2011], and BRCA genes [Gochhait et al., 2007; Sanz et al.,
2010]). We prioritized 346 unique variants that were predicted to result in four nonsense,
three frameshift, two indels with preserved reading frame, 119 missense, four natural
splicing, six cryptic splicing, 17 pseudoexon activating, 148 SRFBS, 36 TFBS, three
UTR structure, and 31 RBBS mutations (Appendix D.16). Among these variants, 101
were novel (see Appendix D.20 for references to previously identified variants).
Compared to our initial seven-gene panel [Mucaki et al., 2016], the inclusion of the
additional genes in this study prioritized at least one variant in 15% additional patients
(increased from 70.6 to 85.7%).
The BRCA genes harbor the majority of known germline pathogenic variants for HBOC
families [Chong et al., 2014]. However, a large proportion of the potentially pathogenic
variants identified in our study were detected in ATM, PALB2, and CHEK2, which,
although of lower penetrance, were enriched because the eligibility criteria excluded
known BRCA1 and BRCA2 carriers. BRCA1 and BRCA2 variants were nevertheless
prioritized in some individuals. We also had expected intragenic clustering of some
BRCA coding variants [Mucaki et al., 2011]. For example, pathogenic variants occurring
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within exon 11 of BRCA2 are known to be associated with higher rates of OC in their
families [Lubinski et al., 2004]. We identified three variants in exon 11; however, there
was no evidence of OC in these families. Overall, ATM and PALB2 had the highest
number of prioritized variants (61 and 26, respectively). However, only 12 variants were
prioritized in CHEK2; potentially pathogenic variants may have been underrepresented
during sequence alignment as a consequence of the known paralogy with CHEK2P2.
Fewer TP53, STK11, and PTEN variants were prioritized, as pathogenic variants in these
genes tend to be infrequent in patients who do not fulfill the clinical criteria for their
associated syndromes (Li-Fraumeni syndrome, Peutz-Jeghers syndrome, and Cowden
syndrome, respectively [Hollestelle et al., 2010]), although they have been indicated as
near moderate to high-risk genes in BC [Easton et al., 2015]. This underrepresentation of
prioritized variants may be supported by the negative Residual Variation Intolerance
Scores (RVIS) for these genes [Petrovski et al., 2013], which are likely indicative of
purifying selection. Although the density of prioritized variants in these genes is below
average (18.2 per gene), the total number was nonetheless important (TP53 = 11, STK11
= 12, PTEN = 15).
The fundamental difference between IT and other approaches such as combined
annotation-dependent depletion [CADD; Kircher et al., 2014] is that IT depends only on
positive experimental data from the same or closely related species. CADD does not
appear to account for unobserved reversions or other hidden mutations [e.g. perform a
Jukes–Cantor correction; Jukes and Cantor, 1969], nor are the effects of these simulated.
Furthermore, the CADD scoring system is ad hoc, which contrasts with strong theoretical
basis on the IT approach [Rogan and Schneider, 1995] in which information changes in
bits represent a formally proven relationship to thermodynamic stability, and therefore
can be used to measure binding affinity. This makes it different from other unitless
methods with unknown distributions, in which differences in binding affinity cannot be
accurately extrapolated from derived scores.
We compared the frequency of all prioritized variants in our patient cohort to the
population allele frequencies [1000 Genomes Project, Phase 3;
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http://www.1000genomes.org; 1000 Genomes Project Consortium, 2012] to determine if
variants more common in our cohort might be suggestive of HBOC association. Three
variants in at least five HBOC patients are present at a much lower frequency in the
general population than in our HBOC population. NBN c.∗2129G>T, present in 4.18% of
study cohort, is considerably rarer globally (0.38% in 1000 Genomes; <0.1% in other
populations). Similarly, the RAD51B c.-3077G>T variant (2.09%) is rare in the general
population (0.08%). Interestingly, BARD1 c.33G>T (1.74% of study cohort) has only
been reported in the American and European populations in 1000 Genomes (0.29% and
0.20%, respectively) and only Europeans in the Exome Variant Server (0.24%;
http://evs.gs.washington.edu/EVS/). In Southwestern Ontario, individuals are often of
American or European ancestry. The variant was found to be more common in the
Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org/) in 1.17% tested
Finnish population (0.41% in their non-Finnish European cohort), though no alleles were
found in the Finnish populations in 1000 Genomes (N = 99). Therefore, the allele
frequency of this BARD1 variant in our HBOC population may simply be enriched in a
founder subset of general populations. While we cannot rule out skewing of these allele
frequencies due to population stratification, our findings suggest that gene expression
levels could be impacted by these variants.
We applied subpopulation allele frequency analysis for all of our prioritized variants.
Appendix D.21 lists the 49 variants that have allele frequencies >1% in various
subpopulations (based on dbSNP). Allele frequencies were as high as 4.2% for the
BRCA2 c.-40+192C>T (8-1G.9-1C), predicted to affect TF binding, in the East Asian
subpopulation. Without additional information on patient ethnicities, it is not possible to
eliminate prioritized variants that are common in specific subpopulations.
Co-segregation analysis is recommended by the American College of Medical Genetics
and Genomics for variant classification [Richards et al., 2015]. Among patients with
likely pathogenic, highly penetrant mutations in our cohort (N = 24), some variants had
LR values consistent with causality, whereas others provided little evidence to support
co-segregation among family members (Table 5.6 and Appendix D.19). An important
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caveat, however, was that the use of BRCA2 penetrance values in non-BRCA genes may
have resulted in underestimates of LR values.
In order to evaluate the application of co-segregation analysis in the context of this study,
we chose to perform this analysis on patients with moderate priority variants (i.e.,
variants affecting binding sites) and patients with no flagged or prioritized variants (N =
25 and 14, respectively). LRs ranged from 0.0034 to 78.0 for moderate-priority variants
and from 0.0005 to 57.0 for patients with no flagged or prioritized variants (Appendix
D.5-Supp. Fig. S2). The proportion of LR values supporting neutrality and those
supporting causation was comparable between patients with prioritized, moderately
prioritized, and flagged variants (Appendix D.5-Supp. Fig. S2). This suggests that cosegregation analysis is only useful in the context of other supporting results for assessing
pathogenicity (e.g., likelihood of being pathogenic or benign). Furthermore, the lack of
genotype information and at times smaller pedigrees likely also contributed to the lack of
concordance between LRs and variant priority.
A small number of patients with a known pathogenic variant carried other prioritized
variants. These were likely benign or possibly phenotypic modifiers. One patient
possessed five prioritized variants (one missense, one SRFBS, one TFBS, and two
RBBSs) in addition to a BRCA1 nonsense mutation (c.5503C>T). While these variants
may not directly contribute to causing HBOC, they may act as a risk modifier and alter
expression levels [Antoniou and Easton, 2006].
Similarly, genes lacking association with HBOC can be used as a metric for determining
a false-positive rate of variant prioritization. In this study, we prioritized 21 ATP8B1
variants among 37 of our HBOC patients (Appendix D.18) despite it having not been
previously associated with any type of cancer. A variant with a deleterious effect on
ATP8B1 may lead to ATP8B1-related diseases, such as progressive familial intrahepatic
cholestasis [Gonzales et al., 2014], but should not increase the chances of developing BC.
Thus, while our framework may be effective at prioritizing variants, only genes with
previous association to a disease should be included in analyses similar to the present
study to minimize falsely prioritized variants.
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Additional workup of prioritized noncoding and non-BRCA variants is particularly
important, because with few exceptions [Easton et al., 2015], the pathogenicity of many
of the genes and variants has not been firmly established. Furthermore, mutations in
several of these genes confer risk to other types of cancer, which alters the management
of these patients [Knappskog and Lønning, 2012]. The next step toward understanding
the role these prioritized variants play in HBOC is to test family members of the proband
and to carry out functional analysis. If this is not possible, then their effects on gene
expression could be evaluated using assays for RNA stability and RNA localization.
Protein function could be evaluated by binding site assays, protein activity, and
quantitative PCR.
A significant challenge associated with VUS analysis, particularly in the case of many of
these recent HBOC gene candidates, is the underreporting of variants and thus positive
findings tend to be overrepresented in the literature [Kraft, 2008]. Hollestelle et al. [2010]
argue that a more stringent statistical standard must be applied (i.e., P-values of 0.01
should be used as opposed to 0.05) to underreported variants (namely in moderate-risk
alleles), because of failure to replicate pathogenic variants, which we have also found
[Viner et al., 2014]. In the same way that we use IT-based analysis to justify prioritizing
variants for further investigation, variants that are disregarded as lower priority (and that
are likely not disease causing) have been subjected to the same thresholds and criteria.
Integrating this set of labeled prioritized and flagged, often rare variants from this cohort
of BRCA-negative HBOC patients, to findings from exome or gene panel studies of
HBOC families should accelerate the classification of some VUS.
Different variant interpretation and reporting guidelines consider the reporting of VUS to
be either optional or essential [Wallis et al., 2013; Richards et al., 2015]. In all cases, a
reported VUS cannot be the basis for a clinical decision and should be followed up and
further investigated. In any case, the number of reported VUS in an individual is
frequently too extensive for detailed characterization. Reducing the full set of variants
obtained by complete gene sequencing to a prioritized list will be an essential prerequisite
for targeting potentially clinically relevant information. Informing patients of prioritized
VUS may increase patient accrual and participation [Murphy et al., 2008]. However, it
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will be critical to explain both the implications and significance of prioritization and the
limitations, namely counselling patients to avoid clinical decisions, based on this
information [Vos et al., 2012].
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Chapter 6

6

Clustered, Information-dense Transcription Factor
Binding Sites Identify Genes with Similar Tissue-wide
Expression Profiles

The work presented in this chapter is reproduced from:
Lu,R., Rogan,P.K. (2018) Clustered, information-dense transcription factor binding sites
identify genes with similar tissue-wide expression profiles. bioRxiv. doi:
https://doi.org/10.1101/283267

6.1 Background
The distinctive organization and combination of transcription factor binding sites
(TFBSs) and regulatory modules in promoters dictates specific expression patterns within
a set of genes [1]. Clustering of multiple adjacent binding sites for the same TF
(homotypic clusters) and for different TFs (heterotypic clusters) defines cis-regulatory
modules (CRMs) in human gene promoters and can amplify the influence of individual
TFBSs on gene expression through increasing binding affinities, facilitated diffusion
mechanisms and funnel effects [2]. Because tissue-specific TF-TF interactions in TFBS
clusters are prevalent, these features can assist in identifying correct target genes by
altering binding specificities of individual TFs [3]. Previously, we derived information theory-based position weight matrices (iPWMs) from ChIP-seq data that can accurately
detect TFBSs and quantify their strengths by computing associated 𝑅𝑖 values (Rate of
Shannon information transmission for an individual sequence [4]), with 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 being
the average of 𝑅𝑖 values of all binding site sequences and representing the average
binding strength of the TF [3]. Furthermore, information density-based clustering (IDBC)
can effectively identify functional TF clusters by taking into account both the spatial
organization (i.e. intersite distances) and information density (i.e. 𝑅𝑖 values) of TFBSs
[5].
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TF binding profiles, either derived from in vivo ChIP-seq peaks [6–8] or computationally
detected binding sites and CRMs [9], have been shown to be predictive of absolute gene
expression levels using a variety of tissue-specific machine learning classifiers and
regression models. Because signal strengths of ChIP-seq peaks are not strictly
proportional to TFBS strengths [3], representing TF binding strengths by ChIP-seq
signals may not be appropriate; nevertheless, both achieved similar accuracy [10]. CRMs
have been formed by combining two or three adjacent TFBSs [9], which is inflexible, as
it arbitrarily limits the number of binding sites contained in a module, and does not
consider differences between information densities of different CRMs. Chromatin
structure (e.g. histone modification (HM) and DNase I hypersensitivity) were also found
to be statistically redundant with TF binding in explaining tissue-specific mRNA
transcript abundance at a genome-wide level [7,8,11,12], which was attributed to the
heterogeneous distribution of HMs across chromatin domains [8]. Combining these two
types of data explained the largest fraction of variance in gene expression levels in
multiple cell lines [7,8], suggesting that either contributes unique information to gene
expression that cannot be compensated for by the other.
The number of genes directly bound by a TF significantly exceeds the number of
differentially expressed (DE) genes whose expression levels significantly change upon
knockdown of the TF. Only a small subset of direct target genes whose promoters
overlap ChIP-seq peaks were DE after individually knocking 59 TFs down using small
interfering RNAs (siRNAs) in the GM19238 cell line [13]. Using these knockdown data
on 8,872 genes as the gold standard, correlation between TFBS counts and gene
expression levels across 10 different cell lines was more predictive of DE targets than
setting a minimum threshold on TFBS counts [14]. Their TFBS counts were defined as
the number of ChIP-seq peaks overlapping the promoter, though it was unknown how
many binding sites were present in these peaks; true positives might not be direct targets
in the TF regulatory cascade, as the promoters of these targets were not intersected with
ChIP-seq peaks. By perturbing gene expression with CAS9-directed clustered regularly
interspaced short palindromic repeats (CRISPR) of 10 different TF genes in K562 cells,
the regulatory effects of each TF on 22,046 genes were dissected by single cell RNA
sequencing with a regularized linear computational model [15]; this accurately revealed
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DE targets and new functions of individual TFs, some of which were likely regulated
through direct interactions at TFBS in their corresponding promoters. Machine learning
classifiers have also been applied in a small number of gene instances to predict targets of
a single TF using features extracted from n-grams derived from consensus binding
sequences [16], or from TFBSs and homotypic binding site clusters [5].
To investigate whether the distribution and composition of CRMs in promoters
substantially determines gene expression profiles of direct TF targets, we developed a
general machine learning framework that predicts which genes have similar expression
profiles to a given gene and predicts DE direct TF targets by combining information
theory-based TF binding profiles with DHSs. Upon filtering for accessible promoter
intervals with DHSs, features designed to capture the spatial distribution and information
composition of CRMs were extracted from clusters identified by the IDBC algorithm
from iPWM-detected TFBSs. Though not all direct targets regulated by multiple TFs
share a common tissue-wide expression profile, this framework provides insight into the
transcriptional program of genes with similar profiles by dissecting their cis-regulatory
element organization and strengths. We identify genes with comparable tissue-wide
expression profiles by application of Bray-Curtis similarity [17]. Using transcriptome
data generated by CRISPR- [15] and siRNA-based [13] TF knockdowns, we predicted
DE TF target genes that are simultaneously direct targets whose promoters overlap tissuespecific ChIP-seq peaks, in contrast with the correlation-based approach [14].

6.2 Methods
To identify genes with similar tissue-wide expression patterns, we formally define gene
expression profiles and pairwise similarity measures between profiles of different genes.
A general machine learning framework relates features extracted from the organization of
TFBSs in these genes to their tissue-wide expression patterns. Positives and negatives for
predicting DE direct protein-coding (PC) TF target genes (TF targets for short below)
were obtained from CRISPR- and siRNA-generated knockdown data (see below). (The
results on the siRNA-generated knockdown data are in progress.)
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6.2.1

Similarity between Gene Expression Profiles

For each of 56,238 genes, the Genotype-Tissue Expression (GTEx) project measured its
expression levels in 53 tissues in a number of individuals (N=5-564), and provides the
median expression value (in RPKM (Reads Per Kilobase of transcript per Million
mapped reads) in the GTEx Analysis v6p release) of each gene in each tissue [18]. To
capture the tissue-wide overall expression pattern of a gene instead of within a single
tissue, the expression profile of a gene was defined as its median RPKM across the 53
tissues (Equation 6.1), which forms a vector of size 53 and does not distinguish between
different isoforms whose expression patterns may significantly differ from each other.
𝐴 ] (𝑖𝑛
𝐸𝑃 𝐴 = [𝑀𝐸𝑉1𝐴 , 𝑀𝐸𝑉2𝐴 , … , 𝑀𝐸𝑉53
𝑅𝑃𝐾𝑀) [6.1]

where 𝐸𝑃 𝐴 is the expression profile of Gene 𝐴, 𝑀𝐸𝑉1𝐴 is the median expression value of
Gene 𝐴 in Tissue 1, 𝑀𝐸𝑉2𝐴 is the median expression value of Gene 𝐴 in Tissue 2, etc.
To obtain ground-truth genes that have similar expression profiles to a given gene, the
Bray-Curtis Similarity (Equation 6.2) was used to compute the similarity value between
the expression profiles of two genes. Compared to other similarity metrics (Table 6.1,
Example 6.1), its application is justified by three desired properties, including 1)
maintaining bounds of 0 and 1, 2) achieving the maximal similarity 1 if and only if two
vectors are identical, and 3) larger values having a larger impact on the resultant
similarity value.
53

1,
𝑠𝑖𝑚𝐵𝑟𝑎𝑦−𝐶𝑢𝑟𝑡𝑖𝑠 (𝐸𝑃 𝐴 , 𝐸𝑃𝐵 ) =
{

1−

53

𝑖𝑓 ∑ 𝑀𝐸𝑉𝑖𝐴 = ∑ 𝑀𝐸𝑉𝑖𝐵 = 0
𝑖=1
𝑖=1
53
𝐴
𝐵
∑𝑖=1|𝑀𝐸𝑉𝑖 − 𝑀𝐸𝑉𝑖 |
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
𝐴
𝐵 ,
∑53
𝑖=1(𝑀𝐸𝑉𝑖 + 𝑀𝐸𝑉𝑖 )

[6.2]

Example 6.1. Assume that Genes A,B,C,D,E,F respectively have the following
expression profiles across two tissues: 𝐸𝑃 𝐴 = [1,1], 𝐸𝑃𝐵 = [2,2], 𝐸𝑃𝐶 = [3,3], 𝐸𝑃𝐷 =
[1,2], 𝐸𝑃𝐸 = [1,99], 𝐸𝑃𝐹 = [1,100]. The ground-truth similarity relationships that we
can intuitively infer include 𝑠𝑖𝑚(𝐸𝑃𝐶 , 𝐸𝑃 𝐴 ) < 𝑠𝑖𝑚(𝐸𝑃𝐶 , 𝐸𝑃𝐵 ) < 1, and
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𝑠𝑖𝑚(𝐸𝑃 𝐴 , 𝐸𝑃𝐷 ) < 𝑠𝑖𝑚(𝐸𝑃𝐸 , 𝐸𝑃𝐹 ) < 1. Only the results computed by the Bray-Curtis
Similarity are completely concordant with these ground-truth relationships (Table 6.2).
Table 6.1: Comparison between metrics in measurement of similarity between gene
expression profiles
Similarity metric

†

Property
1†, ‡

Property 2†

Property 3†

Bray-Curtis

√; [0,1]

√

√

Euclidean

√; (0,1]

√

×

Cosine

√; [0,1]

×

√

Pearson correlation [40]

×; [-1,1]

×

×

Spearman correlation [41]

×; [-1,1]

×

×

√ and × respectively indicate that the similarity metric satisfies and does not satisfy the

property.
‡

The interval in each cell indicates the range in which the result computed by the

similarity metric lies.
Table 6.2: Similarity values computed by different metrics
Similarity

𝒔𝒊𝒎(𝑬𝑷𝑪 , 𝑬𝑷𝑩 )

𝒔𝒊𝒎(𝑬𝑷𝑪 , 𝑬𝑷𝑨 )

Bray-Curtis

0.8

0.5

≈ 0.995

0.8

Euclidean

≈ 0.41

≈ 0.26

0.5

0.5

Cosine

1

1

≈ 0.999999995

≈ 0.949

Undefined

Undefined

1

1

1

1

1

1

metric

Pearson
correlation
Spearman
correlation

𝒔𝒊𝒎(𝑬𝑷𝑬 , 𝑬𝑷𝑭 ) 𝒔𝒊𝒎(𝑬𝑷𝑨 , 𝑬𝑷𝑫 )
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6.2.2

Prediction of Genes with Similar Expression Profiles

The framework for identifying genes that have similar expression profiles to a specific
gene is shown in Figure 6.1A and 6.1B. All DHSs in 95 cell types generated by the
ENCODE project [19; hg38 assembly] were intersected with known promoters [20], then
94 iPWMs exhibiting primary binding motifs for 82 TFs [3] were used to detect TFBSs
in overlapping intervals. When detecting heterotypic TFBS clusters with the IDBC
algorithm, a minimum threshold 0.1 ∗ 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 was set for 𝑅𝑖 values of TFBSs, in order
to remove weak binding sites that were likely to be false positive TFBSs.
The information density-related features derived from each TFBS cluster include: 1) The
distance between this cluster and the transcription start site (TSS); 2) The length of this
cluster; 3) The information content of this cluster (i.e. the sum of 𝑅𝑖 values of all TFBSs
in this cluster); 4) The number of binding sites of each TF within this cluster; 5) The
number of strong binding sites (𝑅𝑖 >𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 ) of each TF within this cluster; 6) The sum
of 𝑅𝑖 values of binding sites of each TF within this cluster; 7) The sum of 𝑅𝑖 values of
strong binding sites (𝑅𝑖 > 𝑅𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒 ) of each TF within this cluster.
For a gene instance, each of Features 1-3 is defined as a vector whose size equals the
number of clusters in the promoter; thus, the entire vector could be input into a classifier.
If two instances contained different numbers of clusters, the maximum number of clusters
among all instances was determined, and null clusters were added at the 5’ end of
promoters with fewer clusters, enabling all instances to have the same cluster count.
Machine learning classifiers with default parameters in MATLAB were used to generate
ROC (Receiver Operating Characteristic) curves.

6.2.3
6.2.3.1

Prediction of Differentially Expressed Direct TF Targets
Using Gene Expression in the CRISPR-based
Perturbations

Dixit et al. performed CRISPR-based perturbation experiments using multiple guide
RNAs for each of ten TFs in K562 cells, resulting in a regulatory matrix of coefficients
that indicate the effect of each guide RNA on each of 22,046 genes [15]. The coefficient
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Figure 6.1: The general framework for predicting genes with similar tissue-wide expression profiles and TF targets. A) An
overview of the machine learning framework. The steps enclosed in the dashed rectangle and for forming training and test sets vary
across prediction of genes with similar expression profiles and DE direct TF targets. The step with a dash-dotted border that intersects
promoters with DHSs is a variant of the primary approach that provided more accurate results. In the IDBC algorithm (Appendix E.1),
the parameter I is the minimum threshold on the total information contents of TFBS clusters. In prediction of genes with similar
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expression profiles, the minimum value was 939, which was the sum of mean information contents (𝑹𝒔𝒆𝒒𝒖𝒆𝒏𝒄𝒆 values) of all 94
iPWMs; in prediction of direct targets, this value was the 𝑹𝒔𝒆𝒒𝒖𝒆𝒏𝒄𝒆 value of the single iPWM used to detect TFBSs in each promoter.
The parameter d is the radius of initial clusters in base pairs, whose value, 25, was determined empirically. Eight types of three
different classifiers were evaluated with statistics (accuracy, sensitivity and specificity) to measure the classifier performance
(Appendix E.1). B) Obtaining of the positives and negatives for identifying genes with similar expression profiles to a given gene
(Appendix E.2). C) Obtaining of the positives and negatives for predicting target genes of seven TFs using the CRISPR-generated
perturbation data in K562 cells (Appendix E.3). D) Formation of the positives and negatives for predicting target genes of 11 TFs
using the siRNA-generated knockdown data in GM19238 cells (Appendix E.4).
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of a guide RNA on a gene is defined as the log10(fold change in gene expression level)
[15]. Among these ten TFs, we have previously derived iPWMs exhibiting primary
binding motifs for seven (EGR1, ELF1, ELK1, ETS1, GABPA, IRF1, YY1) [3].
Therefore, the framework for predicting TF targets in the K562 cell line (Figure 6.1A and
6.1C) was applied to these TFs. The criteria for defining a positive (i.e. a target gene), of
a TF was:
1) The fold change in the expression level of this PC gene for each guide RNA of the
TF was > (or <) 1, consistent with the possibility that the gene was regulated by the
TF, and
2) The average fold change in the expression level of this PC gene for all guide RNAs
of the TF was > threshold 𝜀 (or < 1⁄𝜀 ), and
3) The promoter interval (10 kb) upstream of a TSS of this PC gene overlaps a ChIPseq peak of the TF in the K562 cell line.
If the coefficients of all guide RNAs of the TF for a PC gene are zero, the gene was
defined as a negative. As the threshold ε increases, the number of positives strictly
decreases; as ε decreases, we have increasingly lower confidence in the fact that the
positives were indeed differentially expressed because of the TF perturbation. To achieve
a balance between sensitivity and specificity, we evaluated three different values (i.e.
1.01, 1.05 and 1.1) for ε. For each TF, all ENCODE ChIP-seq peak datasets from the
K562 cell line were merged to determine positives. To make the numbers of negatives
and positives equal to avoid imbalanced datasets that significantly compromise the
classifier performance [21], the Bray-Curtis function was applied to compute the
similarity values in the expression profile between all negatives and the positive with the
largest average coefficient, then the negatives with the smallest values were selected
(Figure 6.1C).
The DHSs in the K562 cell line were intersected with known promoters. Because TFs
may exhibit tissue-specific sequence preferences due to different sets of target genes and
binding sites in different tissues [3], the iPWMs of EGR1, ELK1, ELF1, GABPA, IRF1,
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YY1 from the K562 cell line were used to most accurately detect binding sites; for ETS1,
we used the only available iPWM from the GM12878 cell line [3]. Six features were
derived from each homotypic cluster (i.e. Features 3 and 6 converged to the same value,
because only binding sites from a single TF were used).

6.2.3.2

Using Gene Expression in the siRNA-based Knockdown

In the GM19238 cell line, 59 TFs were individually knocked down using siRNAs, and
significant changes in the expression levels of 8,872 genes were indicated according to
their corresponding P-values [13]. In these cases, the P-value of a gene for a TF is the
probability of observing the change in the expression level of this gene under the null
hypothesis of no differential expression after TF knockdown; thus the larger the change
in the expression level, the smaller the P-value and the more likely this gene is
differentially expressed. They also indicated whether the promoters of these genes
display evidence of binding to TFs by intersecting with ChIP-seq peaks in the GM12838
cell line. Among these 59 TFs, we have previously derived accurate iPWMs exhibiting
primary binding motifs for 11 (BATF, JUND, NFE2L1, PAX5, POU2F2, RELA, RXRA,
SP1, TCF12, USF1, YY1) [3]. Therefore, the framework for predicting TF targets in the
GM19238 cell line (Figure 6.1A and 6.1D) was applied to these 11 TFs.
We defined a positive (i.e. a target gene) for a TF, if the P-value of this gene for the TF
was ≤ 0.01, and the promoter interval (10kb) upstream of a TSS of this gene overlapped a
ChIP-seq peak of the TF in the GM12878 cell line. A negative for a TF exhibited the
following property: a P-value > 0.01 for the TF (Figure 6.1D).
The DHSs in the GM19238 cell line mapped from the hg19 genome assembly were first
remapped to the hg38 assembly using liftOver (available at genome.ucsc.edu) prior to
intersecting with known promoters [22]. Aside from RELA and NFE2L1, the iPWMs of
TFs from the GM12878 cell line were used to detect binding sites. For RELA, the iPWM
from the GM19099 cell line was used; for NFE2L1, the only available iPWM was
derived from K562 cells and was applied. Although the knockdown was performed in
GM19238, GM12878 and GM19099 are also lymphoblastic cell lines, with GM19099
and GM19238 both being derived from Yorubans. For this analysis, the iPWMs derived
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in GM12878 and GM19099 were more appropriate than the iPWM from K562, since
GM12878 and GM19099 are of the same tissue type and are thus more likely comparable
to GM19238 than to K562.

6.2.4

Mutation Analyses on Promoters of Differentially Expressed
Direct Targets

To better understand the significance of individual binding sites for information-dense
clusters and the regulatory state of direct targets, we evaluated the effects of sequence
changes that altered the 𝑅𝑖 values of these sites on cluster formation and whether a gene
was predicted to be a TF target. Mutations were sequentially introduced into the strongest
binding sites in TFBS clusters of the EGR1 target gene, MCM7, to determine the
threshold for cluster formation after disappearing clusters disabled induction of MCM7
expression. For one target gene of each TF from the CRISPR-generated perturbation data,
effects of naturally occurring TFBS variants present in dbSNP
(https://www.ncbi.nlm.nih.gov/projects/SNP/) [23] were also evaluated to explore aspects
of TFBS organization that enabled both clusters and promoter activity to be resilient to
binding site mutations. This was done by analyzing whether the occurrence of individual
or multiple single nucleotide polymorphisms (SNPs) lead to the loss of binding sites and
the clusters that contain them, and result in changes in the predictions of these targets.

6.3 Results
6.3.1

Similarity between Gene Expression Profiles

To confirm that the Bray-Curtis Similarity can indeed effectively measure how akin the
expression profiles of two genes are to each other, it was applied to compute the
similarity values between the expression profiles of the glucocorticoid receptor (GR or
NR3C1) gene and all other 56,237 genes. NR3C1 is an extensively characterized TF with
many known direct target genes [24]. As a constitutively expressed TF activated by
glucocorticoid ligands, it can mediate the up-regulation of anti-inflammatory genes by
binding of homodimers to glucocorticoid response elements and down-regulation of
proinflammatory genes by complexing with other activating TFs (e.g. NFKB and AP1)
and eliminating their ability to bind targets [24]. NR3C1 can bind its own promoter

217

forming an auto-regulatory loop, which also contains functional binding sites of 11 other
TFs (e.g. SP1, YY1, IRF1, NFKB) whose iPWMs have been developed and/or mutual
interactions have been described in Lu et al. [3,24]. However, the expression profile of
NR3C1 integrates all different splicing and translational isoforms (e.g. GRα-A to GRα-D,
GRβ, GRγ, GRδ), whereas these isoforms have tissue-specific expression patterns (e.g.
levels of the GRα-C isoforms are significantly higher in the pancreas and colon, whereas
levels of GRα-D are highest in spleen and lungs) [24]. SLC25A32 and TANK have the
greatest similarity values to NR3C1 (0.880 and 0.877 respectively), which is evident
intuitively based on their overall similar expression patterns across the 53 tissues (Figure
6.2).

6.3.2

Prediction of Genes with Similar Expression Profiles

In prediction of genes with similar expression profiles to NR3C1, we generated ROC
curves to compare the performance of different classifiers (Naïve Bayes, Decision Tree,
Random Forest and Support vector machines (SVM) with four different kernels), under
two scenarios depending on whether promoter sequences were first intersected with
DHSs (Figure 6.3). Decision Tree (DT) exhibited the largest AUC under both scenarios,
and was one of two most stable classifiers (i.e. ΔAUC < 0.01), with the other being the
SVM with RBF kernel. Inclusion of DHS information significantly improved other
classifiers’ AUC except for Naïve Bayes, and generally all TFBSs in a DHS formed a
binding site cluster.

6.3.3

Prediction of Differentially Expressed Direct TF Targets

The best-performing DT classifier in distinguishing genes with NR3C1-like expression
profiles from others was used to predict TF targets respectively based on the CRISPR[15] and siRNA-generated [13] perturbation data.
After eliminating TFBSs in inaccessible promoter intervals, i.e. those excluded from
tissue-specific DHSs, the DT classifier predicted TF targets with greater sensitivity and
specificity (Tables 6.3 and 6.4). Specifically, predictions based on CRISPR-generated
knockdown data for TFs: EGR1, ELK1, ELF1, ETS1, GABPA, and IRF1 were more
accurate than for YY1, which itself represses or activates a wide range of promoters

218

Figure 6.2: Expression profiles of NR3C1, SLC25A32 and TANK. Visualization of
the expression values (in RPKM) of these genes across 53 tissues from GTEx. For each
gene, the colored rectangle belonging to each tissue indicates the valid RPKM of all
samples in the tissue, the black horizontal bar in the rectangle indicates the median
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RPKM, the hollow circles indicate the RPKM of the samples considered as outliers, and
the grey vertical bar indicates the sampling error. By comparing the pictures, the overall
expression patterns of the three genes across the 53 tissues resemble each other (e.g. all
three genes exhibit the highest expression levels in lymphocytes and the lowest levels in
brain tissues).

Figure 6.3: Comparison between the performance of different classifiers in
prediction of genes with similar expression profiles to NR3C1. (A) ROC curves and
AUC of seven classifiers without intersecting promoters with DHSs. (B) ROC curves and
AUC of seven classifiers after intersecting promoters with DHSs. The Decision tree
classifier exhibited the largest AUC under both scenarios, and inclusion of DHS
information significantly improved other classifiers’ AUC except for Naïve Bayes.
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Table 6.3: The Decision tree classifier performance for predicting TF targets using
the CRISPR-generated knockdown data
TF†

Excluding DHS information†

Including DHS information†

Accuracy Sensitivity Specificity Accuracy Sensitivity Specificity

†

EGR1

0.58

0.62

0.60

0.78

0.81

0.80

ELF1

0.59

0.65

0.62

0.83

0.87

0.85

ELK1

0.59

0.59

0.59

0.8

0.81

0.81

ETS1

0.59

0.6

0.59

0.81

0.81

0.81

GABPA

0.55

0.57

0.56

0.72

0.75

0.74

IRF1

0.54

0.55

0.54

0.76

0.64

0.70

YY1

0.5

0.51

0.51

0.45

0.69

0.57

The average performance of 10 rounds of 10-fold cross validation when setting 𝜀 to 1.05

is indicated. The CRISPR-generated knockdown data were obtained from Dixit et al [15].
by binding to sites overlapping the TSS (Table 6.3). Accordingly, the perturbation data
indicated that YY1 has ~4-22 times more PC targets in the K562 cell line than the other
TFs (ε = 1.05), and its binding has a more significant impact on the expression levels of
target genes (for YY1, the ratio of the target counts at ε = 1.1 vs ε = 1.01 was 0.334,
which significantly exceeded those of the other TFs (0.017-0.082); Appendix E.3). This
is concordant with our previous finding that YY1 extensively interacts with 11 cofactors
(e.g. DNA-binding IRF9 and TEAD2; non-DNA-binding DDX20 and PYGO2) in K562
cells, consistent with a central role in specifying erythroid-specific lineage development
[3].
Despite a high accuracy of target recognition, sensitivity did not exceed specificity except
for IRF1 (Table 6.3), due to a relatively large number of false negative genes. Promoters
of most TF targets contain accessible, functional binding sites that significantly change
gene expression levels upon binding. By contrast, promoters of non-targets contain either
no accessible binding sites at all, or accessible, but non-functional sites. The fact that
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Table 6.4: The Decision tree classifier performance for predicting TF targets using
the siRNA-generated knockdown data
TF†

Excluding DHS information†

Including DHS information†

Accuracy Sensitivity Specificity Accuracy Sensitivity Specificity

†

BATF

0.625

0.646

0.604

0.706

0.649

0.763

JUND

0.625

0.646

0.604

0.682

0.682

0.682

NFE2L1

0.633

0.533

0.733

0.75

0.667

0.833

PAX5

0.575

0.614

0.537

0.627

0.563

0.691

POU2F2

0.725

0.818

0.633

0.651

0.796

0.505

RELA

0.591

0.619

0.563

0.690

0.611

0.770

RXRA

0.731

0.813

0.648

0.663

0.793

0.533

SP1

0.561

0.571

0.551

0.579

0.539

0.620

TCF12

0.564

0.638

0.491

0.684

0.597

0.770

USF1

0.737

0.753

0.721

0.723

0.71

0.735

YY1

0.611

0.456

0.765

0.601

0.396

0.807

The average performance of 10 rounds of 10-fold cross validation is indicated. The

siRNA-generated knockdown data were obtained from Cusanovich et al [13].
these false negatives were erroneously predicted to non-targets was attributable to the
indistinguishability between functional binding sites in their promoters and nonfunctional ones in non-targets in the classifier. In vivo co-regulation mediated by
interacting cofactors, which was excluded by the classifier, assisted in distinguishing
these non-functional sites that do not significantly affect gene expression [3,13].
As the threshold 𝜀 increased, the accuracy of the classifier for all the TFs monotonically
increased as expected (Figure 6.4). For a gene to be defined as a DE target of a TF, the
average fold change in its expression level for all guide RNAs that downregulated the TF
were required to reach the minimum threshold 𝜀. Upon TF knockdown, 𝜀 is inversely
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Figure 6.4: Accuracy of the Decision tree classifier when using three different values
for ε. Each accuracy value was averaged from 10 rounds of 10-fold cross validation,
when the minimum threshold  on the average fold change in gene expression levels
under all guide RNAs of the TF took three different values 1.01, 1.05 and 1.1. As 𝜺
increased, accuracy for all seven TFs monotonically increased.
correlated with the number of target genes, but positively correlated with fold changes in
their corresponding expression levels. In general, more significantly DE genes have been
associated with a higher number of TFBSs in their promoters [13]. Thus, at greater 𝜀,
there are larger differences in the values of machine learning features derived from TFBS
clusters between targets and non-targets.
With the siRNA-generated knockdown data, the performance of the DT classifier was
compared to the approach inferring DE targets by correlating TF binding with gene
expression levels across ten cell types [14]. In this correlation-based approach, three
measures (i.e. the absolute Pearson correlation coefficient (PC), the absolute Spearman
correlation coefficient (SC), and the absolute combined angle ratio statistic (CARS)),
whose performance was evaluated with precision-recall curves, were alternatively used to
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compute a correlation score between the number of ChIP-seq peaks overlapping the
promoter and gene expression values. Genes predicted to be DE targets had scores above
the threshold resulting in a 1.5-fold increase compared to the background precision. For
example, in the case of YY1, which was the only TF analyzed by both approaches, the
performance of the DT classifier was 0.66 (precision) and 0.456 (recall) (Table 6.4). This
classifier outperformed all three correlation measures (PC: 0.467 and 0.003; SC: 0.467
and 0.006; CARS: 0.467 and 0.003), even though the correlation approach used a less
stringent P-value threshold (0.05) for defining differential expression of likely non-direct
targets, and intersected ChIP-seq peaks over shorter 5kb promoter intervals upstream of
the TSS.

6.3.4

Intersection of Genes with Similar Expression Profiles and
Direct Targets

To determine how many TF targets have similar tissue-wide expression profiles, we
intersected the set of targets with the set of 500 PC genes with the most similar
expression profiles for each TF (Table 6.5, Appendix E.5). The TFs PAX5 and POU2F2
are primarily expressed in B cells, and their respective targets IL21R and CD86 are also B
cell-specific, which accounts for the high similarity in the expression profile between
them. There are respectively 21 and 7 nuclear mitochondrial genes (e.g. MRPL9
and MRPS10, which are subunits of mitochondrial ribosomes) in the intersections for
YY1 in the K562 and GM19238 cell lines [25]. Previous studies reported that YY1
upregulates a large number of mitochondrial genes by complexing with PGC-1α in
C2C12 cells [26], and genes involved in the mitochondrial respiratory chain in K562 cells
[15], which is consistent with the idea that YY1 may broadly regulate mitochondrial
function (within all 53 tissues in addition to the erythrocyte, lymphocyte and skeletal
muscle cell lines).
Between 0.4%-25% of genes with similar expression profiles to the TFs are actually their
targets (Table 6.5); the majority are non-targets whose promoters contain non-functional
binding sites that are distinguished from targets by their lack of coregulation by
corresponding cofactors. For YY1 and EGR1, we validated this hypothesis by contrasting
the flanking cofactor binding site distributions and strengths in the promoters of the most
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similarly expressed target genes (YY1: MRPL9, BAZ1B; EGR1: CANX, NPM1) and nontarget genes (YY1: ADNP, RNF25; EGR1: AC142293.3, AP000705.7). Strong and
intermediate recognition sites for TFs: SP1, KLF1, CEBPB formed heterotypic clusters
with adjacent YY1 sites; as well TFBSs of SP1, KLF1, and NFY were frequently present
adjacent to EGR1 binding sites. These patterns contrasted with the enrichment of CTCF
and ETS binding sites in gene promoters of YY1 and EGR1 non-targets (Appendix E.6).
Previous studies have reported that KLF1 is essential for terminal erythroid
differentiation and maturation [27], direct physical interactions between YY1 and the
constitutive activator SP1 synergistically induce transcription [28], the activating CEBPB
promotes differentiation and suppresses proliferation of K562 cells by binding the
promoter of the G-CSFR gene encoding a hematopoietin receptor [29], EGR1 and SP1
synergistically cooperate at adjacent non-overlapping sites on EGR1 promoter but
compete binding at overlapping sites [30]; whereas CTCF functions as an insulator
blocking the effects of cis-acting elements and preventing gene activation [31,32], and
ETV6, a member of the ETS family, is a transcriptional repressor required for bone
marrow hematopoiesis and associated with leukemia development [33].

6.3.5

Mutation Analyses on Promoters of Direct Targets

Because the promoters of most direct targets contain multiple binding site clusters, we
anticipate that this enables these genes’ expression to be naturally robust against binding
site mutations; in other words, the other clusters can compensate for the loss of a cluster
destroyed by mutations in binding sites, so that the mutated promoters are still capable of
effectively inducing gene transcription upon TF binding. First, we validated this
hypothesis by examining whether introducing artificial variants into binding sites in the
promoter of the target gene MCM7 in the test set of EGR1 changes the classifier output
(Figure 6.5). Specifically, in the K562 cell line, MCM7 is upregulated by EGR1.
Knockdown of MCM7 has an anti-proliferative and pro-apoptotic effect on K562 cells
[34] and the loss of EGR1 increases leukemia initiating cells [35], which suggests that
EGR1 may act as a tumor suppressor in K562 cells through the MCM7 pathway.
First, the strongest binding site (at position chr7:100103347 [hg38], - strand, 𝑅𝑖 = 12.0
bits) in the promoter was eliminated by a G->A mutation, resulting in the disappearance
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Table 6.5: Intersection of TF targets and 500 protein-coding genes with the most similar expression profiles
Number of targets

Size of intersection

Targets among the most similar 10 genes§

EGR1

169

12

None

ELF1

78

5

None

ELK1

112

4

GNL1(8th)

267

15

None

GABPA

513

25

TAF1(1st)

IRF1

457

10

None

TF

ETS1

Cell line

K562

MRPL9(2nd), BAZ1B(6th), ENY2(7th),

1752

127

1066

61

MED4(1st), SURF6(3rd), BAZ1B(6th)

BATF

193

4

MB21D1(4th), C16orf87(9th)

JUND

44

2

None

60

3

None

RELA

252

22

HMG20B(9th)

RXRA

183

7

None

SP1

1630

96

ACLY(1st), SEC22B(7th), GPX1P1(10th)

YY1

NFE2L1

GM19238

NUB1(8th), USP1(9th), HNRNPR(10th)
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§

TCF12

669

19

None

USF1

309

20

None

PAX5

938

76

IL21R(9th)

POU2F2

550

21

CD86(3rd)

The rank of each target in the list of similar genes in the descending order of Bray-Curtis similarity values is shown in the brackets

immediately following the target.
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of Cluster 1, which consists of two sites (the other site at chr7:100103339, -, 4.3 bits).
EGR1 was still predicted to compensate for this mutation, due to the presence of the other
two clusters comprising weaker binding sites of intermediate strength (chr7:100102252,
+, 7.0 bits; chr7:100102244, +, 1.3 bits; chr7:100101980, +, 8.9 bits; chr7:100101977, +,
2.2 bits; chr7:100101984, +, 1.9 bits), enabling the promoter to maintain capability of
inducing MCM7 expression (Figure 6.5). These adjacent clustered sites, which may not
be strong enough to bind TFs and individually activate transcription, can stabilize each
other’s binding [2]. The weaker sites flanking a strong binding site in a cluster can direct
the TF molecule to the strong site and extend the period of the molecule physically
associating with the strong site, which is termed, the funnel effect [2]. Further, Clusters 2
and Cluster 3 were respectively removed by G->T and C->G mutations abolishing the
strongest site in either cluster, which altered the prediction, that is, EGR1 lost the
capability to induce MCM7 transcription (Figure 6.5). The remaining four sparse weak
sites do not form a cluster and cannot completely supplant the disrupted strong sites.
Further, we examined the impacts of known natural SNPs on binding site strengths,
clusters and the regulatory state of the promoter for a direct target of each of the seven
TFs from the CRISPR-generated perturbation data (Table 6.6). Often a single SNP (e.g.
rs996639427 of EGR1) can affect the strengths of multiple binding sites (Table 6.6).
Apart from SNPs that are predicted to abolish binding (Figure 6.5), leaky variants that
merely weaken TF binding are common (Table 6.6). Binding stabilization between
adjacent sites and the funnel effect enable the CRMs comprised of information-dense
clusters to be robust to mutations in individual binding sites. In this way, neither
mutations that abolish TFBSs nor leaky SNPs in flanking weak sites can destroy
functional clusters (e.g. rs1030185383 and rs5874306 of IRF1), whereas SNPs with large
reductions in 𝑅𝑖 values of central strong sites are more likely to abolish clusters (e.g.
rs865922947, rs946037930, rs917218063 and rs928017336 of YY1) (Table 6.5). More
generally, the presence of multiple clusters enables promoters to be effectively resilient to
the effects binding site mutations; only the complete abolishment of all clusters resulting
from the simultaneous occurrence of multiple SNPs can transform the promoter to be
unresponsive to TF binding to residual weak sites (e.g. rs997328042, rs1020720126 and
rs185306857 of GABPA) (Table 6.6). Furthermore, a relatively small number of SNPs

228

Figure 6.5: Mutation analyses on the target MCM7 in the test set of EGR1. This
figure depicts the effect of a mutation in each EGR1 binding site cluster of the MCM7
promoter on the expression level of MCM7, which is a target of the TF EGR1. The
strongest binding site in each cluster were abolished by a single nucleotide variant. Upon
loss of all three clusters, only weak binding sites remained and EGR1 was predicted to no
longer be able to effectively regulate MCM7 expression. Multiple clusters in the
promoters of TF targets confers robustness against mutations within individual binding
sites that define these clusters.
that strengthen TF binding and eventually amplify the regulatory effect of the TF on the
gene expression level are also present (e.g. rs887888062 of EGR1 and rs751263172 of
ELF1) (Table 6.6), suggesting that, in addition to deleterious mutations, benign variants
may also be found in promoters, consistent with the expectations of neutral theory [36].

6.4 Discussion
In this study, the Bray-Curtis Similarity function was initially shown (for the NR3C1
gene) to measure the relatedness of overall expression patterns between genes across a
diverse set of tissues. The resulting machine learning framework distinguished BrayCurtis function-defined similar from dissimilar genes based on the distribution, strengths
and compositions of TFBS clusters in accessible promoters, which can
substantiallyaccount for the corresponding gene expression patterns. Using knockdown
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Table 6.6: Mutation analyses on promoters of direct targets
Classifier output
TF

Target

Normal
cluster

Normal allele§

SNP ID§

rs538610162

Variant allele§

Variant
cluster‡

Cluster 1
of 2
EGR1
(𝑹𝒔𝒆𝒒𝒖𝒆𝒏𝒄𝒆 =

(chr19:39540286, -,
7.22 bits)

EID2B

12.2899 bits)

C>G)

4.84 bits)

rs759233998

GAAGGGGCATC

(chr19:39540294 (chr19:39540286, -, Abolished
C>T)

0.06 bit)

rs974735901

GAGGGGGCTTC

(chr19:39540288 (chr19:39540286, -,
T>A)

6.90 bits)

rs978230260

GAGGGGGCAAC

Cluster 1
of 2

(chr19:39540287 (chr19:39540286, -, Abolished

Cluster 2
of 2

GCGTGCGTGGG
(chr19:39540162,
+, 1.59 bits)

A>T)

5.31 bits)

rs764734511

ACGTGCGTGGG

(chr19:39540162 (chr19:39540162, +,
G>A)

Wildtype

CAGGGGGCATC

(chr19:39540296 (chr19:39540286, -, Abolished

GAGGGGGCATC

Variant†

-0.72 bit)

(chr19:39540162 CCGTGCGTGGG

Cluster 2
of 2
Cluster 2

√

√

√
×

√

√

√

√
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G>C)

(chr19:39540162, +,

of 2

-0.79 bit)
GCGTGCGTCGG
rs996639427
(chr19:39540170

(chr19:39540162, +,
-5.21 bits)
Abolished

√

(chr19:39540166, (chr19:39540174 (chr19:39540166, +, Abolished

√

G>C)

GCGTCGGCGCT
(chr19:39540165, +,
-0.85 bit)

GCGTGGGCGCT

+, 9.72 bits)

rs1027751538

GCGTGGGCACT

G>A)

5.16 bits)

rs887888062

GCGTGGGCGCA

(chr19:39540176 (chr19:39540166, +,
T>A)
rs760968937
ELF1
(𝑹𝒔𝒆𝒒𝒖𝒆𝒏𝒄𝒆 =
11.2057 bits)

HIST1H Cluster 1 of
4H

2

GCGGAAGCGTG (chr6:26286547
(chr6:26286540,

C>T)

+, 9.92 bits)

(chr6:26286547
C>A)

10.94 bits)
GCGGAAGTGTG
(chr6:26286540,
+, 10.71 bits)
GCGGAAGAGTG
(chr6:26286540,
+, 8.84 bits)

Cluster 2
of 2

Cluster 1 of
2

√

√

√
√

Cluster 1 of
2

√

×
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rs1000196206

GCCGAAGCGTG

(chr6:26286542

(chr6:26286540,

G>C)

+, -6.26 bits)

rs144759258

GCGAAAGCGTG

(chr6:26286543

(chr6:26286540,

G>A)

+, -3.60 bits)

rs966435996

GCGGGAGCGTG

(chr6:26286544

(chr6:26286540,

A>G)

+, 5.28 bits)

rs950986427

GCGGAAGCATG

(chr6:26286548

(chr6:26286540,

G>A)

+, 8.28 bits)

rs373649904

TAGGAGATGCG

(chr6:26286483

(chr6:26286473,

G>A)

-, 0.61 bit)

rs926919149

CAGAAGATGCG

(chr6:26286473,

(chr6:26286480

(chr6:26286473,

-, 6.98 bits)

C>T)

-, -6.53 bits)

rs751263172

CAGGCGATGCG

(chr6:26286479

(chr6:26286473,

CAGGAGATGCG
Cluster 2 of
2

Abolished

√

Abolished

√

Abolished

√

Cluster 1 of
2

√

Abolished

√

Abolished

√

Abolished

√

232

T>G)

-, 1.24 bits)

rs369076253

CAGGAGATGCC

(chr6:26286473

(chr6:26286473,

C>G)

-, 6.92 bits)

rs751263172

CAGGAAATGCG

(chr6:104447431

(chr6:26286473,

4C>T)

-, 11.43 bits)

rs146048477

CAGGGAAGTCC

(chr1:209667961 (chr1:209667959, -,

CAGGGAAGACC

T>A)

2.24 bits)

rs887606802

CGGGGAAGACC

(chr1:209667959, -, (chr1:209667968 (chr1:209667959, -,
Cluster 1 of

ELK1
(𝑹𝒔𝒆𝒒𝒖𝒆𝒏𝒄𝒆 =

G0S2

1.92 bits)

2

T>C)

-3.35 bits)

rs1021034916

CAAGGAAGACC

(chr1:209667967 (chr1:209667959, -,

11.9041 bits)
GAGGAAATGAG

C>T)

-3.57 bits)

rs941962117

GAGGAGATGAG

(chr1:209667969, (chr1:209667974 (chr1:209667969,
+, 8.14 bits)
Cluster 2 of CTGGAAGAGCA

A>G)
rs896117033

Cluster 2 of
2

Cluster 2 of
2

Cluster 1 of
2

Cluster 1 of
2

Cluster 1 of
2

Abolished

√

√

√

√

√

√

√
√
×

√

+, 4.11 bits)
CTGGAAGAGTA Cluster 2 of √
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2

(chr1:209673544, (chr1:209673545 (chr1:209673544,
-, 5.91 bits)

G>A)

-, 3.95 bits)

rs971962577

CTGGAAGAACA

(chr1:209673546 (chr1:209673544,
C>T)

-, 3.49 bits)

2

Cluster 2 of
2

√

GTGGAAGAGCA
rs1011969709
(chr1:209673554
G>C)
CCAGAAGTCAA
(chr1:209673551,
+, 7.44 bits)

ETS1
(𝑹𝒔𝒆𝒒𝒖𝒆𝒏𝒄𝒆 =
10.0788 bits)

TTC19

Cluster 1 of
1

GCAGGGAAAGG
(chr17:16022293,
+, 7.92 bits)

(chr1:209673544,
-, 3.92 bits)
CCACAAGTCAA

Abolished

√

(chr1:209673551,
+, -5.50 bits)

rs1023312090

CCAGAAGTCAG

(chr1:209673561 (chr1:209673551,
A>G)

+, 8.40 bits)

rs1022234223

GCACGGAAAGG

(chr17:16022296 (chr17:16022293,
G>C)

+, -4.98 bits)

rs968299415

GCAGGGAATGG

(chr17:16022301 (chr17:16022293,
A>T)

+, 10.01 bits)

Cluster 2 of
2

Abolished

√

√

×

×
√

Cluster 1 of
1

√

√
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rs997328042
ACAGGAAAGGG
(chr2:131112770,
+, 10.36 bits)

GABPA
(𝑹𝒔𝒆𝒒𝒖𝒆𝒏𝒄𝒆 =

PLEKH Cluster 1 of
B2

ATAGGAAAGGG

(chr2:131112771 (chr2:131112770,
C>T)

+, -3.68 bits)

rs1020720126

ACACGAAAGGG

(chr2:131112773 (chr2:131112770,
G>C)

+, -4.16 bits)

rs185306857

TATGGAAACTA

(chr2:131112761 (chr2:131112760, +,

1

10.8567 bits)
TCTGGAAACTA

C>A)

-2.86 bits)

rs772728699

TCAGGAAACTA

(chr2:131112760, (chr2:131112762 (chr2:131112760, +,
+, 1.53 bits)

T>A)

5.23 bits)

rs965753671

TCTGGAAACCA

(chr2:131112769 (chr2:131112760, +,
T>C)
GAGAATGAAAG

IRF1
(𝑹𝒔𝒆𝒒𝒖𝒆𝒏𝒄𝒆 = SMIM13
13.5544 bits)

Cluster 1 of

CA

1

(chr6:11093663,
+, 12.56 bits)

rs950528541
(chr6:11093663
G>C)

2.13 bits)

Abolished

×

Abolished

×

Cluster 1 of
1

Cluster 1 of
1

Cluster 1 of
1

×

√

√

√

√

CAGAATGAAAG
CA

Cluster 1 of

(chr6:11093663,

1

+, 8.97 bits)

√

×

√

235

GGGAATGAAAG
rs886259573

CA

Cluster 1 of

(chr6:11093663,

1

(chr6:11093664
A>G)

√

+, 9.65 bits)
rs982931728
(chr6:11093666
A>G)

rs1020218811
(chr6:11093668
T>G)

rs570723026
(chr6:11093672
A>G)

GAGGATGAAAG
CA

Cluster 1 of

(chr6:11093663,

1

√

+, 8.09 bits)
GAGAAGGAAAG
CA

Cluster 1 of

(chr6:11093663,

1

√

+, 9.36 bits)
GAGAATGAAGG
CA

Cluster 1 of

(chr6:11093663,

1

√

+, 8.01 bits)

rs1004825794

GAGAATGAAAG

(chr6:11093675

CC

Cluster 1 of

A>C)

(chr6:11093663,

1

(chr6:11093675

+, 10.47 bits)

√
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A>T)

GAGAATGAAAG
CA

Cluster 1 of

(chr6:11093663,

1

√

+, 10.42 bits)
rs1030185383
(chr6:11093649
A>C)
AAGACCAAAGG
CA
(chr6:11093641,
+, 2.43 bits)

rs5874306
(chr6:11093650d
elG)

rs558896490
(chr6:11093643
G>A)
GCGGCCATCGG

YY1
(𝑹𝒔𝒆𝒒𝒖𝒆𝒏𝒄𝒆 =
12.8554 bits)

CKLF

rs865922947

AAGACCAACGG
CA

Cluster 1 of

(chr6:11093641,

1

+, -3.39 bits)
AAGACCAAAGC
AG

Cluster 1 of

(chr6:11093641,

1

C

1

(chr16:66549785,

G>A)

-, 10.06 bits)

rs946037930

√

+, 0.90 bit)
AAAACCAAAGG
CA

Cluster 1 of

(chr6:11093641,

1

√

√

+, 7.06 bits)
CCGGCCATCGGC

(chr16:66549791 (chr16:66549785,

Cluster 1 of

√

Cluster 1

√
×

-, 6.80 bits)
GCTGCCATCGGC Cluster 1

√

√
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(chr16:66549794 (chr16:66549785,
C>A)

-, 8.02 bits)

rs917218063

GCGACCATCGGC

(chr16:66549793 (chr16:66549785,
C>T)

-, 5.41 bits)

rs928017336

GCGGCTATCGGC

(chr16:66549791 (chr16:66549785,
G>A)

Abolished

×

Abolished

×

-, -3.62 bits)

GCCGCCCCCGTC (chr16:66549792, +, 1.34 bits)
§

All coordinates are based on the hg38 genome assembly. A bold italic letter in a binding site sequence indicates the base where a

SNP occurs. The SNPs strengthening binding sites and corresponding variant binding site sequences are underlined.
‡

The impact on whether the occurrence of a single SNP resulted in the disappearance of the cluster containing it is shown.

†

After a single SNP occurred or multiple SNPs simultaneously occurred, the classifier produced a new prediction on whether the TF

is still capable of significantly affecting gene expression via the variant promoter.
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data as the gold standard, the combinatorial use of TF binding profiles and chromatin
accessibility was also demonstrated to be predictive of TF targets. A binding site
comparison confirmed that coregulatory cofactors are responsible for distinguishing
between functional sites in targets and non-functional ones in non-targets. Furthermore,
mutation analyses on binding sites of targets demonstrated that the existence of both
multiple TFBSs in a cluster and multiple information-dense clusters in a promoter
enables both the cluster and the promoter to be resilient to binding site mutations.
The DT classifier improved after intersecting promoters with DHSs in both prediction of
genes with similar expression profiles to NR3C1 and prediction of TF targets (Figure 6.3,
Tables 6.3 and 6.4). This intersection eliminated noisy binding sites that are inaccessible
to TF proteins in promoters; specifically, it widened discrepancies in feature vectors
between positives and negatives. If the 10kb promoter of a gene instance does not overlap
DHSs, its feature vector will only consist of 0; the percentages of negatives whose
promoters do not overlap DHSs considerably exceeded those of positives (Appendix
E.7), which led to an excess of negatives with feature vectors containing only 0 after
intersection. This explains why these negatives are not DE targets of the TFs in the K562
and GM19238 cell lines, because their entire promoters are not open to TF molecules;
other regulatory regions besides the proximal promoters (e.g. intronic enhancers [37])
still enable the TFs to effectively control the expression of the positives with inaccessible
promoters.
The relatively poor performance of the classifier on YY1 (Table 6.3) is attributable to its
smaller percentage of negatives with inaccessible promoters and the larger number of
functional binding sites in the K562 cell line (Appendix E.7). Additionally, the DT
classifier was more predictive of functional TF binding on the CRISPR-generated
knockdown data than the siRNA-generated ones (Tables 6.3 and 6.4). This larger
discrepancy in feature vectors between positives and negatives from CRISPR-based
perturbations is also attributable to the greater differences in the percentages between
positives and negatives with inaccessible promoters (Appendix E.7). Among the 22,046
genes whose expression levels were measured in the CRISPR-based perturbations, most
of the TNs with inaccessible promoters merely have one transcript and specific functions
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(e.g. VENTXP1 for the TF, EGR1), whereas many such negatives were excluded from the
8,872 genes whose knockdown data were generated by siRNA inactivation.
Our in-silico mutation analyses revealed that some deleterious TFBS mutations could be
compensated for by other information-dense clusters in a promoter; thus predicting the
effects of mutations in individual binding sites would not be sufficient to interpretation of
downstream effects. Though compensatory clusters may maintain gene expression, the
promoter will provide lower levels of activity than the wild-type promoter could, which is
a recipe for achieving natural phenotypic diversity. Few published studies in molecular
diagnostics have specifically examined the effects of naturally occurring variants within
clustered TFBSs; thus IDBC-based machine learning provided an alternative
computational approach to predict deleterious mutations that actually impact (i.e. repress
or abolish) transcription of target genes and result in abnormal phenotypes, and to
simultaneously minimize false positive calls of TFBS mutations that individually have
little or no impact.
Apart from these TFs, the Bray-Curtis Similarity can be directly applied to identify the
ground-truth genes with overall similar tissue-wide expression patterns to any other gene
whose expression profile is known. Further studies could investigate the biological
significance underlying the phenomenon that all these genes share a common expression
pattern, including the similarity between other regulatory regions besides proximal
promoters in terms of TFBSs and epigenetic markers. This machine learning framework
can also be applied to predict direct DE targets for other TFs and in other cell lines,
depending on the availability of corresponding knockdown data.
There are a number of limitations of our approach. The Bray-Curtis function seems
unable to accurately measure the similarity between the expression profiles of a gene
(e.g. MIR23A) without any detectable mRNA in any of the 53 tissues analyzed and genes
(e.g. the ubiquitously expressed NR3C1 and stomach-specific PGA3) that are expressed
in at least one tissue. Intuitively, in terms of expression patterns PGA3 is more similar to
MIR23A than NR3C1; however, the Bray-Curtis similarity values indicate that both PGA3
and NR3C1 bear no similarity to MIR23A (i.e. 𝑠𝑖𝑚𝐵𝑟𝑎𝑦−𝐶𝑢𝑟𝑡𝑖𝑠 (𝑁𝑅3𝐶1, 𝑀𝐼𝑅23𝐴) =
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𝑠𝑖𝑚𝐵𝑟𝑎𝑦−𝐶𝑢𝑟𝑡𝑖𝑠 (𝑃𝐺𝐴3, 𝑀𝐼𝑅23𝐴) = 0). Another possible limitation in classifier
performance in the prediction of genes with similar tissue-wide expression profiles is that
only binding sites of 82 TFs were analyzed due to a lack of available iPWMs for other
TFs, given that 2000-3000 sequence-specific DNA-binding TFs are estimated to be
encoded in the human genome [38]. For example, four TFs (CREB, MYB, NF1, GRF1)
were previously reported to bind the promoter of the NR3C1 gene to activate or repress
its expression, however their iPWMs exhibiting known primary motifs could not be
successfully derived from ChIP-seq data [3,24]. Regarding the CRISPR-generated
knockdown data used here, TPs were inferred to be direct targets by intersecting
promoters with their corresponding ChIP-seq peaks, which may not be completely
accurate, due to the presence of noise peaks that do not contain true TFBSs [3,39]. In
instances where small fold changes in the expression levels of DE targets were evident,
these peaks could arise from compromised efficiency of knockdowns as a result of
suboptimal guide RNAs or the limitations of perturbing only a single allele of the TF.
Finally, the framework developed here only takes into account the 10kb interval proximal
to the TSS, and would not therefore capture long range enhancer effects beyond this
distance; by contrast, correlation based approaches have successfully incorporated
multiple definitions of promoter length [14].

6.5 Conclusions
The Bray-Curtis function is able to effectively quantify the similarity between tissuewide gene expression profiles. By analysis of promoter information theory-based TF
binding profiles that captured the spatial distribution and information contents of TFBS
clusters, ChIP-seq and chromatin accessibility data, we described a machine learning
framework that distinguished tissue-wide expression profiles of similar vs dissimilar
genes and identified direct DE targets of TFs. Functional binding sites in target genes that
significantly alter expression levels upon direct binding are at least partially distinguished
by TF-cofactor coregulation from non-functional sites in non-targets. Finally, in-silico
mutation analyses demonstrated that the presence of multiple information-dense clusters
in the promoter reduces deleterious mutations that can significantly alter the regulatory
state and expression level of the gene as a protective mechanism.
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Chapter 7

7

Discussion

In this chapter, we will discuss the advances and generalization of our methods developed
in Chapters 3, 4, 5 and 6, the implications of our results, and the potential limitations and
future studies to overcome them.

7.1 Advances and Generalization of the Methods
Developed in this Thesis
7.1.1

The Maskminent Motif Discovery Pipeline and iPWM
Validation

The Maskminent motif discovery pipeline we developed in Chapter 3 provides a
complete software suite to mine elusive TFBS motifs from ChIP-seq datasets, generate
contiguous and bipartite iPWMs, and scan DNA sequences for binding sites using
iPWMs.
Compared to Bipad, one advance of the Maskminent pipeline is the ability to recursively
mask motifs found in previous iterations to discover additional conserved motifs from the
same dataset. These previous motifs are masked by skipping the binding sites with 𝑅𝑖 >
0 predicted by iPWMs. Bipad can only perform one execution on a ChIP-seq dataset and
return the lowest-entropy motif, regardless of whether this motif is recognized by a TF or
noise. By contrast, MEME uses a likelihood-based approach to mask the motifs that have
been found by the algorithm (1). For each position, MEME computes the probability that
it is not contained in an occurrence of any motif found to date, which further affects the
next estimates for base frequencies in the motif component in the maximization step (1).
The ability to identify the maximum number of top peaks that can produce the primary or
cofactor motif is another advance of the Maskminent pipeline. First, it also enhances the
ability of Bipad to reveal primary and cofactor motifs. If Bipad returns a noise motif from
all peaks in a dataset, this implies the alignment formed by all binding sites in the dataset
has a larger entropy than the noise motif. Since peaks with higher signal values generally
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contain stronger binding sites, sites in a subset of top peaks have higher sequence
conservation (i.e. more similar to the strongest consensus sequence) and form a lowerentropy alignment. Thus this alignment is more likely to suppress the noise motif and be
returned by Maskminent. Second, compared to prior motif discovery pipelines applied
only to a small number of top peaks (2–4), the maximum number of top peaks enable the
derived iPWM to incorporate as many intermediate and weak binding sites as possible.
Thus the iPWM can also accurately quantify the strengths of intermediate and weak
binding sites apart from strong sites.
Compared to the previous studies (2–6) deriving contiguous count matrices or PFMs
from ChIP-seq datasets, the generation of bipartite iPWMs is an advance. From Equation
1.6, the 𝑅𝑖 value of a binding site or a non-site computed from an iPWM is quantitatively
related to the amount of heat energy dissipated or absorbed by the association of the TF
protein with the site or non-site, enabling the accurate quantification of the binding site
strength, in contrast with the log likelihood ratio score computed from a PFM that is not
based on Shannon information theory. In addition, bipartite iPWMs are capable of
accurately modelling the binding behavior of dimeric TFs by allowing the spacer length
to vary and computing a geometry-based spacer penalty.
Using iPWMs to detect experimentally confirmed binding sites and interpret the
experimentally determined effects of SNPs on binding site strengths is an advance to the
methods in the literature to validate the TFBS motifs derived from ChIP-seq datasets, and
ought to be the gold standard. Another method widely used by previous studies (4, 7) is
to generate the ROC (receiver operating characteristics) curve and measure the AUC
(area under the curve), which is not as convincing. For example, when generating the
ROC curve, the negative sequences that supposedly do not contain binding sites were
randomly chosen from the genome (7). In fact, these randomly chosen sequences may
still contain true binding sites, as demonstrated by the false positive detection rate (1.2E7 to 0.06) from the null 𝑅𝑖 distribution in Chapter 3, which results in an inaccuracy.
In Chapter 3 the Maskminent pipeline was applied to analyze almost all ChIP-seq
datasets of human TFs that ENCODE had generated before April 2016. ENCODE has
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been conducting more ChIP-seq experiments, resulting in a total of ~2,400 peak datasets
to date. The Maskminent pipeline can be directly applied to these newly generated data to
derive binding site motifs and iPWMs for more TFs. Furthermore, 2000-3000 sequencespecific DNA-binding TFs are estimated to be encoded in the human genome (8);
specifically, the combination of multiple paper and database sources indicated that 2,765
proteins are likely to act as TFs (9). ChIP-seq experiments have not been performed for
numerous TFs with known or unknown binding specificities, and even unknown TFs,
possibly due to a lack of efficient protein antibodies; for example, 1,211 out of the known
or likely 1,639 TFs with high confidence have known binding motifs, with 1,107
determined experimentally and 104 inferred from a closely-related homolog (9). The
Maskminent pipeline can also be applied to these future ChIP-seq datasets, with the
ultimate objective to determine the sequence preferences for all human TFs.
As the number of available ChIP-seq datasets generated by ENCODE rapidly increases,
the scalability and running efficiency of the Maskminent software become particularly
important. Maskminent, being a C++ software program, is time efficient despite its
output is not transiently generated; for example, on an Intel Xeon processor with a 2.27
GHz clock frequency, it took three hours to find the 22nt-wide optimal multiple
alignment from the top 1,000 ~330nt-long peaks of the TF RFX5. As high-performance
computing facilities with numerous processors like SHARCNET become increasingly
ubiquitous, Maskminent can handle in parallel a large number of ChIP-seq datasets by
running independent instances on multiple processors, further reducing the time required
to analyze all data; for example, it took approximately seven months to obtain the results
from all 765 datasets in Chapter 3 using the Maskminent pipeline on approximately eight
processors of SHARCNET, amounting to about five years of CPU time (i.e. a single CPU
keeps working for five years without any break). Thus we are able to estimate that it will
take ~15 months to finish analyzing these newly generated ~1,635 datasets on the same
processors, amounting to ~10 years of CPU time.
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7.1.2

The Unified Analytic Framework for Prioritization of Noncoding Variants of Uncertain Significance in Heritable Breast
and Ovarian Cancer

One advance of this unified framework is that besides coding variants, it also integrates
information theory-based analyses of multiple types of non-coding variants, including
TFBS, SRBS, RBBS, and splice site variants. Shannon information theory confers this
unifying capability; as long as an iPWM quantifying its base preferences is derived for a
regulatory protein of any type (e.g. TFs, splicing regulatory or RNA-binding proteins),
we will be able to detect its binding sites and predict the effects of variants within these
sites based on changes in the 𝑅𝑖 values.
Another advance of this framework is that its predictions on the effects of non-coding
variants are robust and accurate, due to the quantitative relationship between Shannon
information and the Second Law of Thermodynamics (Equation 1.6). This hypothesis has
been proved by the successful detection of true TFBSs in Chapter 3, explanation of
experimentally observed effects of SNPs on TFBS strengths in Chapter 3, and
interpretation of experimentally determined effects of splice site variants on mRNA
splicing (10–13).
In Chapter 4, this unified framework was applied to identify 15,311 unique variants in 7
complete HBOC genes of 102 patients; on a larger scale, Chapter 5 further identified
38,372 variants in 20 HBOC genes of 287 patients. These genes are known to be
associated with increased risks of HBOC through four pathways; however, variants in
many other genes can also contribute to the onset of HBOC. Furthermore, non-coding
genetic mutations are also responsible for the susceptibility to other types of cancer, such
as lung cancer (14) and colon cancer (15); however, most of these mutations do not lie
within TF-encoding genes based on data from recent CRISPR screens, perhaps because
the human TFs mainly serve developmental or tissue-specific functions (9, 16). By
contrast, 19.1% of TF-encoding genes were found to harbor mutations associated with at
least one disease phenotype, a higher percentage than that observed for all genes (16.2%)
(9). This information theory-based framework can incorporate iPWMs of more TFs that
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will be derived from the newly generated ChIP-seq datasets and be directly applied to
other HBOC genes, cancer types and diseases.
As the cost and time required by whole genome sequencing that sequences the complete
genome of an individual rapidly decrease due to the progressive adoption of nextgeneration sequencing (NGS) technologies, identifying all coding and non-coding
variants in a complete genome instead of specific genes becomes feasible, and the
scalability of this unified framework becomes important in terms of both hardware
consumption and running time. Considering only TFBS variants for simplicity, one can
reasonably estimate that ~3 million binding site variants of ~3,000 TFs will be identified
in the complete genome of a patient. The hardware resources required for applying the
framework to analyze these variants will include a large-capacity disk drive storing the
input data (i.e. the ~3 billion bp-long genome, 3 million variants and ~3,000 TF iPWMs)
and the analysis results, RAM and processors. Based on the current electronics industry,
the amount of available RAM, being several dozen GB in a typical computer system, is
more of a bottleneck compared to the disk drive and processors, due to the low hard drive
cost and high-performance computing facilities. Such an amount is not sufficient for
simultaneously accommodating all the input data and output results, leading to the
common space-time trade-off (17) between hardware consumption and running time
faced by many computational algorithms (e.g. dynamic programming (18)). One batchbased strategy to approach this issue is to maximize space usage and minimize running
time by dividing the input data into as few batches as possible. Each batch contains as
much data (TFBS variants in the case of the unified framework) as possible that can be
processed by the limited RAM at one time.

7.1.3

The General Machine Learning Framework for Prediction of
Gene Expression Profiles and TF Target Genes

Compared to prior studies (19–22) predicting tissue-specific gene expression levels, the
definition of the gene expression profile being the expression values across 53 tissues is
an advance of our machine learning model. Focusing on one single tissue at one time
limits the tissue-wide expandability of the models developed in the prior studies; either a
different model needed to be constructed for each tissue (22) or the same model needed
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to be rerun for each tissue (19–21). By contrast, this definition of the gene expression
profile enabled our machine learning framework to simultaneously take all 53 tissues into
account.
Applying the Bray-Curtis similarity measure to quantify the similarity in the expression
profile between two genes is another advance of our machine learning framework. An
intuitive comparison in the visualized overall expression pattern across the 53 tissues
between NR3C1 and the two genes (i.e. SLC25A32 and TANK) with the highest
similarity values computationally identified by the Bray-Curtis metric proved its efficacy.
The Bray-Curtis similarity measure has three desired mathematical properties described
in Chapter 1 that potently justify its application in this situation. The first is the strict
bounds of 0 and 1 that it maintains, which form a natural similarity range that is easy to
interpret. The second is the similarity between the expression profiles of the two genes
can achieve the maximum value 1, if and only two genes exhibit the same expression
value in each of the 53 tissues. This is attributable to the simultaneous consideration of
both the directions and lengths of vectors by the Bray-Curtis function, compared to the
Cosine similarity. In measurement of similarity between tissue-wide expression profiles,
not only do the relative magnitudes of expression values of the gene across multiple
tissues (i.e. the direction of the vector) matter, but the absolute expression value of the
gene in every single tissue (i.e. the length of the vector) also matters. The third is the
domination of the resulting similarity value by higher expression values. Intuitively, the
proximity between larger expression values is more important in determining the
similarity between the expression profiles of two genes than that between smaller
expression values.
Another advance of the machine learning framework is its unifying capability to predict
both gene expression profiles and TF target genes using the same set of features derived
from heterotypic or homotypic TFBS clusters. These features captured the spatial
distribution (e.g. the distances between clusters and the TSS) and information
composition (e.g. the 𝑅𝑖 values of binding sites) of clusters in the promoter. The rationale
that the organization and composition of cis-regulatory modules in the promoter dictate
gene expression patterns and identify correct TF targets confers this unifying capability.
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The most direct generalization of the Bray-Curtis similarity measure is that it can be
applied on any gene whose expression profile is available from GTEx to identify genes
with overall similar expression patterns across 53 tissues to it. Furthermore, the definition
of the gene expression profile is flexible; if another project other than GTEx also
generated the expression data of genes across multiple tissues, the gene expression profile
can be similarly redefined and the Bray-Curtis similarity measure is still usable. Another
generalization of the Bray-Curtis similarity metric is to measure the similarity in the
expression profile between different transcripts of the same gene.
In Chapter 6, the machine learning framework was applied to the TF knockdown data
respectively in the forms of P-values and regulatory coefficients in the GM19238 and
K562 cell lines generated by Cusanovich et al. (23) and Dixit et al (24). To date
ENCODE has conducted 127 CRISPR- and 54 siRNA-based knockdown experiments for
more TFs in the K562 cell line. Apart from raw RNA-seq reads data, ENCODE also
directly provides the absolute gene expression values before and after TF knockdown,
instead of indirect P-values and regulatory coefficients generated by the computational
models. Thus for the machine learning framework to be applied to these newly generated
ENCODE data, two preconditions need to be met. The first is that we need to derive
iPWMs exhibiting primary binding motifs from ChIP-seq data for the sequence-specific
TFs, enabling us to detect their binding sites. The second is that more flexibility needs to
be added to the initial interface of the framework responsible for identifying DE TF
targets from knockdown data, by adapting it to the different form of knockdown data (i.e.
absolute gene expression values).

7.2 Implications of the Results Obtained in this Thesis
7.2.1

Transcription Factor Binding Site Motifs

The iPWMs exhibiting primary binding motifs of sequence-specific TFs can be used to
detect binding sites and predict the effects of naturally occurring or artificially introduced
variants on binding site strengths, as proved by the accurate detection of true binding
sites and interpretation of effects of experimentally characterized SNPs in Chapter 3,
prioritization of TFBS variants in HBOC genes in Chapters 4 and 5, and analysis on the
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artificial mutations introduced into EGR1 binding sites in the MCM7 promoter and SNPs
in the target genes of seven TFs in Chapter 6.
They can also be used to perform mutation analyses on all known SNPs present in the
dbSNP database by first detecting whether they lie within TFBSs. In fact, these iPWMs
have been integrated into MutationForecaster, a commercial web-based software suite
that provides a single easy-to-navigate interface, interprets mutations that affect
transcription, mRNA splicing and protein coding, and stores the results in a database that
can be compared to other sources of genome variation. Another higher-level use of these
iPWMs is to predict TF target genes, as demonstrated by the successful identification of
DE direct targets of 7 and 11 TFs respectively in the GM19238 and K562 cell lines based
on iPWM-detected binding sites and IDBC-detected clusters in Chapter 6.
Cofactor motifs are a systemic component of ChIP-seq datasets (25); for example, the
CTCF motif frequently is significantly enriched in ChIP-seq peaks of other primary TFs,
consistent with our finding that CTCF is revealed as a cofactor of SMC3, RAD21 and
ZNF143. Peaks only containing CTCF motifs and lacking primary TFs’ motifs compose
up to 45% of a ChIP-seq dataset (25). These novel cofactor motifs enabled us to predict
new TF-TF interactions and complexes. Future experimental studies can confirm the
presence of these predicted complexes, ascertain the underlying physical mechanisms of
these interactions, and investigate functional significance of these complexes (e.g. the
biological pathways that they participate in). They can also confirm that the novel motifs
are indeed functional, independent and can be recognized by TFs, rather than being
general noise.
The list of experimentally confirmed TFBSs and the list of experimentally characterized
SNPs that we compiled from the literature in Chapter 3 can serve as standard datasets to
benchmark the accuracy of TFBS motifs and PWMs that future studies will derive from
ChIP-seq datasets. As experimental studies identify more binding sites and the effects of
more TFBS variants, the two lists will be maintained and expanded by incorporating
these new findings, in terms of the numbers of binding sites, SNPs and different TFs.
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7.2.2

Transcription Factor Binding Site and Other Variants in the
Hereditary Breast and Ovarian Cancer Genes

Future experimental studies can confirm the predicted effects of the TFBS and other
types of non-coding and coding variants that were prioritized in 20 complete genes of
HBOC patients in Chapters 4 and 5 on binding site strengths, mRNA splicing, mRNA
secondary structure and amino acid chains of the final proteins. For TFBS variants, they
can also investigate whether and how the expression levels of these genes are altered, and
whether the expression alterations of these genes are associated with HBOC, establishing
the association of these variants with the increased risks of HBOC. On a higher level,
they can further ascertain the specific functional pathways through which changes in the
concentration and structure of the protein molecules encoded by these genes result in the
onset of HBOC, after statistical studies prove that these variants are associated with the
increased risks of HBOC.

7.2.3

Genes with Similar Tissue-wide Expression Profiles to, and
Differentially Expressed, Direct Target Genes of the
Transcription Factors

In Chapter 6, the genome-wide genes with overall similar expression patterns across 53
tissues to 17 TFs were identified by the Bray-Curtis similarity measure, and the general
machine learning framework partly answered the question of why these genes exhibit
similar tissue-wide expression profiles to the TFs by finding that the similarity in the
distribution and composition of TFBS clusters in the proximal promoters partly explained
the similarity in the expression profiles. Since the expression pattern of a gene is
determined by both TF binding and epigenetic markers within all regulatory sequences
including proximal promoters and distal enhancers/silencers, future studies can explore
the similarity between these genes and the TFs in histone modification patterns within
proximal promoters, and in other regulatory regions both in terms of TFBSs and histone
modifications. In addition, the high similarity in the overall expression pattern across 53
tissues suggests the potential functional relatedness of the TFs to these genes, especially
the subset of genes that are also DE direct targets of the TFs at the same time; for
example, they may serve as key components within the same genomic pathway.
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In Chapter 6, TF-cofactor co-regulation was found to be responsible for distinguishing
functional binding sites in DE targets from non-functional binding sites in non-targets,
which was proved by different flanking cofactor binding sites present in the promoters of
targets and non-targets of YY1 and EGR1. Similar to the discovery of novel cofactor
motifs in Chapter 3, future experimental studies can focus on the interactions between
these cofactors (i.e. SP1, KLF1, CEBPB, NFY determining functional sites and CTCF,
ETV6 determining non-functional sites) and the primary TFs (i.e. YY1 and EGR1), and
how they affect the functional status of the binding sites.
The protection of multiple information-dense clusters in the promoter against TFBS
mutations suggests that it is not sufficient for subsequent studies to predict only the effect
of a mutation on the binding site strength; further, they also need to interpret the more
downstream effects on the cluster and potentially gene expression. TFBS mutations that
can be compensated for by other clusters may lower the promoter activity despite being
still able to induce gene expression, leading to natural phenotypic diversity. The majority
of previous studies focus on truly deleterious mutations leading to the onset of disease
phenotypes; future studies can attempt to relate more mutations that can be compensated
for to diverse non-disease phenotypes.

7.3 Potential Limitations and Future Studies
7.3.1

ChIP-seq datasets from which Maskminent Only Returned
Noise Motifs

Among all ChIP-seq datasets analyzed in Chapter 3, there were ~20 datasets from which
the Maskminent motif discovery pipeline was not able to discover the primary TF or any
cofactor motif, and only returned noise motifs. There are two primary reasons explaining
why these datasets are present, depending on whether the peaks contained in these
datasets were pulled down due to binding by protein molecules (i.e. primary TFs,
cofactors and histones) or by antibodies.
The majority of these datasets belong to non-sequence-specific TFs that primarily serve
as catalyzing enzymes of histone modifications apart from acting as transcriptional
cofactors interacting with DNA-binding TFs. For example, HDAC2 is responsible for the
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deacetylation of lysine residues on the N-terminal region of the core histones (26) while
being capable of forming transcription-repressing complexes with many DNA-binding
TFs (e.g. YY1 (27) and SP1 (28)). And EZH2, as a subunit of PRC2 (Polycomb
repressive complex 2), catalyzes trimethylation of H3K27 (H3K27me3) resulting in silent
chromatin and eventually transcriptional repression (29), whereas it also can activate
transcription via physical association with NFKB (30).
The functional versatility of these TFs explains why Maskminent did not detect any
known TFBS motif from these datasets. Peaks contained in such a dataset can be
classified into two categories, depending on the function that the primary TF was serving
when they were pulled down. A larger number of peaks were bound by histone proteins
that were bound by the primary TF that was catalyzing histone modifications, whereas
histones bind to DNA sequences in a non-sequence-specific way; thus these peaks do not
contain specific sequence motifs directly recognized by TFs. By contrast, the remaining
smaller number of peaks were bound by sequence-specific cofactors with which the
primary TF was associating, so that the binding sites recognized by the cofactor were
enriched in these peaks. For example, in Chapter 3 Maskminent returned a lowcomplexity noise motif from the HepG2 dataset of HDAC2 consisting of 18,836 peaks,
but detected FOXA motif from the top 5,000 peaks.
The other reason is that the peaks in such a dataset were isolated due to direct, nonspecific binding by antibodies, rather than binding by protein molecules; thus these peaks
are known as “noise” in the ChIP-seq technology, in contrast with the “signal” peaks that
are pulled down in TF-DNA complexes and contain TFBSs. Sources that can introduce
noise or bias into a ChIP-seq experiment include antibody quality, sequencing depth,
library complexity, ChIP enrichment, differential protection against sonication across the
genome, and differential mappability of short reads to repeat-rich genomic regions (3133).
In fact, the peak calling step of a ChIP-seq experiment aims to achieve maximal signalnoise ratio when identifying peak intervals based on the enrichment level of isolated
DNA fragments (or tags) (34). Prior studies developed multiple discriminative peak
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Table 7.1: Peak calling algorithms
Algorithm Background tag distribution
SPP

Poisson

Operating process
three binding detection algorithms to take advantage of the
strand-specific tag pattern

Reference
(36)

distinguishing background from signal by maximizing signalCCAT

Poisson

to-noise ratio between immunoprecipitation data and negative

(35,37)

control
scoring signal sites relative to control under the null
PeakSeq

Binomial

hypothesis of a binomial distribution of tags with a mean
estimated from the number of tags in the negative control at

(35,38)

the same site
using a negative binomial regression model, formulated as a
BayesPeak

Binomial

Poisson-Gamma mixture, with parameters estimated from the

(35,39)

negative control via Monte Carlo Markov chain methods
using a variable rate Poisson model, where the model mean is
MACS

Poisson

determined from the negative control by taking the maximum
of average read counts computed on 1kb, 5kb, 10kb, and
genome-wide intervals

(35,40)
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using a negative binomial regression model computed from
MOSAiCS

Binomial

GC content, mappability, and a monomial in tag counts of the

(35,41)

negative control, with a piecewise-defined mean
using convolutional neural networks to learn a generalizable
Coda

N/A

mapping between ‘suboptimal’ and high-quality ChIP-seq
data, while attenuating three primary sources of noise—due to
low sequencing depth, low cell input and low ChIP enrichment

(42)
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calling algorithms that distinguish signal from background noise in immunoprecipitation
data based on a negative control into which the TF proteins of interest were not added
(Table 7.1). Most of these algorithms assume that background noise tags conform to a
null mathematical distribution (Poisson or Binomial), and the parameters of the
distribution are estimated from the negative control and scaled to fit true
immunoprecipitation data (35).

7.3.2

Predicted False Positive Transcription Factor Binding Sites

Traditional PWMs, which assume that individual positions within the binding site are
independent of each other, tend to predict false positives (e.g. low-complexity sequences)
when detecting TFBSs (43). However, position interdependencies within the binding site
were confirmed to be present by the total mutual information of the iPWMs derived in
Chapter 3 (Appendix B.2) and a variety of experimental techniques (44), including
crystal structure analyses (45), quantitative multiple fluorescence relative affinity
(QuMFRA) assays (46) and PBMs (47,48). PBM data have also demonstrated that
position dependencies are stronger between neighboring positions than others (44,47,48).
Thus one possible reason why traditional PWMs predict false positives is the underlying
assumption of independence between individual positions within the binding site.
Note that these false positive binding sites predicted by PWMs differ from the nonfunctional binding sites distinguished by TF-cofactor coregulations from functional sites
in Chapter 6. False positive sites are non-sites that cannot actually be recognized or
bound by TFs (i.e. in the case of iPWMs, their ground-truth 𝑅𝑖 values are < 0, but
predicted 𝑅𝑖 values are > 0); by contrast, both non-functional and functional sites are true
binding sites that can be physically bound by TFs (i.e. their ground-truth 𝑅𝑖 values are >
0), with non-functional sites being unable to alter the gene expression level upon binding.
Apart from different types of interacting cofactors determining the functional state of a
binding site, multiple other approaches that can enrich for functional sites and result in
accurate feature sets were also simultaneously applied in Chapter 6; by contrast, they
were individually used in prior studies, including focusing on proximal promoters (49),
using DNase I hypersensitive data (50) and detecting information-dense clusters (51,52).
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On the other hand, there are two additional approaches that were not incorporated into
Chapter 6, using histone modification data (50) and focusing on phylogenetically
conserved sequences across species (53).

7.3.2.1

Approaches to Reduce Predicted False Positive Binding
Sites by Modelling Position Interdependencies

Prior studies applied three mainstream mathematical approaches to enable PWMs (e.g.
frequency matrices) to capture position interdependencies within the TFBS and reduce
the number of predicted false positive binding sites (Table 7.2), including Hidden
Markov Models (HMMs) (44,47,54,55), straightforward oligonucleotide frequency
matrices (56-58), and Bayesian networks (59-61). Other approaches include directly
adding additional terms representing extra energy dissipated from the appearance of
specific dinucleotides at pairwise positions into the equation to compute the energy
dissipation of a TFBS from a binding energy-based PWM (62), and mixing frequency
matrices computed from all binding sites and individual sites using a variable mixing
parameter and pseudocount (63). These more complicated PWMs incorporating position
interdependencies did achieve a higher specificity in detecting TFBSs; however, the
improvement for most TFs is minor (44,62).
First-order HMMs can capture adjacent dinucleotide interdependencies: each position
within the binding site corresponds to four internal states each of which emits one base
with certainty, and a background state describing the nucleotide frequencies of flanking
sequences is also present. The transition from the background state to an internal state
represents the start of a binding site, and the transition probability between two internal
states is the frequency of the dinucleotide appearing at the two positions (44,47).
However, HMMs are less scalable; modelling interdependencies among multiple
positions requires an increase in the order of HMMs, resulting in an exponential increase
in the size and complexity of HMMs (55). Similarly, oligonucleotide frequency matrices
also have a limited scalability; for example, modelling trinucleotide interdependencies
implies that the frequencies of 43 = 256 3-mers need to be computed for every three
positions. Thus only one prior study attempted to select a subset of 𝑘-mers (𝑘 ≥ 3) based
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Table 7.2: Approaches to model position interdependencies in PWMs to reduce predicted false positive binding sites
Approach

Mathematical
model

Operating process

Reference

1st-order HMMs were used to model dinucleotide
interdependencies and variable motif lengths. Each position

TFFMs (TF
flexible models),
Bulyk et al.,
PVLMM
(permutated variablelength Markov model),

Hidden Markov
Models (HMMs)
and Markov
networks

corresponded to four states (i.e. four bases occurring at the
position), and the transition probability between two states was
derived from the frequency of the dinucleotide occurring at the

(44,47,54,55)

two positions. To model interdependencies between nonadjacent positions, PVLMM searched for the best permutation
of the motif positions. FMM used log-linear representations of

FMM (feature motif model)

Markov networks to model position interdependencies.
Based on thermodynamic, conformational and electrostatic
Oligonucleotide
Ponomarenko et al., Stormo

alphabets/PWMs,

et al., Zhou et al.

dinucleotide
PWMs

properties of adjacent bases, a subset of oligonucleotides of each
different length was contained in an alphabet. Then the
frequency of each oligonucleotide was derived to form a
frequency matrix in Ponomarenko et al. In Stormo et al. and
Zhou et al. position frequency matrices contain the frequencies
of dinucleotides occurring at adjacent pairwise positions. Zhou

(56-58)
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et al. restricts that any position can at most correlate with one
other position.
Applying the Bayesian Theorem to model position
interdependencies (e.g. the probability of a dinucleotide
Barash et al., Ben-Gal et al.,
Pudimat et al.,

Bayesian networks

occurring at two positions is the probability of the 1st base
occurring at the 1st position, times the probability of the 2nd base

(59-61)

occurring at the 2nd position under the condition that the 1st base
has occurred at the 1st position).
A binding energy-based PWM indicates the heat energy
dissipated by each base at each position during the binding
BEM (binding energy

Binding energy-

model)

based PWMs

process. The additional energy dissipation caused by the
occurrence of the specific dinucleotide at the two positions was

(62)

explicitly added into the equation to compute the energy of a
binding site.
Frequency matrices were derived from all binding sites and each

King et al.

A parametric

individual site. One parameter was the pseudocount used to

mixture of

compute frequency matrices, and the other was the mixing

frequency matrices weight between the two matrices from all sites and from one
single site.

(63)
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on thermodynamic, conformational and electrostatic properties of adjacent bases (56),
whereas other studies adopted dinucleotide frequency matrices (57,58).
A Bayesian network can be represented by a directed acyclic graph in which a node
denotes a position in the binding site and an edge denotes a dependency between two
positions (59-61). This dependency is naturally modelled by the conditional probability in
the Bayes’ Theorem, which is used to compute the probability of a DNA sequence being
a binding site (Equation 7.1).
𝑃(𝑁1 , 𝑁2 ) = 𝑃(𝑁1 ) ∙ 𝑃(𝑁2 |𝑁1 ) = 𝑃(𝑁2 ) ∙ 𝑃(𝑁1 |𝑁2 ) [7.1]
where 𝑁1 and 𝑁2 are respectively the nucleotides appearing at Positions 1 and 2.
Equation 7.1 computes the probability of this dinucleotide appearing at the two positions
in the presence of an interdependency between Position 1 and Position 2.

7.3.2.2

High-dimensional iPWMs to Model Position
Interdependencies

Alternatively, we propose to use high-dimensional iPWMs, a natural generalization of the
current two-dimensional (2D) iPWMs, to capture position interdependencies within the
TFBS. For example, a 3D iPWM is capable of capturing dinucleotide interdependencies;
the 𝑥 and 𝑦 dimensions represent individual positions, and the 𝑧 dimension represents the
sequence conservation of each dinucleotide appearing at the 𝑥 and 𝑦 positions, computed
from its frequency and measured in bits of information.
From a multiple alignment of 𝑛 binding sites, the frequencies of 16 dinucleotides at each
pair of positions are determined. A contiguous 3D iPWM will be computed from
𝑅𝑖𝑤 (𝑑𝑛, 𝑙1 , 𝑙2 ) = 4 − (− log 2 𝑓(𝑑𝑛, 𝑙1 , 𝑙2 ) + 𝑒(𝑛(𝑙1 , 𝑙2 ))) (𝑏𝑖𝑡𝑠 𝑝𝑒𝑟 𝑏𝑎𝑠𝑒)

[7.2]

where 𝑓(𝑑𝑛, 𝑙1 , 𝑙2 ) is the frequency of dinucleotide 𝑑𝑛 at positions 𝑙1 and 𝑙2 in the
aligned binding site sequences and 𝑒(𝑛(𝑙1 , 𝑙2 )) is a sampling error correction factor (64)
at positions 𝑙1 and 𝑙2 for the 𝑛 sequences used to create 𝑓(𝑑𝑛, 𝑙1 , 𝑙2 ).
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Similarly, Equation 1.3 will also be generalized to compute the 𝑅𝑖 value of a contiguous
binding site 𝑗, which is the dot product between the sequence and the 3D iPWM.
𝑇

𝑅𝑖 (𝑗) = ∑ ∑ 𝑠(𝑑𝑛, 𝑙1 , 𝑙2 , 𝑗)𝑅𝑖𝑤 (𝑑𝑛, 𝑙1 , 𝑙2 ) (𝑏𝑖𝑡𝑠 𝑝𝑒𝑟 𝑠𝑖𝑡𝑒)

[7.3]

𝑙1 ,𝑙2 𝑏=𝐴

where 𝑠(𝑑𝑛, 𝑙1 , 𝑙2 , 𝑗) is a 3D binary matrix for the sequence 𝑗, in which cells have a value
of 1 for dinucleotide 𝑑𝑛 at position 𝑙1 and 𝑙2 , and a value of 0 elsewhere. Assuming
dinucleotide interdependencies only occur within the half site and do not occur across
two half sites, the calculation of the 𝑅𝑖 value of a bipartite binding site 𝑗 will remain the
same, except that the 𝑅𝑖 value of either half site is computed from a 3D iPWM using
Equation 7.2.
It can be anticipated that the unique binding site sequences predicted by the 3D iPWM
will be a subset of those predicted by the 2D iPWM (Figure 7.1, Example 7.1), resulting
in a smaller number of false positives and true positives (i.e. missing more true binding
sites) at the same time.
Similarly, a 4D iPWM can model trinucleotide interdependencies, etc. The highest
possible dimension is the binding site length, which can simultaneously capture
interdependencies among all positions. The minimum set of unique binding site
sequences detected by such an iPWM is identical to that contained in the multiple
alignment used to compute the iPWM.
Compared to the aforementioned approaches modelling position interdependencies, highdimensional iPWMs can simultaneously capture the interdependencies among all
possible combinations of positions. For example, the widely used 1st-order HMM only
naturally captures adjacent dinucleotide dependencies, since taking into account nonadjacent positions will significantly increase its complexity. By contrast, a 3D iPWM
automatically incorporates the interactions between all pairwise positions. However,
further studies on experimentally confirmed non-sites are needed to prove that highdimensional iPWMs are indeed capable of predicting less false positives, which is
beyond the scope of this thesis.
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Figure 7.1: Unique binding site sequences predicted by a 2D iPWM and a 3D
iPWM. The unique binding site sequences predicted by an iPWM include true sites, as
well as non-sites. Using a 3D iPWM will simultaneously increase specificity and
decrease sensitivity compared to a 2D one.
Example 7.1: Suppose that TATA, TAAT, TAGC, TACG are four true binding sites of
some TF. According to Equations 1.1 and 1.3, the information content of the DNA
sequence TAAA computed from the 2D iPWM is 𝑅𝑖 (𝑇𝐴𝐴𝐴) = 4 𝑏𝑖𝑡𝑠 (for simplicity, the
pseudocount and sampling error correction factor are not taken into account). Thus
TAAA will be predicted to be a binding site. On the other hand, according to Equation
7.2 the 3D iPWM derived from the alignment of the four binding sites is shown in Table
7.3.
According to Equation 7.3, the information content of the DNA sequence TAAA
computed from the 3D iPWM is 𝑅𝑖 (𝑇𝐴𝐴𝐴) = −∞ bits. Thus it will not be predicted to
be a binding site. Since TAAA is a lower-complexity sequence compared to the four true
sites and the dinucleotide AA never appears at Positions 3 and 4, it is more likely to be a
non-site, which justifies the prediction made by the 3D iPWM.

266

Table 7.3: The 3D iPWM in Example 7.1
Pairwise positions
Dinucleotide

7.3.3

1,2

1,3

1,4

2,3

2,4

3,4

AA

−∞

−∞

−∞

2

2

−∞

AT

−∞

−∞

−∞

2

2

2

AC

−∞

−∞

−∞

2

2

−∞

AG

−∞

−∞

−∞

2

2

−∞

TA

4

2

2

−∞

−∞

2

TT

4

2

2

−∞

−∞

−∞

TC

4

2

2

−∞

−∞

−∞

TG

4

2

2

−∞

−∞

−∞

CA

−∞

−∞

−∞

−∞

−∞

−∞

CT

−∞

−∞

−∞

−∞

−∞

−∞

CC

−∞

−∞

−∞

−∞

−∞

−∞

CG

−∞

−∞

−∞

−∞

−∞

2

GA

−∞

−∞

−∞

−∞

−∞

−∞

GT

−∞

−∞

−∞

−∞

−∞

−∞

GC

−∞

−∞

−∞

−∞

−∞

2

GG

−∞

−∞

−∞

−∞

−∞

−∞

Downstream Effects of Transcription Factor Binding Site
Variants and Long-range DNA Interactions

As described in Chapter 6, the ideal prediction of effects of a TFBS variant of uncertain
significance ought to include three levels, the binding site strength, binding site cluster,
and gene expression. In Chapters 4 and 5, the unified framework prioritized a number of
variants within binding sites of multiple TFs (e.g. CEBPB, HSF1) known to play a role in
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breast cancer development in the HBOC genes. However, this framework only predicted
the effects of these variants on binding site strengths, since this study had been conducted
earlier.
Thus a future study will extend the framework by integrating predictions of effects of
TFBS variants on information-dense clusters and gene expression, and apply this
extended framework to reanalyze the prioritized variants in Chapters 4 and 5. This will
further prioritize these variants by classifying them into two categories, truly deleterious
mutations that can actually significantly alter gene expression and result in disease
phenotypes, and variants that can be compensated for by other clusters and result in
diverse natural phenotypes.
In fact, deleterious variants in the binding sites of many TFs have been known to be
associated with a variety of diseases (Table 7.4), which in turn reflect the tissue-specific
functions of the TFs. For example, 797 established SNPs associating with 144 diseases
were found to lie within binding sites of NFKB, a significant overrepresentation (2.25fold) compared with all common variants (P-value = 4.2 × 10-90) (65). SNPs associated
with primarily inflammatory and autoimmune diseases and cancers, including rheumatoid
arthritis, systemic lupus erythematosus, primary biliary cirrhosis, asthma, and lymphoma,
were highly enriched in NFKB binding sites (65). This is consistent with the known
NFKB-mediated regulation of various aspects of innate and adaptive immune responses,
including the transcription of cytokines and antimicrobial effectors, and the development
and survival of the cells and tissues that carry out immune responses (66). Similarly, the
B cell-specific EBF1 is essential for maintaining B cell identity and preventing
alternative fates in committed cells (76), which accounts for the correlation between
SNPs resulting in allele-specific binding of EBF1 and autoimmune diseases (77-80).
A recent study used the Hi-C technology to identify TF-mediated long-range interactions
between 31,253 promoters and distant regulatory elements (e.g. distal enhancers and
promoters of other genes) in 17 human primary hematopoietic cell types (81). 698,187
high-confidence unique promoter interactions were detected across all cell types, of
which 9.6% were promoter-to-promoter interactions and 90.4% promoter-to-enhancers,
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Table 7.4: Association of TFBS variants with diseases
Diseases with which SNPs
TF

in the binding sites of the

Functions of the TF in the
specific tissue

TF are associated

NFKB

Inflammatory and

Regulates various aspects of

autoimmune diseases and

innate and adaptive immune

cancers (e.g. asthma)

responses

Reference

(65,66)

Affects BC development by
Breast cancer (BC)

regulating target genes; the

(e.g. rs11540855)

hypopoly(ADPribosyl)ated

(67-69)

isoform is characteristic for BC
Skin cancer

CTCF knockdown promoted
invasion, metastasis and

CTCF

(70,71)

epithelial-mesenchymal transition
Liver cancer

in liver and skin cancer.

(71,72)

Associations were established
Gastrointestinal Cancers

between motif mutations and late

(70,71)

replication.
GABPA BC (e.g. rs2853669)

Controls cell migration in breast
epithelial cells

(67,73,74)

Have a potent growth-inhibitory
USF1/2

BC (e.g. rs3760982)

effect and loss of USF function

(67,75)

favors cell proliferation.
Autoimmune diseases
(psoriasis, primary biliary
EBF1

cirrhosis and rheumatoid
arthritis) (e.g. rs909685,
rs9603612)

Essential for the maintenance of
B cell identity and prevention of
alternative fates in committed
cells.

(76-80)
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with a median linear distance between promoters and their interacting regions of 331 kb
(81). These promoter interactions were found to be highly cell type specific, and
interacting regions are enriched in genetic variants linked with altered expression of
genes they contact (81). However, this study did not identify which specific TFBSs
present in the promoters and distal interacting regions are responsible for the formation of
long-range loops. As described above, this unified framework can be directly generalized
to analyze all variants in the whole genome instead of specific genes. Therefore, this
unified framework can be further extended by first ascertaining whether the prioritized
TFBS variants lie in distal interacting regions using the Hi-C data, then predicting how
these variants affect the expression levels of the distant genes whose promoters form
long-range loops with the interacting regions. For example, the intron 19 of the
CLEC16A gene serves as a distal enhancer (∼160 kb away) interacting with the promoter
of DEXI gene (82), and the SNP (rs12708716) within this intron associated with the type
1 diabetes significantly altered the expression level of DEXI (82).
The Hi-C long-range interacting data can also be used to improve the general machine
learning framework for prediction of genes with similar tissue-wide expression profiles in
Chapter 6. After the Bray-Curtis similarity measure identify the genes with similar
expression profiles to the TFs, distal interacting regions that can perform long-range
interactions with the promoters of these genes can be further obtained using the Hi-C
data. The same feature sets will be derived from the information-dense clusters detected
from iPWM-detected TFBSs within these interacting regions by the IDBC algorithm.
Since the expression pattern of a gene is determined by all regulatory regions, the high
similarity between these genes and the TFs in the tissue-wide expression profile is
attributable to the high similarity in all regulatory regions including long-range
interactions. Therefore, the incorporation of the spatial organization and information
composition of transcriptional regulatory modules in the distal interacting regions into the
machine learning framework, in addition to those in the proximal promoters, will result in
an improvement in the classifier performance.
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7.4 Conclusions
Compared to prior studies, this thesis presents an improved three-level computational
modelling of the transcriptional regulation of human genes, involving TFBSs,
information-dense clusters, and gene expression. The ultimate goal of transcriptional
regulation is to accurately regulate expression levels of TF target genes via the
underlying physical interactions between TFs and individual binding sites.
The lowest level is the derivation of contiguous and bipartite iPWMs from ENCODE
ChIP-seq datasets modelling TF binding specificities in Chapter 3. The information
content of a binding site computed from an iPWM is quantitatively related to the amount
of heat energy dissipated by the TF-binding site physical association, enabling iPWMs to
more accurately quantify binding site strengths than log likelihood ratio-based PWMs
derived by prior studies. The bipartite iPWMs more precisely model the binding behavior
of dimeric TFs by taking into account the variable-length spacers within bipartite binding
sites. Compared to prior studies only analyzing a small number of top peaks, the derived
iPWMs incorporated the maximum number of intermediate and weak binding sites via
the recursive thresholding functionality. This enabled the accurate quantification of
binding site strengths across a broad range of affinities, which was proven by the
successful detection of true binding sites and interpretation of experimentally measured
effects of SNPs in Chapter 3, and prioritization of TFBS variants in HBOC genes in
Chapters 4 and 5.
The intermediate level is the relationship between individual binding sites and clusters in
terms of composition and variation in Chapter 6. Compared to prior clustering
algorithms, the detection of the information-dense clusters by the IDBC algorithm
simultaneously rely on both the spatial distribution and information contents of binding
sites, enabling the more accurate modelling of the clustering composition of binding sites.
Apart from the additive, complementary cooperation between individual sites within a
cluster on inducing gene expression found by prior studies, mutation analyses on
artificially introduced mutations and naturally occurring SNPs also revealed another
compensatory cooperation; that is, the presence of multiple binding sites in a cluster
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enable the cluster to be robust against mutations by compensating for each other’s
destruction, with the central strong site playing a more significant role.
The highest level is the relationship between individual clusters and gene expression in
terms of composition and variation in Chapter 6. The Bray-Curtis similarity measure and
gene knockdown data respectively enabled the accurate identification of similar tissuewide gene expression profiles and differentially expressed TF target genes. Machine
learning features accurately modeled the spatial organization and information
composition of TFBS clusters in proximal promoters, which substantially dictate the
expression profiles of TF target genes. Mutation analyses on TF targets revealed that the
presence of multiple information-dense clusters in a promoter enable gene expression to
be robust against TFBS mutations by compensating for each other’s destruction, relating
deleterious and protective variants respectively to disease and diverse natural phenotypes.
Therefore, by comprehensively delineating physical TF-binding site interactions,
functional binding site-binding site interactions within the information-dense cluster and
cluster-cluster interactions within the promoter, this thesis aims to improve the current
computational modelling of human transcriptional regulation.
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